

HIGHLIGHT set on as ''  
HIGHLIGHT set on as ''  
? begin 5,73,155,399  
25may08 08:07:11 User208760 Session D2943.2  
\$0.00 0.115 DialUnits File410  
\$0.00 Estimated cost File410  
\$0.06 TELNET  
\$0.06 Estimated cost this search  
\$0.61 Estimated total session cost 0.267 DialUnits

SYSTEM:OS - DIALOG OneSearch  
File 5:Biosis Previews(R) 1926-2008/May W3  
(c) 2008 The Thomson Corporation  
File 73:EMBASE 1974-2008/May 22  
(c) 2008 Elsevier B.V.  
\*File 73: The 2008 EMTREE Thesaurus has been loaded. Please see  
HELP NEWS 72 for details.  
File 155:MEDLINE(R) 1950-2008/May 26  
(c) format only 2008 Dialog  
\*File 155: MEDLINE has reloaded. Please see HELP NEWS 155  
for details.  
File 399:CA SEARCH(R) 1967-2008/UD=14821  
(c) 2008 American Chemical Society  
\*File 399: Use is subject to the terms of your user/customer agreement.  
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

Set Items Description  
--- -----

? e au=amagai masayuki

Ref	Items	Index-term
E1	1	AU=AMAGAI MASAHIRO
E2	1	AU=AMAGAI MASAYUK
E3	208	*AU=AMAGAI MASAYUKI
E4	2	AU=AMAGAI MIEKO
E5	1	AU=AMAGAI MIKIKO
E6	8	AU=AMAGAI N
E7	9	AU=AMAGAI N.
E8	2	AU=AMAGAI NAKO
E9	4	AU=AMAGAI NAOMI
E10	3	AU=AMAGAI NORIKO
E11	1	AU=AMAGAI R
E12	5	AU=AMAGAI R.

Enter P or PAGE for more

? s e2,e3

	1	AU=AMAGAI MASAYUK
	208	AU=AMAGAI MASAYUKI
S1	209	E2,E3

? e au=nishikawa takeji ?

Ref	Items	Index-term
E1	1	AU=NISHIKAWA TAKEIJI
E2	266	AU=NISHIKAWA TAKEJI
E3	0	*AU=NISHIKAWA TAKEJI ?
E4	1	AU=NISHIKAWA TAKENOB
E5	2	AU=NISHIKAWA TAKEO
E6	108	AU=NISHIKAWA TAKESHI
E7	2	AU=NISHIKAWA TAKEYO
E8	1	AU=NISHIKAWA TAKU
E9	4	AU=NISHIKAWA TAKUJI

E10 4 AU=NISHIKAWA TAKURO  
E11 1 AU=NISHIKAWA TAKUROH  
E12 3 AU=NISHIKAWA TAKUSHI

Enter P or PAGE for more

? s e1,e2

1 AU=NISHIKAWA TAKEIJI  
266 AU=NISHIKAWA TAKEJI  
S2 267 E1,E2

? s (s1 or s2) and (pemphigus) and (cd40L or cd40(w)ligand or cd154 or gp39 or cd154)

209 S1  
267 S2  
18072 PEMPHIGUS  
8469 CD40L  
34411 CD40  
539602 LIGAND  
16205 CD40(W)LIGAND  
3765 CD154  
798 GP39  
3765 CD154

S3 2 (S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)

? rd s3

S4 1 RD S3 (unique items)

? t s4/7/all

4/7/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

19097585 BIOSIS NO.: 200600442980

Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model

AUTHOR: Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki; Iwasaki Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji; Amagai Masayuki (Reprint)

AUTHOR ADDRESS: Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan\*\*Japan

AUTHOR E-MAIL ADDRESS: amagai@sc.itc.keio.ac.jp

JOURNAL: Journal of Investigative Dermatology 126 (1): p105-113 JAN 2006 2006

ISSN: 0022-202X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by IgG autoantibodies against desmoglein 3 (Dsg3). We have recently developed an active disease mouse model for PV by adoptive transfer of splenocytes from Dsg3(-/-) mice. The purpose of this study was to determine the role of CD40/CD154 interaction in the pathogenic antibody production and development of the disease in PV model mice. When anti-CD154 monoclonal antibody (mAb) was administered to recipient mice prior to adoptive transfer, anti-CD154 mAb almost completely blocked the anti-Dsg3 IgG production and prevented blister formation. The blockade of CD40/CD154 interaction induced tolerance against Dsg3 as the suppression of antibody production was observed through day 70, and it was maintained even after challenge by immunization with recombinant mouse Dsg3 or by adoptive transfer of immunized Dsg3(-/-) splenocytes. Furthermore, the tolerance to Dsg3 was transferable because cotransfer of

splenocytes from anti-CD154 mAb-treated mice and naive Dsg3(-/-) splenocytes significantly suppressed anti- Dsg3 IgG production in recipient mice. In contrast, when anti-CD154 mAb was injected after the mice had developed the PV phenotype, no significant suppression of the production of anti- Dsg3 IgG was observed. These findings indicate that the CD40/CD154 interaction is essential for the induction of pathogenic anti- Dsg3 IgG antibodies and that antigen-specific immune-regulatory cells induced by anti-CD154 mAb would hold a therapeutic option for autoimmune diseases.

```
? s (pemphigus) and (cd40L or cd40(w)ligand or cd154 or gp39 or cd154)
      18072 PEMPHIGUS
      8469 CD40L
      34411 CD40
      539602 LIGAND
      16205 CD40(W)LIGAND
      3765 CD154
      798 GP39
      3765 CD154
      S5      37 (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39
                OR CD154)
? rd s5
      S6      25 RD S5 (unique items)
? t s6/7/all
```

6/7/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0020104725 BIOSIS NO.: 200800151664  
T-B cell interaction is crucial for the induction of desmoglein 3-specific IgG autoantibodies in an HLA-class II transgenic mouse model of pemphigus vulgaris  
AUTHOR: Eming R (Reprint); Hertl M; Schmidt J; Podstawa E; Feliciani C; Sonderstrup G  
AUTHOR ADDRESS: Univ Marburg, Marburg, Germany\*\*Germany  
JOURNAL: Journal of Investigative Dermatology 127 (Suppl. 2): pS66 OCT 2007 2007  
CONFERENCE/MEETING: 37th Annual Meeting of the European-Society-for-Dermatological-Research Zurich, SWITZERLAND September 05 -08, 2007; 20070905  
SPONSOR: European Soc Dermatol Res  
ISSN: 0022-202X  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

6/7/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019927481 BIOSIS NO.: 200700587222  
Increased serum levels of circulating CD40 ligand in patients with bullous pemphigoid: Preliminary results  
AUTHOR: Watanabe R (Reprint); Ishiura N; Nakashima H; Yazawa N; Kuwano Y; Tada Y; Okochi H; Fujimoto M; Tamaki K  
AUTHOR ADDRESS: Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan\*\*Japan  
AUTHOR E-MAIL ADDRESS: fujimoto-m@umin.ac.jp  
JOURNAL: Dermatology (Basel) 215 (3): p180-186 2007 2007  
ITEM IDENTIFIER: doi:10.1159/000106573

ISSN: 1018-8665  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Background: Autoimmune bullous diseases are characterized by autoantibodies against specific adhesion molecules of the skin and/or mucous membrane. While these autoantibodies are known to play a primary role in the disease manifestation, it remains unknown how disease-specific autoreactive B cells and autoantibodies are induced. Recent studies have indicated the importance of the CD40 and CD40 ligand (CD40L) receptor-ligand pair in the immunopathogenesis of autoimmune diseases. \*\*\*CD40L\*\*\* circulates in soluble form, and some reports suggest that serum soluble CD40L (sCD40L) levels are increased in various autoimmune diseases. Objectives: To determine serum sCD40L levels in patients with pemphigus vulgaris (PV) and bullous pemphigoid (BP), and to determine their correlation with clinical findings and laboratory findings. Patients and Methods: Sera from 10 PV patients, 35 BP patients and 12 normal controls were subjected to ELISA assays to measure serum levels of sCD40L, anti-desmoglein-3 antibody and anti-BP180 antibody. Results and Conclusions: Circulating sCD40L levels were significantly elevated in BP patients, but not in PV patients. Serum sCD40L levels increased in the early stage of disease onset and recurrence in BP patients. In conclusion, circulating sCD40L levels may be a useful marker for early activation of autoimmune diathesis and, furthermore, an effective therapeutic target in patients with BP. Copyright (C) 2007 S. Karger AG, Basel.

6/7/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019830322 BIOSIS NO.: 200700490063  
The CD40/CD40 ligand system is involved in the pathogenesis of pemphigus  
AUTHOR: Caproni Marzia; Antiga Emiliano; Torchia Daniele; Volpi Walter; del Bianco Elena; Cappetti Alessio; Feliciani Claudio; Fabbri Paolo (Reprint)  
AUTHOR ADDRESS: Via Pergola, 58-60, I-50121 Florence, Italy\*\*Italy  
AUTHOR E-MAIL ADDRESS: fabbri@unifi.it  
JOURNAL: Clinical Immunology (Orlando) 124 (1): p22-25 JUL 2007 2007  
ITEM IDENTIFIER: doi:10.1016/j.clim.2007.04.007  
ISSN: 1521-6616  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: The CD40/CD40 ligand (CD40L) system has never been investigated in autoimmune bullous diseases belonging to the \*\*\*pemphigus\*\*\* group in humans. Skin biopsy specimens from 21 patients with pemphigus vulgaris, 10 with pemphigus foliaceus and healthy volunteers were studied by immunohistochemistry (for CD40 and CD40L) and reversal transcriptase polymerase-chain reaction (for CD40L), while sera were analyzed by enzyme-linked immunosorbent assay for soluble \*\*\*CD40L\*\*\*. In all \*\*\*pemphigus\*\*\* specimens, the basal and suprabasal layers of the epidermis and perivascular infiltrating cells were CD40+. \*\*\*CD40L\*\*\*+ cells moderately infiltrated the perivascular and interstitial dermis of \*\*\*pemphigus\*\*\* specimens. CD40L mRNA was strongly evident in all pemphigus samples while no signal was detected in the healthy controls. The expression of soluble CD40L was significantly greater in pemphigus sera

than in controls. We showed here that the CD40/ \*\*\*CD40L\*\*\* system is upregulated both in lesional skin and in serum of patients with pemphigus. (c) 2007 Elsevier Inc. All rights reserved.

6/7/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

19097585 BIOSIS NO.: 200600442980  
Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model  
AUTHOR: Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki; Iwasaki Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji; Amagai Masayuki (Reprint)  
AUTHOR ADDRESS: Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan\*\*Japan  
AUTHOR E-MAIL ADDRESS: amagai@sc.itc.keio.ac.jp  
JOURNAL: Journal of Investigative Dermatology 126 (1): p105-113 JAN 2006  
2006  
ISSN: 0022-202X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by IgG autoantibodies against desmoglein 3 (Dsg3). We have recently developed an active disease mouse model for PV by adoptive transfer of splenocytes from Dsg3(-/-) mice. The purpose of this study was to determine the role of CD40/CD154 interaction in the pathogenic antibody production and development of the disease in PV model mice. When anti- \*\*\*CD154\*\*\* monoclonal antibody (mAb) was administered to recipient mice prior to adoptive transfer, anti-CD154 mAb almost completely blocked the anti- Dsg3 IgG production and prevented blister formation. The blockade of CD40/ \*\*\*CD154\*\*\* interaction induced tolerance against Dsg3 as the suppression of antibody production was observed through day 70, and it was maintained even after challenge by immunization with recombinant mouse Dsg3 or by adoptive transfer of immunized Dsg3(-/-) splenocytes. Furthermore, the tolerance to Dsg3 was transferable because cotransfer of splenocytes from anti-CD154 mAb-treated mice and naive Dsg3(-/-) splenocytes significantly suppressed anti- Dsg3 IgG production in recipient mice. In contrast, when anti-CD154 mAb was injected after the mice had developed the PV phenotype, no significant suppression of the production of anti- Dsg3 IgG was observed. These findings indicate that the CD40/ \*\*\*CD154\*\*\* interaction is essential for the induction of pathogenic anti- Dsg3 IgG antibodies and that antigen-specific immune-regulatory cells induced by anti-CD154 mAb would hold a therapeutic option for autoimmune diseases.

6/7/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

19097571 BIOSIS NO.: 200600442966  
Inhibition of pemphigus vulgaris by targeting of the CD40-CD154 co-stimulatory pathway: A step toward antigen-specific therapy?  
AUTHOR: Liu Zhi (Reprint); Li Ning; Diaz Luis A  
AUTHOR ADDRESS: Univ N Carolina, Dept Dermatol, 3100 Thuston Bowles, Chapel Hill, NC 27599 USA\*\*USA

AUTHOR E-MAIL ADDRESS: zhiliu@med.unc.edu  
JOURNAL: Journal of Investigative Dermatology 126 (1): p11-13 JAN 2006  
2006  
ISSN: 0022-202X  
DOCUMENT TYPE: Article; Editorial  
RECORD TYPE: Citation  
LANGUAGE: English

6/7/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

16901534 BIOSIS NO.: 200200495045  
Blockade of CD40/CD40L interaction has therapeutic benefits in the  
pemphigus vulgaris mouse model  
AUTHOR: Aoki M (Reprint); Tsunoda K (Reprint); Ota T (Reprint); Iwasaki T;  
Tanaka S; Koyasu S; Amagai M (Reprint); Nishikawa T (Reprint)  
AUTHOR ADDRESS: Dermatology, Keio University of School of Medicine, Tokyo,  
Japan\*\*Japan  
JOURNAL: Journal of Investigative Dermatology 119 (1): p317 July, 2002  
2002  
MEDIUM: print  
CONFERENCE/MEETING: 63rd Annual Meeting of the Society for Investigative  
Dermatology Los Angeles, California, USA May 15-18, 2002; 20020515  
ISSN: 0022-202X  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

6/7/7 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081248610 EMBASE No: 2006310874  
B cells move to centre stage: Novel opportunities for autoimmune disease  
treatment  
Browning J.L.  
Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge,  
MA 02445, United States  
AUTHOR EMAIL: Jeff.Browning@biogenidec.com  
CORRESP. AUTHOR: Browning J.L.  
CORRESP. AUTHOR AFFIL: Department of Immunobiology USA, Biogen Idec, 12  
Cambridge Center, Cambridge, MA 02445, United States  
CORRESP. AUTHOR EMAIL: Jeff.Browning@biogenidec.com

Nature Reviews Drug Discovery ( Nat. Rev. Drug Discov. ) (United Kingdom)  
July 1, 2006, 5/7 (564-576)  
CODEN: NRDDA ISSN: 14741776 eISSN: 14741784  
PUBLISHER ITEM IDENTIFIER: N2085  
DOI: 10.1038/nrd2085  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 173

The B-cell arm of the immune system has long been appreciated for its  
crucial role in pathogen resistance, but in the study of many autoimmune  
diseases, T cells have dominated the limelight for decades. However, the  
development of the B-cell-depleting antibody rituximab as a lymphoma  
therapy has provided a tool to probe the contribution made by B cells in  
several immune disorders. Recently, the success of B-cell depletion with

rituximab in the treatment of rheumatoid arthritis has stimulated investigation of its effects in several other immune disorders, and considerable interest in the potential of drugs that can modulate B-cell function for the treatment of such diseases in general. This article discusses the role of B cells in a range of autoimmune disorders, including rheumatoid arthritis and systemic lupus erythematosus, and analyses approaches to therapeutic B-cell manipulation.

6/7/8 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

148306456 CA: 148(14)306456e PATENT  
Methods of identifying a marker of regulatory CD4+ T cells  
INVENTOR(AUTHOR): Dromey, James A.; Mannering, Stuart I.; Harrison, Leonard C.  
LOCATION: Australia  
ASSIGNEE: The Walter and Eliza Hall Institute of Medical Research  
PATENT: PCT International ; WO 200828229 A1 DATE: 20080313  
APPLICATION: WO 2007AU1302 (20070905) \*US 2006PV842548 (20060905)  
PAGES: 78pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
IPCR/8 + Level Value Position Status Version Action Source Office:  
C12N-0005/08 A I F B 20060101 H AU  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM  
SECTION:  
CA215010 Immunochemistry  
IDENTIFIERS: regulatory T lymphocyte CD52 immunotherapy autoimmune disease cancer infection  
DESCRIPTORS:  
Apoidea... Cat... Dermatophagoides... Felis catus...  
allergy; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer  
Transplant rejection...  
allotransplant; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer  
Inflammation... Spinal column,disease...  
ankylosing spondylitis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer  
Kidney,disease...  
anti-tubular basement membrane disease; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer  
Blood transfusion...  
apheresis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer  
Antigens...  
autoantigens; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer  
Autoimmune disease... Inflammation... Thyroid gland,disease...  
autoimmune thyroiditis; regulatory CD4+CD52+ T cells and their use in

immunotherapy for autoimmune disease, infection, and cancer

Myocarditis... Thyroid gland,disease...  
autoimmune; regulatory CD4+CD52+ T cells and their use in immunotherapy  
for autoimmune disease, infection, and cancer

CD antigens...  
CD52; regulatory CD4+CD52+ T cells and their use in immunotherapy for  
autoimmune disease, infection, and cancer

Uterus,neoplasm...  
cervix; regulatory CD4+CD52+ T cells and their use in immunotherapy for  
autoimmune disease, infection, and cancer

Inflammatory bowel disease...  
Crohn's disease; regulatory CD4+CD52+ T cells and their use in  
immunotherapy for autoimmune disease, infection, and cancer

Glycoproteins...  
desmoglein 1; regulatory CD4+CD52+ T cells and their use in  
immunotherapy for autoimmune disease, infection, and cancer

Glycoproteins...  
desmoglein 3; regulatory CD4+CD52+ T cells and their use in  
immunotherapy for autoimmune disease, infection, and cancer

Cardiomyopathy...  
dilated, familial; regulatory CD4+CD52+ T cells and their use in  
immunotherapy for autoimmune disease, infection, and cancer

Ileitis...  
distal; regulatory CD4+CD52+ T cells and their use in immunotherapy for  
autoimmune disease, infection, and cancer

Interferons...  
 $\gamma$ ; regulatory CD4+CD52+ T cells and their use in immunotherapy  
for autoimmune disease, infection, and cancer

Kidney,disease...  
Goodpasture's syndrome; regulatory CD4+CD52+ T cells and their use in  
immunotherapy for autoimmune disease, infection, and cancer

Glycoproteins...  
gp39; regulatory CD4+CD52+ T cells and their use in immunotherapy for  
autoimmune disease, infection, and cancer

Transplant and Transplantation...  
graft-vs.-host reaction; regulatory CD4+CD52+ T cells and their use in  
immunotherapy for autoimmune disease, infection, and cancer

Lymphatic system...  
gut-assocd.; regulatory CD4+CD52+ T cells and their use in  
immunotherapy for autoimmune disease, infection, and cancer

Aggrecans...  
G1; regulatory CD4+CD52+ T cells and their use in immunotherapy for  
autoimmune disease, infection, and cancer

Heat-shock proteins...  
HSP 60; regulatory CD4+CD52+T cells and their use in immunotherapy for  
autoimmune disease, infection, and cancer

Proteins...  
IGRP (islet-specific glucose-6-phosphate catalytic subunit-related  
protein); regulatory CD4+CD52+ T cells and their use in immunotherapy  
for autoimmune disease, infection, and cancer

Cell proliferation...  
inhibition; regulatory CD4+CD52+ T cells and their use in immunotherapy  
for autoimmune disease, infection, and cancer

Autoimmune disease...  
insulin autoimmune syndrome; regulatory CD4+CD52+ T cells and their use  
in immunotherapy for autoimmune disease, infection, and cancer

Autoimmune disease...  
insulin-dependent diabetes mellitus; regulatory CD4+CD52+ T cells and  
their use in immunotherapy for autoimmune disease, infection, and  
cancer

Diabetes mellitus...



insulin-dependent; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Dermatomyositis...  
juvenile; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Plasmapheresis...  
leukapheresis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Infection...  
measles; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Glycoproteins...  
MOG (myelin oligodendrocyte glycoprotein); regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Lymphatic system...  
mucosa-assocd.; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Skin,disease...  
pemphigus; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Bone,disease... Inflammation...  
polychondritis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Arthritis...  
psoriatic arthritis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Addison's disease... Allergy... Antigens... Autoimmune disease...  
Autoimmune hepatitis... Biomarkers... Bladder,neoplasm... Bone marrow...  
CD4-positive T cell... Celiac disease... Cholinergic receptors... Cord blood... Cytokines... Diagnosis... Filaggrin... Food allergy... Gliadins...  
Glutenins... Graves' disease... Hematopoietic neoplasm... Hepatitis...  
Human immunodeficiency virus... Human... Immunotherapy... Infection...  
Inflammatory bowel disease... Interleukin 17... Liver... Lung,neoplasm...  
Lupus erythematosus... Lyme disease... Lymph node... Lymphatic system...  
Lymphoma... Malaria... Mammary gland,neoplasm... Meningitis... Mononuclear cell(leukocyte)... Multiple sclerosis... Myasthenia gravis... Myelin basic protein... Neoplasm... Ovary,neoplasm... Pancreas,neoplasm... Pertussis...  
Phenotypes... Prostate gland,neoplasm... Proteolipid protein... Rheumatoid arthritis... Scleroderma... Sjogren syndrome... Skin,neoplasm... Spleen...  
Tetanus... Thymus gland... Thyroglobulin... Thyrotropin receptors...  
Tuberculosis... Vimentins...  
regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Toxoids...  
tetanus; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Autoimmune disease...  
thyroid; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Collagens...  
type II; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

CAS REGISTRY NUMBERS:  
7440-41-7 biological studies, syndrome; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer  
9024-58-2 GAD65; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer  
9031-28-1 9035-68-1 80449-01-0 302355-25-5 regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and

cancer

6/7/9 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

148055086 CA: 148(3)55086n PATENT  
Preparation of pyrrolopyrimidine compounds as protein kinase inhibitors  
INVENTOR(AUTHOR): Brain, Christopher Thomas; Thoma, Gebhard; Sung, Moo Je  
LOCATION: Switz.  
ASSIGNEE: Novartis A.-G.; Novartis Pharma G.m.b.H.  
PATENT: PCT International ; WO 2007140222 A2 DATE: 20071206  
APPLICATION: WO 2007US69595 (20070524) \*US 2006PV808605 (20060526)  
PAGES: 213pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:

CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;  
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;  
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ;  
NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL;  
SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

SECTION:

CA228016 Heterocyclic Compounds (More Than One Hetero Atom)

CA201XXX Pharmacology

CA263XXX Pharmaceuticals

IDENTIFIERS: pyrrolopyrimidine prepn protein kinase inhibitor  
proliferative disease treatment

DESCRIPTORS:

Transplant rejection...

acute; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful  
in treatment and prevention of diseases as well as in combination  
therapy

Drug resistance...

adrenergic; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
useful in treatment and prevention of diseases as well as in  
combination therapy

Nervous system,disease...

amyotrophic lateral sclerosis, familial; prepn. of pyrrolopyrimidines  
as protein kinase inhibitors useful in treatment and prevention of  
diseases as well as in combination therapy

Antibodies and Immunoglobulins...

anti- CD45RB; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
useful in treatment and prevention of diseases as well as in  
combination therapy

Antibodies and Immunoglobulins...

anti-CD2; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
useful in treatment and prevention of diseases as well as in  
combination therapy

Antibodies and Immunoglobulins...

anti-CD3; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
useful in treatment and prevention of diseases as well as in  
combination therapy

Antibodies and Immunoglobulins...

anti-CD4; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
useful in treatment and prevention of diseases as well as in

combination therapy

Antibodies and Immunoglobulins...  
 anti-CD80; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
 useful in treatment and prevention of diseases as well as in  
 combination therapy

Antibodies and Immunoglobulins...  
 anti-CD86; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
 useful in treatment and prevention of diseases as well as in  
 combination therapy

Antibodies and Immunoglobulins...  
 anti-icaM-3; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
 useful in treatment and prevention of diseases as well as in  
 combination therapy

Antibodies and Immunoglobulins...  
 anti-IL-2 receptor; prepn. of pyrrolopyrimidines as protein kinase  
 inhibitors useful in treatment and prevention of diseases as well as in  
 combination therapy

Antibodies and Immunoglobulins...  
 anti-TNF; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
 useful in treatment and prevention of diseases as well as in  
 combination therapy

Dermatitis...  
 atopic; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
 useful in treatment and prevention of diseases as well as in  
 combination therapy

Mental and behavioral disorders...  
 autism; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
 useful in treatment and prevention of diseases as well as in  
 combination therapy

Anemia(disease)... Anemia(disease)... Autoimmune disease... Autoimmune  
 disease...  
 autoimmune hemolytic anemia; prepn. of pyrrolopyrimidines as protein  
 kinase inhibitors useful in treatment and prevention of diseases as  
 well as in combination therapy

Autoimmune disease...  
 autoimmune thrombocytopenia, neonatal; prepn. of pyrrolopyrimidines as  
 protein kinase inhibitors useful in treatment and prevention of  
 diseases as well as in combination therapy

Autoimmune disease... Inflammation... Thyroid gland,disease...  
 autoimmune thyroiditis; prepn. of pyrrolopyrimidines as protein kinase  
 inhibitors useful in treatment and prevention of diseases as well as in  
 combination therapy

Skin,disease...  
 bullous pemphigoid; prepn. of pyrrolopyrimidines as protein kinase  
 inhibitors useful in treatment and prevention of diseases as well as in  
 combination therapy

Disease,animal...  
 cardiomyopathy syndrome; prepn. of pyrrolopyrimidines as protein kinase  
 inhibitors useful in treatment and prevention of diseases as well as in  
 combination therapy

Viral hepatitis...  
 chronic active; prepn. of pyrrolopyrimidines as protein kinase  
 inhibitors useful in treatment and prevention of diseases as well as in  
 combination therapy

Intestine,neoplasm...  
 colon; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful  
 in treatment and prevention of diseases as well as in combination  
 therapy

Intestine,neoplasm...  
 colorectal; prepn. of pyrrolopyrimidines as protein kinase inhibitors  
 useful in treatment and prevention of diseases as well as in

combination therapy

Diabetes mellitus...  
complications from; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Fusion proteins(chimeric proteins)...  
constructed from CD40 and gp39; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Inflammation...  
Crohn's disease; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Intestine,disease...  
Crohn's; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Fusion proteins(chimeric proteins)...  
CTLA4-Ig; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Blood,disease...  
cytopenia, autoimmune; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Nervous system,disease...  
degeneration; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Platelet(blood)...  
disease, autoimmune thrombocytopenia, neonatal; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Blood cell...  
disease, cytopenia, autoimmune; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Immunity...  
disorders; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Macrolides...  
epothilones; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Autoimmune disease...  
exptl. autoimmune encephalomyelitis; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Encephalomyelitis...  
exptl. autoimmune; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Enzymes...  
FLK-4 kinase; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Inflammation... Kidney,disease...  
glomerulonephritis; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Kidney,disease...

Goodpasture's syndrome; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Glycoproteins...

gp39; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Transplant and Transplantation...

graft-vs.-host reaction; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Nervous system,disease...

Guillain-Barre syndrome; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Neoplasm...

head and neck; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Anemia(disease)...

hemolytic; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Cytoprotective agents...

hepatoprotective agents; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Allergy...

hypersensitivity, T-cell mediated; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Purpura(disease)...

idiopathic thrombocytopenic; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Addison's disease...

idiopathic; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Allergy...

immediate hypersensitivity; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Tumor necrosis factors...

inhibitors; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Reperfusion...

injury, incurred during organ transplantation; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Autoimmune disease...

insulin-dependent diabetes mellitus; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Diabetes mellitus...

insulin-dependent; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Kidney...

mesangium, proliferative disorders; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Connective tissue,disease...

mixed connective tissue disease; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Antibodies and Immunoglobulins...

monoclonal, OKT3; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

(etc.)...

CAS REGISTRY NUMBERS:

7440-57-5D compds., prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

150977-45-0D fusion with Gst, GST-Flk1; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

9031-44-1 329900-75-6 inhibitors; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

50-07-7 50-44-2 51-21-8 54-62-6 57-22-7 59-05-2 96-22-0 99-05-8  
107-11-9 109-01-3 109-04-6 147-94-4 148-82-3 364-76-1 402-67-5  
518-28-5 577-72-0 616-24-0 617-89-0 801-52-5 927-80-0 2028-63-9  
2410-93-7 2955-88-6P 4744-08-5 7154-73-6 9059-09-0 10160-87-9  
13889-98-0 14254-57-0 15228-71-4 15663-27-1 20830-81-3 23214-92-8  
23326-27-4 23360-92-1 23499-01-6P 26905-03-3 27301-54-8 29767-20-2  
33069-62-4 33419-42-0 34334-19-5P 36082-50-5 39856-50-3 41575-94-4  
49845-33-2 50609-01-3P 50935-04-1 53123-88-9 53643-48-4 59865-13-3  
64099-82-7 64724-29-4 75706-12-6 79079-06-4 79421-45-7 80449-02-1  
88201-45-0 92394-00-8 95058-81-4 98037-52-6 101463-26-7  
103843-29-4 104775-65-7P 104987-11-3 108891-60-7 112677-72-2P  
114051-78-4 114899-77-3 117091-64-2 128794-94-5 137632-03-2  
137632-06-5 137632-09-8 138238-67-2 138359-29-2 139691-76-2  
140208-17-9 141349-86-2 141349-87-3 141349-89-5 141349-91-9  
141350-03-0 141436-78-4 141460-90-4 142243-02-5 143375-65-9  
143597-35-7 144114-11-4 144114-16-9 144697-17-6 144941-32-2  
144941-35-5 145539-86-2 146702-84-3 147014-95-7 147014-96-8  
147014-97-9 148047-29-4 148047-34-1 149146-03-2 149146-92-9  
149147-12-6 149147-16-0 150027-15-9 150316-06-6 150428-23-2  
150977-45-0 151769-13-0 152478-56-3 152478-57-4 152743-99-2  
153190-51-3 153190-61-5 153190-71-7 153570-69-5 155215-87-5  
155948-74-6 157482-36-5 160647-73-4P 161384-16-3 165245-96-5  
165245-99-8 170780-46-8 170911-92-9 182372-13-0 182938-13-2  
221198-99-8 303014-92-8 330197-29-0 372092-80-3 373824-30-7P  
386705-49-3 403652-37-9 519003-68-0P 571188-59-5 571189-49-6P  
657410-79-2P 733039-20-8 885693-22-1P 890652-00-3P 900507-37-1P  
909562-81-8P 926200-11-5P 926211-47-4P 926227-55-6P 959795-56-3P  
959795-57-4P 959795-58-5P 959795-59-6P 959795-60-9P 959795-61-0P  
959795-62-1P 959795-63-2P 959795-64-3P 959795-65-4P 959795-66-5P  
959795-67-6P 959795-68-7P 959795-69-8P 959795-70-1P 959795-71-2P  
959795-72-3P 959795-73-4P 959795-74-5P 959795-75-6P 959795-76-7P  
959795-77-8P 959795-78-9P 959795-79-0P 959795-80-3P 959795-81-4P  
959795-82-5P 959795-83-6P 959795-84-7P 959795-85-8P 959795-86-9P  
959795-87-0P 959795-88-1P 959795-89-2P 959795-90-5P 959795-91-6P  
959795-92-7P 959795-93-8P 959795-94-9P 959795-95-0P 959795-96-1P  
959795-97-2P 959795-98-3P 959795-99-4P 959796-00-0P 959796-01-1P  
959796-02-2P 959796-03-3P 959796-04-4P 959796-05-5P 959796-06-6P  
959796-07-7P 959796-08-8P 959796-09-9P 959796-10-2P 959796-11-3P  
959796-12-4P 959796-13-5P 959796-14-6P 959796-15-7P 959796-16-8P

959796-17-9P	959796-18-0P	959796-19-1P	959796-20-4P	959796-21-5P
959796-22-6P	959796-23-7P	959796-24-8P	959796-25-9P	959796-26-0P
959796-27-1P	959796-28-2P	959796-29-3P	959796-30-6P	959796-31-7P
959796-32-8P	959796-33-9P	959796-34-0P	959796-35-1P	959796-36-2P
959796-37-3P	959796-38-4P	959796-39-5P	959796-40-8P	959796-41-9P
959796-42-0P	959796-43-1P	959796-44-2P	959796-45-3P	959796-46-4P
959796-47-5P	959796-48-6P	959796-49-7P	959796-50-0P	959796-51-1P
959796-52-2P	959796-53-3P	959796-54-4P	959796-55-5P	959796-56-6P
959796-57-7P	959796-58-8P	959796-59-9P	959796-60-2P	959796-61-3P
959796-62-4P	959796-63-5P	959796-64-6P	959796-65-7P	959796-66-8P
959796-67-9P	959796-68-0P	959796-69-1P	959796-70-4P	959796-71-5P
959796-72-6P	959796-73-7P	959796-74-8P	959796-75-9P	959796-76-0P
959796-77-1P	959796-78-2P	959796-79-3P	959796-80-6P	959796-81-7P
959796-82-8P	959796-83-9P	959796-84-0P	959796-85-1P	959796-86-2P
959796-87-3P	959796-88-4P	959796-89-5P	959796-90-8P	959796-91-9P
959796-92-0P	959796-93-1P	959796-94-2P	959796-95-3P	959796-96-4P
959796-97-5P	959796-98-6P	959796-99-7P	959797-00-3P	959797-01-4P
959797-02-5P	959797-03-6P	959797-04-7P	959797-05-8P	959797-06-9P
959797-07-0P	959797-08-1P	959797-09-2P	959797-10-5P	959797-11-6P
959797-12-7P	959797-13-8P	959797-14-9P	959797-15-0P	959797-16-1P
959797-17-2P	959797-18-3P	959797-19-4P	959797-20-7P	959797-21-8P
959797-22-9P	959797-23-0P	959797-24-1P	959797-25-2P	959797-26-3P
959797-27-4P	959797-28-5P	959797-29-6P	959797-30-9P	959797-31-0P
959797-32-1P	959797-33-2P	959797-34-3P	959797-35-4P	959797-36-5P
959797-37-6P	959797-38-7P	959797-39-8P	959797-40-1P	959797-41-2P
959797-42-3P	959797-43-4P	959797-44-5P	959797-45-6P	959797-46-7P
959797-47-8P	959797-48-9P	959797-49-0P	959797-50-3P	959797-51-4P
959797-52-5P	959797-53-6P	959797-54-7P	959797-55-8P	959797-56-9P
959797-57-0P	959797-58-1P	959797-59-2P	959797-60-5P	959797-61-6P
959797-62-7P	959797-63-8P	959797-64-9P	959797-65-0P	959797-66-1P
959797-67-2P	959797-68-3P	959797-69-4P	959797-70-7P	959797-71-8P
959797-72-9P	959797-73-0P	959797-74-1P	959797-75-2P	959797-76-3P
959797-77-4P	959797-78-5P	959797-79-6P	959797-80-9P	959797-81-0P
959797-82-1P	959797-83-2P	959797-84-3P	959797-85-4P	959797-86-5P
959797-87-6P	959797-88-7P	959797-89-8P	959797-90-1P	959797-91-2P
959797-92-3P	959797-93-4P	959797-94-5P	959797-95-6P	959797-96-7P
959797-97-8P	959797-98-9P	959797-99-0P	959798-00-6P	959798-01-7P
959798-02-8P	959798-03-9P	959798-04-0P	959798-05-1P	959798-06-2P
959798-07-3P	959798-08-4P	959798-09-5P	959798-10-8P	959798-11-9P
959798-12-0P	959798-13-1P	959798-14-2P	959798-15-3P	959798-16-4P
959798-17-5P	959798-18-6P	959798-19-7P	959798-20-0P	959798-21-1P
959798-22-2P	959798-23-3P	959798-24-4P	959798-25-5P	959798-26-6P
959798-27-7P	959798-28-8P	959798-29-9P	959798-30-2P	959798-31-3P
959798-32-4P	959798-33-5P	959798-34-6P	959798-35-7P	959798-36-8P
959798-37-9P	959798-38-0P	959798-40-4P	959798-42-6P	959798-43-7P
959798-44-8P	959798-45-9P	959798-46-0P	959798-47-1P	959798-48-2P
959798-49-3P	959798-50-6P	959798-51-7P	959798-52-8P	959798-53-9P
959798-54-0P	959798-55-1P	959798-56-2P	959798-57-3P	959798-58-4P
959798-59-5P	959798-60-8P	959798-61-9P	959798-62-0P	959798-63-1P
959798-64-2P	959798-65-3P	959798-66-4P	959798-67-5P	959798-68-6P
959798-69-7P	959798-70-0P	959798-71-1P	959798-72-2P	959798-73-3P
959798-74-4P	959798-75-5P	959798-76-6P	959798-77-7P	959798-78-8P
959798-79-9P	959798-80-2P	959798-81-3P	959798-82-4P	959798-83-5P
959798-84-6P	959798-85-7P	959798-86-8P	959798-87-9P	959798-88-0P
959798-89-1P	959798-90-4P	959798-91-5P	959798-92-6P	959798-93-7P
959798-94-8P	959798-95-9P	959798-96-0P	959798-97-1P	959798-98-2P
959798-99-3P	959799-00-9P	959799-01-0P	959799-02-1P	959799-03-2P
959799-04-3P	959799-05-4P	959799-06-5P	959799-07-6P	959799-08-7P
959799-09-8P	959799-10-1	959799-11-2	959799-12-3P	959799-13-4P
959799-14-5P	959799-15-6P	959799-16-7P	959799-17-8P	959799-18-9P
959799-19-0P	959799-20-3P	959799-22-5P	959799-24-7P	959799-26-9P

959799-28-1P 959799-30-5P 959799-31-6 959799-32-7P 959799-33-8P  
prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in  
treatment and prevention of diseases as well as in combination therapy  
100-02-7 reactions, prepn. of pyrrolopyrimidines as protein kinase  
inhibitors useful in treatment and prevention of diseases as well as in  
combination therapy

6/7/10 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

147534655 CA: 147(26)534655d PATENT  
Use of a compound with receptor activator of nuclear factor-kB ligand  
(RANKL) activity  
INVENTOR(AUTHOR): Penninger, Josef; Loser, Karin; Beissert, Stefan  
LOCATION: Austria  
ASSIGNEE: Imba-Institut Fuer Molekulare Biotechnologie GmbH  
PATENT: PCT International ; WO 2007128564 A2 DATE: 20071115  
APPLICATION: WO 2007EP4045 (20070508) \*EP 2006450071 (20060508)  
PAGES: 44pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0031/00	A	I	F	B	20060101		H	EP
A61P-0037/00	A	I	L	B	20060101		H	EP
A61P-0017/00	A	I	L	B	20060101		H	EP
A61K-0038/20	A	I	L	B	20060101		H	EP
A61K-0038/16	A	I	L	B	20060101		H	EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;  
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;  
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;  
NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;  
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

SECTION:

CA201007 Pharmacology

IDENTIFIERS: RANKL regulatory T cell modulation antiinflammatory skin  
disease treatment

DESCRIPTORS:

Keratosis...

actinic; compd. with RANKL activity for treatment of inflammatory and  
skin disease

Allergy...

allergic contact dermatitis; compd. with RANKL activity for treatment  
of inflammatory and skin disease

Dermatitis...

allergic contact; compd. with RANKL activity for treatment of  
inflammatory and skin disease

Interleukin 2 receptors...

$\alpha$  chain; compd. with RANKL activity for treatment of inflammatory  
and skin disease

Antiartherosclerotics...

antiatherosclerotics; compd. with RANKL activity for treatment of  
inflammatory and skin disease

Alopecia...

areata, ophiasis-type; compd. with RANKL activity for treatment of  
inflammatory and skin disease



Alopecia...  
     areata; compd. with RANKL activity for treatment of inflammatory and skin disease

Dermatitis...  
     atopic; compd. with RANKL activity for treatment of inflammatory and skin disease

Autoimmune disease... Inflammation... Thyroid gland,disease...  
     autoimmune thyroiditis; compd. with RANKL activity for treatment of inflammatory and skin disease

Dermatitis... Liver,disease...  
     autoimmune; compd. with RANKL activity for treatment of inflammatory and skin disease

Infection...  
     bacterial, bacterial inflammation; compd. with RANKL activity for treatment of inflammatory and skin disease

Cirrhosis...  
     biliary; compd. with RANKL activity for treatment of inflammatory and skin disease

Psoriasis...  
     capitis; compd. with RANKL activity for treatment of inflammatory and skin disease

CD antigens...  
     CD103; compd. with RANKL activity for treatment of inflammatory and skin disease

Glycoproteins...  
     CD40-L (antigen CD40 ligand); compd. with RANKL activity for treatment of inflammatory and skin disease

Acne... Allergy inhibitors... Allergy... Antidiabetic agents...  
 Antirheumatic agents... Antitumor agents... Anti-inflammatory agents...  
 Atherosclerosis... Autoimmune disease... Autoimmune hepatitis...  
 Cardiovascular agents... CD45RB(antigen)... CD4(antigen)... CD4-positive T cell... CD86(antigen)... CTLA-4(antigen)... Dermatitis... Dermatomyositis  
 ... Drug toxicity... Eczema... Gastrointestinal agents... Genetic engineering... Human herpesvirus... Human... Immunomodulators...  
 Inflammation... Interleukin 10... Interleukin 17... Interleukin 1...  
 Interleukin 6... Interleukins... Keloid... Multiple sclerosis...  
 Myocarditis... Nervous system agents... Prophylaxis... Psoriasis...  
 Rheumatoid arthritis... Scleroderma... Skin,disease... Skin,neoplasm...  
 Sunburn... Tumor necrosis factors... Urticaria... Uveitis... Vitiligo...  
     compd. with RANKL activity for treatment of inflammatory and skin disease

Dermatitis...  
     contact, irritative; compd. with RANKL activity for treatment of inflammatory and skin disease

Dermatitis...  
     contact; compd. with RANKL activity for treatment of inflammatory and skin disease

Drug delivery systems...  
     creams; compd. with RANKL activity for treatment of inflammatory and skin disease

Lupus erythematosus...  
     cutaneous; compd. with RANKL activity for treatment of inflammatory and skin disease

Antigen receptors...  
     DEC-205 (dendritic epidermal cell, 205 kDa); compd. with RANKL activity for treatment of inflammatory and skin disease

Alopecia...  
     diffusa; compd. with RANKL activity for treatment of inflammatory and skin disease

Eczema...  
     dihidrotic; compd. with RANKL activity for treatment of inflammatory

and skin disease  
Drug delivery systems...  
emulsions; compd. with RANKL activity for treatment of inflammatory and skin disease  
Keratosis...  
epidermolytic hyperkeratosis; compd. with RANKL activity for treatment of inflammatory and skin disease  
Skin,disease...  
erythema nodosum; compd. with RANKL activity for treatment of inflammatory and skin disease  
Drug delivery systems...  
foams; compd. with RANKL activity for treatment of inflammatory and skin disease  
Interferons...  
 $\gamma$ ; compd. with RANKL activity for treatment of inflammatory and skin disease  
Drug delivery systems...  
gels; compd. with RANKL activity for treatment of inflammatory and skin disease  
Inflammation... Kidney,disease...  
glomerulonephritis; compd. with RANKL activity for treatment of inflammatory and skin disease  
Transplant and Transplantation...  
graft-vs.-host reaction; compd. with RANKL activity for treatment of inflammatory and skin disease  
Psoriasis...  
guttata; compd. with RANKL activity for treatment of inflammatory and skin disease  
Autoimmune disease...  
hepatic; compd. with RANKL activity for treatment of inflammatory and skin disease  
Dermatitis...  
herpetiformis, Duhring; compd. with RANKL activity for treatment of inflammatory and skin disease  
Keratosis...  
hyperkeratosis, hyperkeratosis lenticularis perstans; compd. with RANKL activity for treatment of inflammatory and skin disease  
Keratosis...  
hyperkeratosis; compd. with RANKL activity for treatment of inflammatory and skin disease  
Allergy...  
hypersensitivity; compd. with RANKL activity for treatment of inflammatory and skin disease  
Histocompatibility antigens...  
I-A; compd. with RANKL activity for treatment of inflammatory and skin disease  
Skin,disease...  
ichthyosis; compd. with RANKL activity for treatment of inflammatory and skin disease  
Antibodies and Immunoglobulins...  
IgA, linear IgA dermatosis; compd. with RANKL activity for treatment of inflammatory and skin disease  
Irritants... Radiation... UV radiation...  
inflammation caused by; compd. with RANKL activity for treatment of inflammatory and skin disease  
Intestine,disease...  
inflammatory; compd. with RANKL activity for treatment of inflammatory and skin disease  
Autoimmune disease...  
insulin-dependent diabetes mellitus; compd. with RANKL activity for treatment of inflammatory and skin disease

Diabetes mellitus...  
insulin-dependent; compd. with RANKL activity for treatment of  
inflammatory and skin disease

Psoriasis...  
inversa; compd. with RANKL activity for treatment of inflammatory and  
skin disease

Skin...  
keratinocyte; compd. with RANKL activity for treatment of inflammatory  
and skin disease

Skin...  
Langerhans cell; compd. with RANKL activity for treatment of  
inflammatory and skin disease

Skin,disease...  
lichen planus; compd. with RANKL activity for treatment of inflammatory  
and skin disease

Skin,disease...  
lichen sclerosus et atrophicans; compd. with RANKL activity for  
treatment of inflammatory and skin disease

Skin,disease...  
lichen vidal; compd. with RANKL activity for treatment of inflammatory  
and skin disease

Skin,disease...  
lichen; compd. with RANKL activity for treatment of inflammatory and  
skin disease

Skin,disease...  
linear IgA dermatosis; compd. with RANKL activity for treatment of  
inflammatory and skin disease

Drug delivery systems...  
liposomes; compd. with RANKL activity for treatment of inflammatory and  
skin disease

Drug delivery systems...  
lotions; compd. with RANKL activity for treatment of inflammatory and  
skin disease

Alopecia...  
male pattern; compd. with RANKL activity for treatment of inflammatory  
and skin disease

Skin,disease...  
morphea; compd. with RANKL activity for treatment of inflammatory and  
skin disease

Skin,disease...  
necrobiosis lipoidica; compd. with RANKL activity for treatment of  
inflammatory and skin disease

Drug delivery systems...  
ointments; compd. with RANKL activity for treatment of inflammatory and  
skin disease

Drug delivery systems...  
pastes; compd. with RANKL activity for treatment of inflammatory and  
skin disease

Skin,disease...  
pemphigoid, bullous; compd. with RANKL activity for treatment of  
inflammatory and skin disease

Skin,disease...  
pemphigoid, mucous; compd. with RANKL activity for treatment of  
inflammatory and skin disease

Skin,disease...  
pemphigoid, scarring mucosal; compd. with RANKL activity for treatment  
of inflammatory and skin disease

Skin,disease...  
pemphigus foliaceus; compd. with RANKL activity for treatment of  
inflammatory and skin disease

Skin,disease...

pemphigus, vegetans; compd. with RANKL activity for treatment of inflammatory and skin disease

CAS REGISTRY NUMBERS:

53-06-5 67-97-0 363-24-6 207621-35-0 214210-47-6 compd. with RANKL activity for treatment of inflammatory and skin disease  
53-06-5D derivs., compd. with RANKL activity for treatment of inflammatory and skin disease  
956655-07-5 956655-08-6 956655-09-7 956655-10-0 956655-11-1  
956655-12-2 956655-13-3 956655-15-5 unclaimed sequence; use of a compd. with receptor activator of nuclear factor-kB ligand (RANKL) activity

6/7/11 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146006355 CA: 146(1)6355z PATENT

Biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

INVENTOR(AUTHOR): Aukerman, Sharon Lea; Jallal, Bahija; Luqman, Mohammad

LOCATION: USA

ASSIGNEE: Novartis AG; Xoma Technology

PATENT: PCT International ; WO 2006125117 A2 DATE: 20061123

APPLICATION: WO 2006US19325 (20060518) \*US 2005PV682575 (20050518) \*US 2005PV749336 (20051209)

PAGES: 145pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

G01N-0033/564 A I F B 20060101 H EP

G01N-0033/68 A I L B 20060101 H EP

A61P-0037/00 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

SECTION:

CA215008 Immunochemistry

CA201XXX Pharmacology

IDENTIFIERS: autoimmune inflammatory disease diagnosis treatment CD40 signaling, monoclonal antibody CD40 autoimmune disease inflammation, biomarker apoptosis survival signaling CD40 autoimmune inflammation

DESCRIPTORS:

Inflammation... Spinal column,disease...

ankylosing spondylitis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Dermatitis...

atopic; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Anemia(disease)... Autoimmune disease...

autoimmune hemolytic anemia; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive

to anti-CD40 monoclonal antibodies

Autoimmune disease... Inflammation... Thyroid gland,disease...  
autoimmune thyroiditis; biomarkers for diagnosis and treatment of  
diseases having an autoimmune and/or inflammatory component responsive  
to anti-CD40 monoclonal antibodies

Hepatitis...  
autoimmune; biomarkers for diagnosis and treatment of diseases having  
an autoimmune and/or inflammatory component responsive to anti-CD40  
monoclonal antibodies

Proteins...  
Bcl-xL, biomarker for cell survival; biomarkers for diagnosis and  
treatment of diseases having an autoimmune and/or inflammatory  
component responsive to anti-CD40 monoclonal antibodies

Proteins...  
Bcl-2, biomarker for cell survival; biomarkers for diagnosis and  
treatment of diseases having an autoimmune and/or inflammatory  
component responsive to anti-CD40 monoclonal antibodies

Immunoassay... Nucleic acid hybridization... Radioimmunoassay...  
biomarker detn. by; biomarkers for diagnosis and treatment of diseases  
having an autoimmune and/or inflammatory component responsive to  
anti-CD40 monoclonal antibodies

DNA fragmentation...  
biomarker for apoptosis; biomarkers for diagnosis and treatment of  
diseases having an autoimmune and/or inflammatory component responsive  
to anti-CD40 monoclonal antibodies

Cytokines... Interleukin 10... Interleukin 6... Interleukin 8... Macrophage  
inflammatory protein 1 $\beta$ ... Monocyte chemoattractant protein-1... Tumor  
necrosis factors...  
biomarker for CD40 signaling; biomarkers for diagnosis and treatment of  
diseases having an autoimmune and/or inflammatory component responsive  
to anti-CD40 monoclonal antibodies

Allergy... Alzheimer's disease... Asthma... Atherosclerosis... Autoimmune  
disease... Biomarkers... cDNA sequences... CD40(antigen)... Celiac disease  
... Dermatomyositis... Gout... Graves' disease... Hemolysis... Human...  
Immune disease... Inflammation... Multiple sclerosis... Myasthenia gravis  
... Prognosis... Protein sequences... Psoriasis... Rheumatoid arthritis...  
Sarcoidosis... Thrombolysis... Transplant rejection... Urticaria...  
biomarkers for diagnosis and treatment of diseases having an autoimmune  
and/or inflammatory component responsive to anti-CD40 monoclonal  
antibodies

Apoptosis... Cell proliferation...  
biomarkers; biomarkers for diagnosis and treatment of diseases having  
an autoimmune and/or inflammatory component responsive to anti-CD40  
monoclonal antibodies

Heart,disease...  
cardiomyopathy; biomarkers for diagnosis and treatment of diseases  
having an autoimmune and/or inflammatory component responsive to  
anti-CD40 monoclonal antibodies

Signal transduction,biological...  
CD40-CD40L-mediated biomarkers; biomarkers for diagnosis and treatment  
of diseases having an autoimmune and/or inflammatory component  
responsive to anti-CD40 monoclonal antibodies

Glycoproteins...  
CD40-L (antigen CD40 ligand); biomarkers for diagnosis and treatment of  
diseases having an autoimmune and/or inflammatory component responsive  
to anti-CD40 monoclonal antibodies

Phosphatidylserines...  
cell surface-expressed biomarker for apoptosis; biomarkers for  
diagnosis and treatment of diseases having an autoimmune and/or  
inflammatory component responsive to anti-CD40 monoclonal antibodies

Fatigue,biological...

chronic fatigue syndrome; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Nerve,disease...

chronic inflammatory demyelinating polyneuropathy; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Blood vessel,disease...

Churg-Strauss syndrome; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Proteins...

cIAP-1 (cellular inhibitor of apoptosis protein 1), biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to ant

Dermatitis...

contact; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Inflammation...

Crohn's disease; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Intestine,disease...

Crohn's; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Cryoglobulins...

cryoglobulinemia; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

delayed hypersensitivity; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Lupus erythematosus...

discoid; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Chemiluminescence...

electrochemiluminescence, biomarker detn. by; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Immunoassay...

enzyme-linked immunosorbent assay, biomarker detn. by; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Antibodies and Immunoglobulins...

fragments; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Transplant and Transplantation...

graft-vs.-host reaction; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Heat-shock proteins...

HSP 75, biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Disease,animal...

hyperimmunoglobulinemia E syndrome; biomarkers for diagnosis and

treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

hypersensitivity, type 2; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

hypersensitivity, type 3; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

hypersensitivity, type 4; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Transcription factors...

I $\kappa$ B (inhibitor of NF- $\kappa$ B), phosphorylated, biomarker for CD40 signaling pathway; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component respon

Proteins...

IAP (inhibitor of apoptosis proteins), biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Purpura(disease)...

idiopathic thrombocytopenic; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Myositis...

idiopathic; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

IgE-mediated; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

immediate hypersensitivity; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Intestine,disease...

inflammatory; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Autoimmune disease...

insulin-dependent diabetes mellitus; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Diabetes mellitus...

insulin-dependent; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Lung,disease...

interstitial fibrosis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Rheumatoid arthritis...

juvenile; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Inflammation... Kidney,disease...

lupus nephritis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to

anti-CD40 monoclonal antibodies

Proteins...

Mcl-1 (myeloid cell leukemia sequence-1), biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 mon

Diagnosis...

mol.; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Antibodies and Immunoglobulins...

monoclonal; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Transcription factors...

NF- $\kappa$ B (nuclear factor of  $\kappa$  light chain gene enhancer in B-cells), biomarker for CD40 signaling pathway; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or infla

Diabetes mellitus...

non-insulin-dependent; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Skin,disease...

pemphigus vulgaris; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Artery,disease... Inflammation...

periarteritis nodosa; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Anemia(disease)...

pernicious anemia; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Myositis...

polymyositis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Biliary tract,disease...

primary biliary cirrhosis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Arthritis...

psoriatic arthritis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Fibrosis...

pulmonary interstitial; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Arthritis...

Reiter's syndrome; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Epitopes...

residues 82-87 of human CD40; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

PCR(polymerase chain reaction)...

RT-PCR (reverse transcription-PCR), biomarker detn. by; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibod



Connective tissue,disease...

scleroderma; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Antibodies and Immunoglobulins...

single chain; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

CAS REGISTRY NUMBERS:

915425-15-9 915425-17-1 915425-18-2 915425-19-3 915425-20-6  
915425-21-7 915425-22-8 915425-23-9 amino acid sequence; biomarkers  
for diagnosis and treatment of diseases having an autoimmune and/or  
inflammatory component responsive to anti-CD40 monoclonal antibodies  
142243-02-5 148640-14-6 165245-96-5 biomarker for CD40 signaling  
pathway; biomarkers for diagnosis and treatment of diseases having an  
autoimmune and/or inflammatory component responsive to anti-CD40  
monoclonal antibodies  
83869-56-1 127464-60-2 biomarker for CD40 signaling; biomarkers for  
diagnosis and treatment of diseases having an autoimmune and/or  
inflammatory component responsive to anti-CD40 monoclonal antibodies  
371761-91-0 biomarker for cell survival; biomarkers for diagnosis and  
treatment of diseases having an autoimmune and/or inflammatory  
component responsive to anti-CD40 monoclonal antibodies  
173296-31-6 176630-81-2 220138-87-4 220153-31-1 225541-59-3  
331696-20-9 384417-51-0 384522-15-0 384522-17-2 384581-28-6  
384585-58-4 384661-90-9 384771-52-2 384779-76-4 389189-13-3  
391544-63-1 391961-37-8 391964-48-0 391965-83-6 391965-84-7  
391973-87-8 391974-16-6 392055-61-7 392079-74-2 459530-42-8  
459552-50-2 459598-47-1 459656-13-4 459690-00-7 480530-68-5  
480760-82-5 480954-56-1 520893-87-2 520894-47-7 520896-15-5  
624651-71-4 624653-99-2 biomarkers for diagnosis and treatment of  
diseases having an autoimmune and/or inflammatory component responsive  
to anti-CD40 monoclonal antibodies  
9055-67-8D 169592-56-7D 180189-96-2D 186322-81-6D 189258-14-8D  
cleaved, biomarker for apoptosis; biomarkers for diagnosis and  
treatment of diseases having an autoimmune and/or inflammatory  
component responsive to anti-CD40 monoclonal antibodies  
915425-14-8 915425-16-0 nucleotide sequence; biomarkers for diagnosis and  
treatment of diseases having an autoimmune and/or inflammatory  
component responsive to anti-CD40 monoclonal antibodies  
115926-52-8D 191808-15-8D 362516-16-3D 362517-43-9D phosphorylated,  
biomarker for CD40 signaling pathway; biomarkers for diagnosis and  
treatment of diseases having an autoimmune and/or inflammatory  
component responsive to anti-CD40 monoclonal antibodies  
915425-75-1 915425-76-2 915425-77-3 915425-79-5 unclaimed nucleotide  
sequence; biomarkers for diagnosis and treatment of diseases having an  
autoimmune and/or inflammatory component responsive to anti-CD40  
monoclonal antibodies  
915425-78-4 915425-80-8 unclaimed protein sequence; biomarkers for  
diagnosis and treatment of diseases having an autoimmune and/or  
inflammatory component responsive to anti-CD40 monoclonal antibodies

6/7/12 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

145055995 CA: 145(4)55995w PATENT

Modulation of Fc gamma receptors for optimizing immunotherapy

INVENTOR(AUTHOR): Boruchov, Adam; Young, James W.

LOCATION: USA

ASSIGNEE: Memorial Sloan-Kettering Cancer Center  
PATENT: European Pat. Appl. ; EP 1674479 A1 DATE: 20060628  
APPLICATION: EP 2005250446 (20050128) \*US 2004PV638422 (20041222) \*US  
2004PV640685 (20041230) \*US 2005PV647616 (20050127)  
PAGES: 77 pp. CODEN: EPXXDW LANGUAGE: English  
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;  
SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR; BG; CZ; EE; HU; PL; SK;  
BA; HR; IS; YU  
SECTION:  
CA201012 Pharmacology  
CA202XXX Mammalian Hormones  
CA214XXX Mammalian Pathological Biochemistry  
CA215XXX Immunochemistry  
IDENTIFIERS: Fc gamma receptor modulator dendritic cell maturation  
immunotherapy autoimmune disease, antitumor antiinfective dendritic  
cell maturation prevention cancer infection vaccine  
DESCRIPTORS:  
Monocyte...  
-derived dendritic cell; modulation of Fc gamma receptors for  
optimizing immunotherapy  
Antibodies and Immunoglobulins...  
agammaglobulinemia, primary; modulation of Fc gamma receptors for  
optimizing immunotherapy  
Immunity... Disease, animal...  
agglutinin disease, cold; modulation of Fc gamma receptors for  
optimizing immunotherapy  
Interferons...  
 $\alpha$ ; modulation of Fc gamma receptors for optimizing immunotherapy  
Spinal column, disease... Inflammation...  
ankylosing spondylitis; modulation of Fc gamma receptors for optimizing  
immunotherapy  
Antibodies and Immunoglobulins...  
anti-CD32a; modulation of Fc gamma receptors for optimizing  
immunotherapy  
Antibodies and Immunoglobulins...  
anti-CD32b; modulation of Fc gamma receptors for optimizing  
immunotherapy  
Vaccines...  
antiinfectives; modulation of Fc gamma receptors for optimizing  
immunotherapy  
Alopecia...  
areata; modulation of Fc gamma receptors for optimizing immunotherapy  
Artery, disease... Inflammation...  
arteritis, giant cell; modulation of Fc gamma receptors for optimizing  
immunotherapy  
Artery, disease... Inflammation...  
arteritis, takayasu; modulation of Fc gamma receptors for optimizing  
immunotherapy  
Artery, disease... Inflammation...  
arteritis, temporal; modulation of Fc gamma receptors for optimizing  
immunotherapy  
Immunosuppression...  
assocd. with alc. consumption prior to burn injuries; modulation of Fc  
gamma receptors for optimizing immunotherapy  
Muscle, disease...  
atrophy, cancer-related; modulation of Fc gamma receptors for  
optimizing immunotherapy  
Anemia(disease)... Autoimmune disease...  
autoimmune hemolytic anemia; modulation of Fc gamma receptors for  
optimizing immunotherapy  
Autoimmune disease... Ovary, disease... Inflammation...

- autoimmune oophoritis; modulation of Fc gamma receptors for optimizing immunotherapy
- Autoimmune disease...
  - autoimmune thrombocytopenia; modulation of Fc gamma receptors for optimizing immunotherapy
- Thyroid gland,disease... Autoimmune disease... Inflammation...
  - autoimmune thyroiditis; modulation of Fc gamma receptors for optimizing immunotherapy
- Addison's disease... Adrenal gland,disease... Hepatitis...
  - autoimmune; modulation of Fc gamma receptors for optimizing immunotherapy
- Immunity...
  - autoimmunity; modulation of Fc gamma receptors for optimizing immunotherapy
- Interferons...
  - $\beta$ ; modulation of Fc gamma receptors for optimizing immunotherapy
- Transforming growth factors...
  - $\beta$ -; modulation of Fc gamma receptors for optimizing immunotherapy
- Transplant and Transplantation...
  - bone marrow; modulation of Fc gamma receptors for optimizing immunotherapy
- Skin,disease...
  - bullous pemphigoid; modulation of Fc gamma receptors for optimizing immunotherapy
- Immunosuppression...
  - burn-induced; modulation of Fc gamma receptors for optimizing immunotherapy
- Cachexia... Anorexia...
  - cancer-related; modulation of Fc gamma receptors for optimizing immunotherapy
- Heart,disease...
  - cardiomyopathy; modulation of Fc gamma receptors for optimizing immunotherapy
- Lymph node,disease...
  - Castleman's; modulation of Fc gamma receptors for optimizing immunotherapy
- Glycoproteins...
  - CD40-L (antigen CD40 ligand); modulation of Fc gamma receptors for optimizing immunotherapy
- CD antigens...
  - CD83; modulation of Fc gamma receptors for optimizing immunotherapy
- Fatigue,biological...
  - chronic fatigue syndrome; modulation of Fc gamma receptors for optimizing immunotherapy
- Blood vessel,disease...
  - Churg-Strauss syndrome; modulation of Fc gamma receptors for optimizing immunotherapy
- Cryoglobulins...
  - cryoglobulinemia; modulation of Fc gamma receptors for optimizing immunotherapy
- Lupus erythematosus...
  - discoid; modulation of Fc gamma receptors for optimizing immunotherapy
- Platelet(blood)...
  - disease, autoimmune thrombocytopenia; modulation of Fc gamma receptors for optimizing immunotherapy
- Flow cytometry...
  - FACS (fluorescence-activated cell sorting); modulation of Fc gamma receptors for optimizing immunotherapy
- Muscle,disease...
  - fibromyalgia; modulation of Fc gamma receptors for optimizing immunotherapy

Lung,disease...  
    fibrosis; modulation of Fc gamma receptors for optimizing immunotherapy  
Interferons...  
     $\gamma$ ; modulation of Fc gamma receptors for optimizing immunotherapy  
Kidney,disease... Inflammation...  
    glomerulonephritis; modulation of Fc gamma receptors for optimizing immunotherapy  
Transplant and Transplantation...  
    graft-vs.-host reaction; modulation of Fc gamma receptors for optimizing immunotherapy  
Nervous system,disease...  
    Guillain-Barre syndrome; modulation of Fc gamma receptors for optimizing immunotherapy  
Dermatitis...  
    herpetiformis; modulation of Fc gamma receptors for optimizing immunotherapy  
Purpura(disease)...  
    idiopathic thrombocytopenic; modulation of Fc gamma receptors for optimizing immunotherapy  
Antibodies and Immunoglobulins...  
    IgA; modulation of Fc gamma receptors for optimizing immunotherapy  
Antibodies and Immunoglobulins...  
    IgG, complexed; modulation of Fc gamma receptors for optimizing immunotherapy  
Antibodies and Immunoglobulins...  
    IgG, immobilized; modulation of Fc gamma receptors for optimizing immunotherapy  
Antibodies and Immunoglobulins...  
    IgG, sol. monomers of; modulation of Fc gamma receptors for optimizing immunotherapy  
Antibodies and Immunoglobulins...  
    IgG; modulation of Fc gamma receptors for optimizing immunotherapy  
Antibodies and Immunoglobulins...  
    IgG2; modulation of Fc gamma receptors for optimizing immunotherapy  
Antibodies and Immunoglobulins...  
    IgG3; modulation of Fc gamma receptors for optimizing immunotherapy  
Antibodies and Immunoglobulins...  
    IgG4; modulation of Fc gamma receptors for optimizing immunotherapy  
Gene,animal...  
    IL1B; modulation of Fc gamma receptors for optimizing immunotherapy  
Diabetes mellitus...  
    immune-mediated; modulation of Fc gamma receptors for optimizing immunotherapy  
Autoimmune disease...  
    insulin-dependent diabetes mellitus; modulation of Fc gamma receptors for optimizing immunotherapy  
Diabetes mellitus...  
    insulin-dependent; modulation of Fc gamma receptors for optimizing immunotherapy  
Rheumatoid arthritis...  
    juvenile; modulation of Fc gamma receptors for optimizing immunotherapy  
Skin...  
    Langerhans cell; modulation of Fc gamma receptors for optimizing immunotherapy  
Skin,disease... Mouth,disease...  
    lichen planus; modulation of Fc gamma receptors for optimizing immunotherapy  
Disease,animal...  
    Menibre's; modulation of Fc gamma receptors for optimizing immunotherapy  
Connective tissue,disease...

mixed connective tissue disease; modulation of Fc gamma receptors for  
optimizing immunotherapy  
FcγR receptors... Immunotherapy... Autoimmune disease... Antitumor  
agents... Anti-infective agents... Combination chemotherapy... Infection...  
Lipopolysaccharides... FcγRIIb receptors... Immunomodulators...  
FcγRIIa receptors... Signal transduction,biological...  
Antiphospholipid syndrome... Population genetics... Behcet's syndrome...  
Dermatitis... Human... Cytokines... Interleukin 8... Tumor necrosis factors  
... Drug targets... Celiac disease... Graves' disease... Multiple sclerosis  
... Myasthenia gravis... Psoriasis... Sarcoidosis... Sjogren syndrome...  
Dendritic cell... Vitiligo... Vaccines... T cell(lymphocyte)...  
CD4-positive T cell... CD8-positive T cell... Interleukin 10... Interleukin  
6... Anti-AIDS agents... AIDS(disease)... Lymphoma... Transplant and  
Transplantation... Prostate gland,neoplasm... Amyloidosis... Interleukin 2  
... Mus musculus... B cell(lymphocyte)... Blood... FcγRIII receptors  
... FcγRI receptors... Monocyte... Neutrophil... Antifibrotic agents  
... Antirheumatic agents... Antidiabetic agents... Dermatomyositis...  
Antiarthritics... Rheumatoid arthritis... Human immunodeficiency virus...  
Multiple myeloma... Burn... Cytotoxic agents... Neoplasm... Sepsis...  
Alcoholism... Human immunodeficiency virus 1...  
modulation of Fc gamma receptors for optimizing immunotherapy  
Antibodies and Immunoglobulins...  
monoclonal, IV3; modulation of Fc gamma receptors for optimizing  
immunotherapy  
Antibodies and Immunoglobulins...  
monoclonal, 2B6; modulation of Fc gamma receptors for optimizing  
immunotherapy  
CAS REGISTRY NUMBERS:  
363-24-6 modulation of Fc gamma receptors for optimizing immunotherapy

6/7/13 (Item 6 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

143241985 CA: 143(14)241985b PATENT  
Inhibition of T cell activation in the treatment of immunological disease  
by blocking class II MHC antigen function  
INVENTOR(AUTHOR): Chung, Yong-Hoon; Cho, Hoon-Sik; Park, Hong-Gyu; Yi,  
Ki-Wan  
LOCATION: S. Korea  
ASSIGNEE: Medexgen Inc.  
PATENT: PCT International ; WO 200577415 A1 DATE: 20050825  
APPLICATION: WO 2005KR457 (20050218) \*KR 10835 (20040218)  
PAGES: 141 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/395A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU;  
MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG  
SECTION:  
CA201007 Pharmacology  
CA215XXX Immunochemistry  
IDENTIFIERS: T lymphocyte activation inhibition MHCII antigen receptor

binding, immune disorder T lymphocyte activation inhibition

DESCRIPTORS:

T cell(lymphocyte)...

- activation of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

T cell(lymphocyte)...

- activation; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Brain,disease...

- adrenoleukodystrophy, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Interferon receptors...

- $\alpha$ -interferon, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Integrins...

- $\alpha\beta 1$ , inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Spinal column,disease... Inflammation...

- ankylosing spondylitis, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Thyroid gland,disease... Autoimmune disease... Inflammation...

- autoimmune thyroiditis, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Anemia(disease)...

- autoimmune, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Interferon receptors...

- $\beta$ , inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD4(antigen)...

- blocking MHC antigen interaction with; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD antigens...

- CD106, inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD antigens...

- CD27, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Glycoproteins...

- CD40-L (antigen CD40 ligand), inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD antigens...

- CD54, inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Disease models...

- collagen induced arthritis, control of inflammation in; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Inflammation...

- Crohn's disease, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Intestine,disease...  
 Crohn's, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cryoglobulins...  
 cryoglobulinemia, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Arthritis...  
 disease model, control of inflammation in; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Immunity...  
 disorder, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Antibodies and Immunoglobulins...  
 fusion products, with MHC antigen receptors; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD2(antigen)... CTLA-4(antigen)...  
 fusion protein with Igs; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Interferon receptors...  
 γ-interferon, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Proteins...  
 gene LAG3, blocking MHC antigen interaction with; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Kidney,disease...  
 Goodpasture's syndrome, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Transplant and Transplantation...  
 graft-vs.-host reaction, treatment of, control of inflammation in; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cell adhesion molecules...  
 ICAM-1 (intercellular adhesion mol. 1), inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Proteins...  
 ICOS (inducible co-stimulator), inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD28(antigen)... CD40(antigen)... Fas antigen... LFA-1(antigen)...  
 Interleukin 1 receptors... Interleukin 2 receptors... Interleukin 3 receptors... Interleukin 4 receptors... Interleukin 5 receptors...  
 Interleukin 6 receptors... Interleukin 7 receptors... Tumor necrosis factor receptors... Transforming growth factor receptors... Interferon receptors ... Granulocyte-macrophage colony-stimulating factor receptors...  
 Granulocyte colony-stimulating factor receptors... Macrophage colony-stimulating factor receptors... Erythropoietin receptors... MPL receptor...  
 inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD80(antigen)... Fas ligand... Cell adhesion molecules... LFA-3(antigen)...  
 Interleukin 1... Interleukin 2... Interleukin 3... Interleukin 4...  
 Interleukin 5... Interleukin 6... Interleukin 7... Tumor necrosis factors ... Transforming growth factors... Interferons...  
 inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Autoimmune disease...  
insulin-dependent diabetes mellitus, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Diabetes mellitus...  
insulin-dependent, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Receptors...  
LIGHT, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Histocompatibility antigens...  
MHC (major histocompatibility complex), class II, blocking action of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cell adhesion molecules...  
nectin-1, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Antigens...  
OX40L, inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Receptors...  
PD-1, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Proteins...  
PDL-1, inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Skin,disease...  
pemphigus vulgaris, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Interleukin 6 receptors...  
receptor-assocd. glycoprotein gp130, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Connective tissue,disease...  
scleroderma, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Lupus erythematosus...  
systemic, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cell activation...  
T cell; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Purpura(disease)...  
thrombocytopenic, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Autoimmune disease... Transplant rejection... Rheumatoid arthritis... Multiple sclerosis... Myasthenia gravis... Graves' disease... Addison's disease... Vitiligo... Behcet's syndrome...  
treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Tumor necrosis factor receptors...  
type 1, fusion protein with Igs; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Tumor necrosis factor receptors...  
type 2, fusion protein with Igs; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function



Eye,disease... Inflammation...

uveitis, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cell adhesion molecules...

VCAM-1 (vascular cell adhesion mol. 1), inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Receptors...

4-1BB, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CAS REGISTRY NUMBERS:

83869-56-1 143011-72-7 81627-83-0 11096-26-7 9014-42-0 inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function  
863278-37-9 863278-38-0 863278-39-1 863278-40-4 863278-41-5 863278-42-6 863278-43-7 863278-45-9 863278-47-1 863278-49-3 863278-51-7 863278-53-9 863278-56-2 863278-59-5 unclaimed nucleotide sequence; inhibition of T cell activation in the treatment of immunol. disease by blocking class II MHC antigen function  
863278-44-8 863278-46-0 863278-48-2 863278-50-6 863278-52-8 863278-54-0 863278-55-1 863278-57-3 863278-58-4 863278-60-8 unclaimed protein sequence; inhibition of T cell activation in the treatment of immunol. disease by blocking class II MHC antigen function  
863281-19-0 863281-20-3 unclaimed sequence; inhibition of T cell activation in the treatment of immunol. disease by blocking class II MHC antigen function

6/7/14 (Item 7 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142480770 CA: 142(26)480770p PATENT

Antagonistic monoclonal antibodies and derivatives specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror, Isabel

LOCATION: USA

ASSIGNEE: Chiron Corporation

PATENT: PCT International ; WO 200544306 A2 DATE: 20050519

APPLICATION: WO 2004US36957 (20041104) \*US 2003PV517337 (20031104) \*US 2003PV525579 (20031126) \*US 2004PV565710 (20040427)

PAGES: 114 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

CA201XXX Pharmacology

CA203XXX Biochemical Genetics

CA209XXX Biochemical Methods

CA263XXX Pharmaceuticals

IDENTIFIERS: human CD40 antigen monoclonal antibody autoimmune disease  
inflammation allergy

DESCRIPTORS:

Allergy...

allergic asthma; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Allergy...

allergic contact dermatitis; antagonistic monoclonal antibodies and  
derivs. specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Dermatitis...

allergic contact; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Asthma...

allergic; antagonistic monoclonal antibodies and derivs. specific to  
human CD40 antigen for treatment of autoimmune and inflammatory  
diseases

Spinal column,disease... Inflammation...

ankylosing spondylitis; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Human... Corticosteroids,biological studies... CD40(antigen)... Sarcoidosis

... Affinity... Dissociation constant... Nucleic acids... Gout...

Transplant rejection... Autoimmune disease... Rheumatoid arthritis...

Multiple sclerosis... Myasthenia gravis... Drug delivery systems... Celiac

disease... Psoriasis... Graves' disease... Dermatomyositis... Thrombolysis

... Allergy... Asthma... Molecular cloning... DNA sequences... Protein

sequences... Urticaria... Atherosclerosis... Hemolysis... Alzheimer's

disease... Immunosuppressants... Signal transduction,biological...

antagonistic monoclonal antibodies and derivs. specific to human CD40  
antigen for treatment of autoimmune and inflammatory diseases

Structure-activity relationship...

antibody-binding, epitope mapping; antagonistic monoclonal antibodies  
and derivs. specific to human CD40 antigen for treatment of autoimmune  
and inflammatory diseases

Dermatitis...

atopic; antagonistic monoclonal antibodies and derivs. specific to  
human CD40 antigen for treatment of autoimmune and inflammatory  
diseases

Anemia(disease)... Autoimmune disease...

autoimmune hemolytic anemia; antagonistic monoclonal antibodies and  
derivs. specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Thyroid gland,disease... Autoimmune disease... Inflammation...

autoimmune thyroiditis; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Hepatitis...

autoimmune; antagonistic monoclonal antibodies and derivs. specific to  
human CD40 antigen for treatment of autoimmune and inflammatory  
diseases

Heart,disease...

cardiomyopathy; antagonistic monoclonal antibodies and derivs. specific  
to human CD40 antigen for treatment of autoimmune and inflammatory  
diseases

Animal cell...

CD40-expressing; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and

inflammatory diseases

Glycoproteins...  
 CD40-L (antigen CD40 ligand); antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...  
 chimeric; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Hybridoma...  
 CHIR-12.12 or 153.8E2D10D6.12.12 or ATCC No. PTA-5543; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Hybridoma...  
 CHIR-5.9 or 131.2F8.5.9 or ATCC No. PTA-5542; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Fatigue,biological...  
 chronic fatigue syndrome; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Nerve,disease...  
 chronic inflammatory demyelinating polyneuropathy; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Blood vessel,disease...  
 Churg-Strauss syndrome; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Immunoassay...  
 competitive binding assay; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Dermatitis...  
 contact, irritant; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Inflammation...  
 Crohn's disease; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Intestine,disease...  
 Crohn's; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Cryoglobulins...  
 cryoglobulinemia; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...  
 CTLA-4 fusion proteins; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Fusion proteins(chimeric proteins)...  
 CTLA-4-Ig; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Allergy...  
 delayed hypersensitivity, type 1, 2, 3 and 4; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Nerve,disease...  
 demyelination, chronic inflammatory polyneuropathy; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Lupus erythematosus...  
 discoid; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Immune complexes...  
 disease; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Protein motifs...  
 Domain 2 of CD40; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...  
 fragments; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Transplant and Transplantation...  
 graft-vs.-host reaction; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...  
 heavy chain; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...  
 humanized; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Disease,animal...  
 hyperimmunoglobulinemia E syndrome, hyper IgE syndrome; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Purpura(disease)...  
 idiopathic thrombocytopenic; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Myositis...  
 idiopathic; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

CTLA-4(antigen)...  
 Ig fusion proteins; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...  
 IgE, -mediated allergy; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...  
 IgG; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...  
 IgG1; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Autoimmune disease...  
 insulin-dependent diabetes mellitus; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune

and inflammatory diseases

Diabetes mellitus...  
insulin-dependent; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Lung,disease...  
interstitial fibrosis; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Rheumatoid arthritis...  
juvenile; antagonistic monoclonal antibodies and derivs. specific to  
human CD40 antigen for treatment of autoimmune and inflammatory  
diseases

Antibodies and Immunoglobulins...  
light chain; antagonistic monoclonal antibodies and derivs. specific to  
human CD40 antigen for treatment of autoimmune and inflammatory  
diseases

Kidney,disease... Inflammation...  
lupus nephritis; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Epitopes...  
mapping; antagonistic monoclonal antibodies and derivs. specific to  
human CD40 antigen for treatment of autoimmune and inflammatory  
diseases

Antibodies and Immunoglobulins...  
monoclonal; antagonistic monoclonal antibodies and derivs. specific to  
human CD40 antigen for treatment of autoimmune and inflammatory  
diseases

Diabetes mellitus...  
non-insulin-dependent; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Skin,disease...  
pemphigus vulgaris; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Artery,disease... Inflammation...  
periarteritis nodosa; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Anemia(disease)...  
pernicious anemia; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Myositis...  
polymyositis; antagonistic monoclonal antibodies and derivs. specific  
to human CD40 antigen for treatment of autoimmune and inflammatory  
diseases

Nerve,disease...  
polyneuropathy, chronic inflammatory demyelinating; antagonistic  
monoclonal antibodies and derivs. specific to human CD40 antigen for  
treatment of autoimmune and inflammatory diseases

Biliary tract,disease...  
primary biliary cirrhosis; antagonistic monoclonal antibodies and  
derivs. specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Arthritis...  
psoriatic arthritis; antagonistic monoclonal antibodies and derivs.  
specific to human CD40 antigen for treatment of autoimmune and  
inflammatory diseases

Fibrosis...  
 pulmonary interstitial; antagonistic monoclonal antibodies and derivs.  
 specific to human CD40 antigen for treatment of autoimmune and  
 inflammatory diseases

Arthritis...  
 Reiter's syndrome; antagonistic monoclonal antibodies and derivs.  
 specific to human CD40 antigen for treatment of autoimmune and  
 inflammatory diseases

Connective tissue,disease...  
 scleroderma; antagonistic monoclonal antibodies and derivs. specific to  
 human CD40 antigen for treatment of autoimmune and inflammatory  
 diseases

B cell(lymphocyte)...  
 stimulator; antagonistic monoclonal antibodies and derivs. specific to  
 human CD40 antigen for treatment of autoimmune and inflammatory  
 diseases

Lupus erythematosus...  
 systemic; antagonistic monoclonal antibodies and derivs. specific to  
 human CD40 antigen for treatment of autoimmune and inflammatory  
 diseases

CAS REGISTRY NUMBERS:  
 852007-27-3P 852007-29-5P 852007-30-8P 852007-31-9P 852007-32-0P  
 852007-33-1P 852007-35-3P 852007-37-5P amino acid sequence;  
 antagonistic monoclonal antibodies and derivs. specific to human CD40  
 antigen for treatment of autoimmune and inflammatory diseases

59865-13-3 104987-11-3 53123-88-9 356547-88-1 852006-91-8 851779-28-7  
 851779-29-8 antagonistic monoclonal antibodies and derivs. specific to  
 human CD40 antigen for treatment of autoimmune and inflammatory  
 diseases

852007-26-2P 852007-28-4P 852007-34-2P 852007-36-4P nucleotide  
 sequence; antagonistic monoclonal antibodies and derivs. specific to  
 human CD40 antigen for treatment of autoimmune and inflammatory  
 diseases

6/7/15 (Item 8 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2008 American Chemical Society. All rts. reserv.

142409698 CA: 142(22)409698r PATENT  
 Vaccines for cancer, autoimmune disease and infections  
 INVENTOR(AUTHOR): Molldrem, Jeffrey  
 LOCATION: USA  
 ASSIGNEE: Board of Regents, the University of Texas System  
 PATENT: PCT International ; WO 200535714 A2 DATE: 20050421  
 APPLICATION: WO 2004US27792 (20040826) \*US 2003PV498238 (20030826)  
 PAGES: 235 pp. CODEN: PIXXD2 LANGUAGE: English  
 PATENT CLASSIFICATIONS:  
 CLASS: C12N-000/A  
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
 BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
 GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
 LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
 PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ;  
 VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA  
 ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;  
 BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;  
 PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;  
 SN; TD; TG  
 SECTION:  
 CA215002 Immunochemistry

CA201XXX Pharmacology

CA202XXX Mammalian Hormones

CA208XXX Radiation Biochemistry

CA214XXX Mammalian Pathological Biochemistry

IDENTIFIERS: peptide vaccine cancer autoimmune disease infection

DESCRIPTORS:

Leukemia...

acute myeloid; HLA class I-restricted peptides for protective  
vaccination against

Mycobacterium BCG...

adjuvant for HLA class I-restricted peptide vaccines

Immunostimulants...

adjuvants, Freund's incomplete; for HLA class I-restricted peptide  
vaccines

Immunostimulants...

adjuvants, Freund's; for HLA class I-restricted peptide vaccines

Transplant rejection...

allotransplant; HLA class I-restricted peptides for protective  
vaccination against

Interferons...

$\alpha$ ; in combination therapy with HLA class I-restricted peptide  
vaccines

Spinal column,disease... Inflammation...

ankylosing spondylitis; HLA class I-restricted peptides for protective  
vaccination against

Antibodies and Immunoglobulins...

anti-TRAIL receptor; in combination therapy with HLA class I-restricted  
peptide vaccines

Anemia(disease)...

aplastic; HLA class I-restricted peptides for protective vaccination  
against

Autoimmune disease... Stomach,disease... Inflammation...

autoimmune gastritis; HLA class I-restricted peptides for protective  
vaccination against

Hepatitis...

autoimmune; HLA class I-restricted peptides for protective vaccination  
against

Hepatitis...

B; HLA class I-restricted peptides for protective vaccination against

Hepatitis...

C; HLA class I-restricted peptides for protective vaccination against

Glycoproteins...

CD40-L (antigen CD40 ligand); in combination therapy with HLA class  
I-restricted peptide vaccines

Fatigue,biological...

chronic fatigue syndrome; HLA class I-restricted peptides for  
protective vaccination against

Leukemia...

chronic myelocytic; HLA class I-restricted peptides for protective  
vaccination against

Intestine,neoplasm...

colon; HLA class I-restricted peptides for protective vaccination  
against

Inflammation...

Crohn's disease; HLA class I-restricted peptides for protective  
vaccination against

Intestine,disease...

Crohn's; HLA class I-restricted peptides for protective vaccination  
against

Agranulocytosis...

cyclic neutropenia; HLA class I-restricted peptides for protective

vaccination against  
 T cell(lymphocyte)...  
     cytotoxic; protective vaccination with HLA class I-restricted peptides  
     for  
 Cyclins...  
     D; protective vaccination with HLA class I-restricted peptides from  
 Cytokine receptors...  
     DR4 (death receptor 4), agonists; in combination therapy with HLA class  
     I-restricted peptide vaccines  
 Cytokine receptors...  
     DR5 (death receptor 5), agonists; in combination therapy with HLA class  
     I-restricted peptide vaccines  
 Cyclins...  
     E; protective vaccination with HLA class I-restricted peptides from  
 TCR(T cell receptors)...  
     engineering of cytotoxic T-cells for tumor peptide specificity by  
     transfection with  
 Cyclins...  
     E2; protective vaccination with HLA class I-restricted peptides from  
 Muscle,disease...  
     fibromyalgia; HLA class I-restricted peptides for protective  
     vaccination against  
 Cytometry...  
     flow; for isolation of cytotoxic T-cells specific for HLA class  
     I-restricted peptides  
 Genetic vectors...  
     for expression of HLA class I-restricted peptides  
 Microspheres...  
     for prepn. of cytotoxic T-cells specific for HLA class I-restricted  
     peptides  
 Interferons...  
      $\gamma$ ; in combination therapy with HLA class I-restricted peptide  
     vaccines  
 Immunization...  
     genetic; with HLA class I-restricted peptides  
 Kidney,disease...  
     Goodpasture's syndrome; HLA class I-restricted peptides for protective  
     vaccination against  
 Transplant and Transplantation...  
     graft-vs.-host reaction; HLA class I-restricted peptides for protective  
     vaccination against  
 Leukemia...  
     hairy-cell; HLA class I-restricted peptides for protective vaccination  
     against  
 Infection...  
     hepatitis B; HLA class I-restricted peptides for protective vaccination  
     against  
 Infection...  
     hepatitis C; HLA class I-restricted peptides for protective vaccination  
     against  
 CD28(antigen)... CTLA-4(antigen)...  
     HLA class I-restricted peptide vaccines in combination therapy with  
     antibodies to  
 Human... Dendritic cell...  
     HLA class I-restricted peptides for protective vaccination  
 Neoplasm... Myelodysplastic syndromes... Bladder,neoplasm... Mammary  
 gland,neoplasm... Lung,neoplasm... Prostate gland,neoplasm...  
 Liver,neoplasm... Pancreas,neoplasm... Stomach,neoplasm... Testis,neoplasm  
 ... Brain,neoplasm... Ovary,neoplasm... Skin,neoplasm... Bone,neoplasm...  
 Autoimmune disease... Infection... Addison's disease... Alopecia...  
 Antiphospholipid syndrome... Behcet's syndrome... Celiac disease... Graves'



disease... Lupus erythematosus... Multiple sclerosis... Myasthenia gravis  
... Psoriasis... Rheumatoid arthritis... Rheumatic fever... Sarcoidosis...  
Vitiligo...

HLA class I-restricted peptides for protective vaccination against  
Histocompatibility antigens...

HLA-A11; HLA class I-restricted peptides for protective vaccination  
Histocompatibility antigens...

HLA-A2.1; HLA class I-restricted peptides for protective vaccination  
Histocompatibility antigens...

HLA-A3; HLA class I-restricted peptides for protective vaccination  
Histocompatibility antigens...

HLA-B27; HLA class I-restricted peptides for protective vaccination  
Histocompatibility antigens...

HLA-B35; HLA class I-restricted peptides for protective vaccination  
Histocompatibility antigens...

HLA-B7; HLA class I-restricted peptides for protective vaccination  
Purpura(disease)...

idiopathic thrombocytopenic; HLA class I-restricted peptides for  
protective vaccination against

Angiogenesis inhibitors... Interleukin 2... Interleukin 12...

Oligonucleotides...

in combination therapy with HLA class I-restricted peptide vaccines

Radiotherapy...

in combination with HLA class I-restricted peptides for protective  
vaccination

Autoimmune disease...

insulin-dependent diabetes mellitus; HLA class I-restricted peptides  
for protective vaccination against

Diabetes mellitus...

insulin-dependent; HLA class I-restricted peptides for protective  
vaccination against

Leukemia...

large granular lymphocytic; HLA class I-restricted peptides for  
protective vaccination against

Leukemia...

lymphocytic; HLA class I-restricted peptides for protective vaccination  
against

Animal tissue culture...

mammalian; expansion of cytotoxic T-cells to HLA class I-restricted  
peptides in

Ear,disease...

Meniere's; HLA class I-restricted peptides for protective vaccination  
against

Cell adhesion molecules...

modifiers; adjuvant for HLA class I-restricted peptide vaccines

Leukemia...

monocytic; HLA class I-restricted peptides for protective vaccination  
against

Lipid A...

monophosphates; adjuvant for HLA class I-restricted peptide vaccines

Leukemia...

myeloblastic; HLA class I-restricted peptides for protective  
vaccination against

Leukemia... Leukemia...

myelogenous; HLA class I-restricted peptides for protective vaccination  
against

Skin,disease...

pemphigus vulgaris; HLA class I-restricted peptides for protective  
vaccination against

Biliary tract,disease...

primary biliary cirrhosis; HLA class I-restricted peptides for

protective vaccination against  
 Leukemia...  
 promyelocytic; HLA class I-restricted peptides for protective  
 vaccination against  
 CAS REGISTRY NUMBERS:  
 99011-02-6 141256-04-4 adjuvant for HLA class I-restricted peptide  
 vaccines  
 7722-84-1 biological studies, in combination therapy with HLA class  
 I-restricted peptide vaccines  
 225478-04-6 225478-05-7 for prepn. of cytotoxic T-cells specific for HLA  
 class I-restricted peptides  
 182253-77-6 182253-78-7 847201-80-3 847201-81-4 847201-82-5  
 847201-83-6 847201-86-9 847201-87-0 847201-88-1 847201-89-2  
 847201-90-5 847201-91-6 847201-92-7 847201-94-9 204391-91-3  
 850146-69-9 850146-70-2 HLA class I-restricted peptides for  
 protective vaccination  
 23214-92-8 20830-81-3 50-76-0 65271-80-9 15663-27-1 671-16-9  
 1404-00-8 41575-94-4 11056-06-7 33419-42-0 29767-20-2 51-75-2  
 50-18-0 3778-73-2 148-82-3 305-03-3 645-05-6 76-75-5 55-98-1  
 154-93-8 13010-47-4 13909-09-6 18883-66-4 4342-03-4 25316-40-9  
 51-21-8 7689-03-4 13010-20-3 18378-89-7 10540-29-1 33069-62-4  
 14913-33-8 57-22-7 865-21-4 110417-88-4 100629-51-4 92689-49-1  
 220578-59-6 114-70-5 156-54-7 59-05-2 2353-33-5 220127-57-1  
 216974-75-3 205923-56-4 50-35-1 179324-69-7 184475-35-2  
 183321-74-6 320-67-2 191732-72-6 83869-56-1 in combination therapy  
 with HLA class I-restricted peptide vaccines  
 9003-99-0 9004-06-2 128028-50-2 protective vaccination with HLA class  
 I-restricted peptides from  
 7429-90-5D salts, adjuvant for HLA class I-restricted peptide vaccines  
 850280-40-9 850280-41-0 850280-42-1 850280-43-2 850280-44-3  
 850280-45-4 850280-46-5 850280-47-6 850280-48-7 850280-49-8  
 850280-50-1 850280-51-2 850280-52-3 850280-53-4 850280-54-5  
 850280-55-6 unclaimed nucleotide sequence; vaccines for cancer,  
 autoimmune disease and infections  
 153045-21-7 847201-84-7 847201-85-8 847201-93-8 847201-95-0  
 847201-96-1 847201-97-2 847201-98-3 847201-99-4 847202-00-0  
 847202-01-1 847202-02-2 847202-03-3 847202-04-4 847202-05-5  
 847202-06-6 847202-07-7 847202-08-8 847202-09-9 847202-10-2  
 847202-11-3 847202-12-4 847202-13-5 847202-14-6 847202-15-7  
 847202-16-8 847202-17-9 847202-18-0 847202-19-1 847202-20-4  
 unclaimed sequence; vaccines for cancer, autoimmune disease and  
 infections

6/7/16 (Item 9 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2008 American Chemical Society. All rts. reserv.

142334937 CA: 142(18)334937g PATENT  
 Regulatory leukocytes repressing B cell autoantibody secretion  
 INVENTOR(AUTHOR): Vilen, Barbara J.; Kilmon, Michelle; Rutan, Jennifer A.  
 LOCATION: USA  
 ASSIGNEE: University of North Carolina At Chapel Hill  
 PATENT: PCT International ; WO 200527841 A2 DATE: 20050331  
 APPLICATION: WO 2004US30325 (20040916) \*US 2003PV503534 (20030916)  
 PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English  
 PATENT CLASSIFICATIONS:  
 CLASS: A61K-000/A  
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
 BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
 GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;

LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

CA202XXX Mammalian Hormones

IDENTIFIERS: B cell autoantibody Sm antigen regulatory leukocyte

DESCRIPTORS:

CD40(antigen)... Tumor necrosis factor receptors...

activation of regulatory immune cells by

Interferons...

$\alpha$ ; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Transforming growth factors...

$\alpha$ -; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Integrins...

$\alpha$ M; expression by immune cells mediating peripheral anergy of autoreactive B-cells

Integrins...

$\alpha$ X; expression by immune cells mediating peripheral anergy of autoreactive B-cells

Immune tolerance...

anergy; interleukin-6- and contact-dependent mechanisms for regulatory immune cells mediating peripheral anergy of autoreactive B-cells

CD20(antigen)...

antibodies to B-cells in treatment of autoimmune disease

Cytokines...

APRIL; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Kidney,disease... Autoimmune disease... Inflammation...

autoimmune glomerulonephritis; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Thyroid gland,disease... Autoimmune disease... Inflammation...

autoimmune thyroiditis; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Cytokines...

BAFF; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Interferons...

$\beta$ ; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Transforming growth factors...

$\beta$ -; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

CD antigens...

CD11B; expression by immune cells mediating peripheral anergy of autoreactive B-cells

CD antigens...

CD11C; expression by immune cells mediating peripheral anergy of autoreactive B-cells

Cytokines...

CD30 ligand; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Glycoproteins...

CD40-L (antigen CD40 ligand); expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

CD antigens...  
 CD70; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Inflammation...  
 Crohn's disease; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Intestine,disease...  
 Crohn's; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Antigens...  
 DX5; expression by immune cells mediating peripheral anergy of autoreactive B-cells

Interleukin 1... Interleukin 2... Interleukin 3... Interleukin 4...  
 Interleukin 5... Interleukin 6... Interleukin 7... Interleukin 8...  
 Interleukin 10... Interleukin 12... Interleukin 13... Interleukin 14...  
 Interleukin 15... Interleukin 18... Interleukin 24... Macrophage migration inhibitory factor... Monocyte chemoattractant protein-1... Lymphotoxin...  
 Fas ligand...  
 expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Interferons...  
 $\gamma$ ; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Proteins...  
 GITR ligand; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Kidney,disease...  
 Goodpasture's syndrome; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Antibodies and Immunoglobulins...  
 IgM autoantibodies; prodn. is lupus model is repressed by regulatory leukocytes

Dendritic cell... Macrophage... Animal tissue culture... Human...  
 Immunotherapy...  
 interleukin-6- and contact-dependent mechanisms for regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Chemokines...  
 macrophage inflammatory protein 1; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Lymphocyte...  
 natural killer cell; interleukin-6- and contact-dependent mechanisms for regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Antigens...  
 nuclear antigens; surface expression by immune cells mediating peripheral anergy of autoreactive B-cells

Proteins...  
 OX40L; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Skin,disease...  
 pemphigus vulgaris; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Artery,disease... Inflammation...  
 periarteritis nodosa; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Lymphocyte...  
 plasma cell; regulatory leukocytes repress autoantibody secretion by

Arthritis...  
 psoriatic arthritis; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Diagnosis...

regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to  
Rheumatoid arthritis... Psoriasis... Antiphospholipid syndrome... Sjogren's syndrome...  
regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of  
B cell(lymphocyte)...  
regulatory leukocytes repress autoantibody secretion by  
Autoimmune disease...  
regulatory leukocytes repress autoantibody secretion in lupus model  
Connective tissue,disease...  
scleroderma; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of  
Antigens...  
Sm; regulatory leukocytes repress B-cell prodn. of autoantibodies to  
Lupus erythematosus...  
systemic; regulatory leukocytes repress autoantibody secretion in model for  
Receptors...  
TLR (Toll-like receptor); activation of regulatory immune cells by  
Cytokines...  
TNFSF7 (tumor necrosis factor superfamily member 7); expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells  
Antibodies and Immunoglobulins...  
to B-cells in treatment of autoimmune disease  
Proteins...  
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand); expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells  
Cytokines...  
TWEAK (TNF-like weak inducer of apoptosis); expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells  
Blood vessel,disease... Inflammation...  
vasculitis, autoimmune, ANCA-assocd.; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of  
Blood vessel,disease... Inflammation...  
vasculitis, necrotizing; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of  
Interleukins...  
23; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells  
Interleukins...  
25; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells  
Interleukins...  
26; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells  
Proteins...  
4-1BBL; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells  
CAS REGISTRY NUMBERS:  
81627-83-0 207621-35-0 expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

6/7/17 (Item 10 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

142259982 CA: 142(14)259982n PATENT

Compositions comprising autoantigen and antigen-specific multivalent antibody for treating cancer, infection and autoimmune disease

INVENTOR(AUTHOR): Barabas, Arpad Z.

LOCATION: Can.,

ASSIGNEE: The Governors of the University of Calgary

PATENT: PCT International ; WO 200516379 A1 DATE: 20050224

APPLICATION: WO 2004CA1494 (20040812) \*US 2003PV495804 (20030815)

PAGES: 104 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A; A61K-039/00B; A61P-037/00B; A61P-037/02B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

CA263XXX Pharmaceuticals

IDENTIFIERS: antigen autoantigen antibody IgM IgG cancer infection autoimmune disease

DESCRIPTORS:

Immunostimulants...

adjuvants, Freund's; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Immunostimulants...

adjuvants; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Eubacteria... Animal virus... Fungi... Yeast...

antigen; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Drug delivery systems...

aq.; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...

autoantibodies, downregulation; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens... Antibodies and Immunoglobulins... Mammalia... Human... Tumor

antigens... Antitumor agents... Vaccines... Infection... Mycosis...

Parasite... Protozoa... Fusion proteins(chimeric proteins)... Buffers...

Myelin basic protein... Animal cell... Animal tissue... Organ,animal...

Rheumatoid arthritis... Myasthenia gravis... Sjogren's syndrome... Multiple

sclerosis... Melanoma... Prostate gland,neoplasm... Thyroid gland,neoplasm

... Pancreas,neoplasm... Liver,neoplasm... Mammary gland,neoplasm...

Lung,neoplasm... Stomach,neoplasm... Pathogen... Staphylococcus...

Streptococcus... Escherichia coli... Influenza virus... Hepatitis A virus

... Hepatitis B virus... Hepatitis C virus... Malaria... Alums... Haptens

...

autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens...

autoantigens, 70 kD mitochondrial biliary; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens...

autoantigens; autoantigens and antigen-specific multivalent antibodies

for treating cancer, infection and autoimmune disease

Anemia(disease)... Autoimmune disease...  
autoimmune hemolytic anemia; autoantigens and antigen-specific  
multivalent antibodies for treating cancer, infection and autoimmune  
disease

Thyroid gland,disease... Autoimmune disease... Inflammation...  
autoimmune thyroiditis; autoantigens and antigen-specific multivalent  
antibodies for treating cancer, infection and autoimmune disease

Kidney,disease... Hypoparathyroidism... Blister... Addison's disease...  
autoimmune; autoantigens and antigen-specific multivalent antibodies  
for treating cancer, infection and autoimmune disease

Infection...  
bacterial; autoantigens and antigen-specific multivalent antibodies for  
treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...  
bispecific; autoantigens and antigen-specific multivalent antibodies  
for treating cancer, infection and autoimmune disease

Glycoproteins...  
cartilage GP39, human; autoantigens and antigen-specific multivalent  
antibodies for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...  
chimeric; autoantigens and antigen-specific multivalent antibodies for  
treating cancer, infection and autoimmune disease

Proteins... Haptens...  
conjugates; autoantigens and antigen-specific multivalent antibodies  
for treating cancer, infection and autoimmune disease

Dermatitis...  
contact, sensitivity; autoantigens and antigen-specific multivalent  
antibodies for treating cancer, infection and autoimmune disease

Fertility...  
disorder, autoimmune; autoantigens and antigen-specific multivalent  
antibodies for treating cancer, infection and autoimmune disease

Uterus,disease...  
endometriosis; autoantigens and antigen-specific multivalent antibodies  
for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...  
fragments; autoantigens and antigen-specific multivalent antibodies for  
treating cancer, infection and autoimmune disease

Drug delivery systems...  
freeze-dried; autoantigens and antigen-specific multivalent antibodies  
for treating cancer, infection and autoimmune disease

Antigens...  
glomerular nephritogenic; autoantigens and antigen-specific multivalent  
antibodies for treating cancer, infection and autoimmune disease

Basement membrane...  
glomerular; autoantigens and antigen-specific multivalent antibodies  
for treating cancer, infection and autoimmune disease

Kidney,disease... Inflammation...  
Heymann nephritis; autoantigens and antigen-specific multivalent  
antibodies for treating cancer, infection and autoimmune disease

Gene,animal...  
human Ig; autoantigens and antigen-specific multivalent antibodies for  
treating cancer, infection and autoimmune disease

Antigens...  
human placental Hp-8; autoantigens and antigen-specific multivalent  
antibodies for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...  
humanized; autoantigens and antigen-specific multivalent antibodies for  
treating cancer, infection and autoimmune disease

Antigens...  
IB1; endometrial; autoantigens and antigen-specific multivalent

antibodies for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...

IgG; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...

IgM; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Autoimmune disease...

insulin-dependent diabetes mellitus; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Diabetes mellitus...

insulin-dependent; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens...

kidney tubular nephritogenic; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens...

La/SSB; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Kidney,disease... Inflammation...

lupus nephritis; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Kidney,disease... Inflammation...

membranous glomerulonephritis; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Drug delivery systems...

nasal, intra-; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens...

nucleolar ASE-1; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Drug delivery systems...

ophthalmic; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Drug delivery systems...

oral; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Drug delivery systems...

parenterals; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Skin,disease...

pemphigoid, bolus; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Skin,disease...

pemphigus foliaceus; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Skin,disease...

pemphigus vulgaris; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Biliary tract,disease...

primary biliary cirrhosis; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Kidney...

proximal tubule; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Proteins...

recombinant; autoantigens and antigen-specific multivalent antibodies



for treating cancer, infection and autoimmune disease

Antigens...  
 repro-EN-1.0; endometrial; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens...  
 Ro/SSA; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Connective tissue,disease...  
 scleroderma; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens...  
 Sm; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Ribonucleoproteins...  
 snRNP (small nuclear ribonucleoprotein); autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Proteins...  
 Sp17; human; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Lupus erythematosus...  
 systemic; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Mus musculus...  
 transgenic; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Vaccines...  
 tumor; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antitumor agents...  
 vaccines; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Infection...  
 viral; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

CAS REGISTRY NUMBERS:

9024-58-2 9014-46-4 autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

7732-18-5 biological studies, sterile; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

98-50-0D 63-74-1D conjugates, autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

7429-90-5D salts, autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

6/7/18 (Item 11 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2008 American Chemical Society. All rts. reserv.

141122334 CA: 141(8)122334n PATENT  
 Immunotherapy of B cell malignancies and autoimmune disease using unconjugated and conjugated antibodies, fragments or fusion proteins  
 INVENTOR(AUTHOR): Goldenberg, David M.; Hansen, Hans  
 LOCATION: USA  
 ASSIGNEE: Immunomedics, Inc.; McCall, John Douglas  
 PATENT: PCT International ; WO 200458298 A1 DATE: 20040715  
 APPLICATION: WO 2003GB5700 (20031231) \*US PV437145 (20021231)

PAGES: 49 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/00A; A61K-041/00B; A61K-051/10B; A61K-039/395B;  
A61P-005/00B; A61P-037/06B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT;  
RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ;  
VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; SD  
; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG;  
CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO;  
SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD;  
TG

SECTION:

CA215003 Immunochemistry  
CA209XXX Biochemical Methods  
CA263XXX Pharmaceuticals

IDENTIFIERS: immunotherapy B cell malignancy autoimmune disease conjugate  
unconjugate antibody

DESCRIPTORS:

Leukemia...

acute lymphocytic; unconjugated and conjugated antibodies, fragments or  
antibody fusion proteins for immunotherapy and immunodiagnosis of B  
cell malignancies and autoimmune disease

Sulfonic acids,biological studies...

alkanesulfonic, salts; unconjugated and conjugated antibodies,  
fragments or antibody fusion proteins for immunotherapy and  
immunodiagnosis of B cell malignancies and autoimmune disease

Interferons...

$\alpha$ ; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

Toxins...

$\alpha$ -; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

Interleukin 2 receptors...

$\alpha$  chain; unconjugated and conjugated antibodies, fragments or  
antibody fusion proteins for immunotherapy and immunodiagnosis of B  
cell malignancies and autoimmune disease

Integrins...

$\alpha$ X; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

Nervous system,disease...

amyotrophic lateral sclerosis; unconjugated and conjugated antibodies,  
fragments or antibody fusion proteins for immunotherapy and  
immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Spinal column,disease...

ankylosing spondylitis; unconjugated and conjugated antibodies,  
fragments or antibody fusion proteins for immunotherapy and  
immunodiagnosis of B cell malignancies and autoimmune disease

Cytotoxic agents...

antimetabolites; unconjugated and conjugated antibodies, fragments or  
antibody fusion proteins for immunotherapy and immunodiagnosis of B  
cell malignancies and autoimmune disease

Inflammation... Artery,disease...

arteritis, giant cell; unconjugated and conjugated antibodies,  
fragments or antibody fusion proteins for immunotherapy and  
immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Artery,disease...  
arteritis, Takayasu's; unconjugated and conjugated antibodies,  
fragments or antibody fusion proteins for immunotherapy and  
immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Autoimmune disease... Thyroid gland,disease...  
autoimmune thyroiditis; unconjugated and conjugated antibodies,  
fragments or antibody fusion proteins for immunotherapy and  
immunodiagnosis of B cell malignancies and autoimmune disease

Lymphoma...  
B-cell; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

Disease,animal...  
B-lymphocyte, malignancy; unconjugated and conjugated antibodies,  
fragments or antibody fusion proteins for immunotherapy and  
immunodiagnosis of B cell malignancies and autoimmune disease

Interferons...  
 $\beta$ ; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

Skin,disease...  
bullous pemphigoid; unconjugated and conjugated antibodies, fragments  
or antibody fusion proteins for immunotherapy and immunodiagnosis of B  
cell malignancies and autoimmune disease

CD antigens...  
CD11C; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

Antigens...  
CD126; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

CD antigens...  
CD33; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

CD antigens...  
CD37; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

Glycoproteins...  
CD40-L (antigen CD40 ligand); unconjugated and conjugated antibodies,  
fragments or antibody fusion proteins for immunotherapy and  
immunodiagnosis of B cell malignancies and autoimmune disease

CD antigens...  
CD52; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

Antibodies and Immunoglobulins...  
chimeric; unconjugated and conjugated antibodies, fragments or antibody  
fusion proteins for immunotherapy and immunodiagnosis of B cell  
malignancies and autoimmune disease

Leukemia...  
chronic lymphocytic; unconjugated and conjugated antibodies, fragments  
or antibody fusion proteins for immunotherapy and immunodiagnosis of B  
cell malignancies and autoimmune disease

Infection...  
chronic viral hepatitis; unconjugated and conjugated antibodies,  
fragments or antibody fusion proteins for immunotherapy and  
immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...

conjugates; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Toxins...

diphtheria; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

T cell(lymphocyte)...

disease; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Blood vessel...

endothelium, antigen; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Toxins...

enterotoxin A, Staphylococcal; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Toxins...

enterotoxins, staphylococcal A; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Toxins...

exotoxins, Pseudomonas; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Lung,disease...

fibrosis; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...

fragments; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Mycosis...

fungoides; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Interferons...

$\gamma$ ; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Kidney,disease...

glomerulonephritis, rapidly progressive; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Kidney,disease...

Goodpasture's syndrome; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Purpura(disease)...

Henoch-Schoenlein's; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Histocompatibility antigens...

HLA-DR; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Antigens...

HMI.24; unconjugated and conjugated antibodies, fragments or antibody

fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...  
humanized; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Histocompatibility antigens...  
I-A; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Cell adhesion molecules...  
ICAM-1 (intercellular adhesion mol. 1); unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune diseases

Purpura(disease)...  
idiopathic thrombocytopenic, acute and chronic; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Kidney,disease...  
IgA nephropathy; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Immunoglobulin receptors...  
IgE type II; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...  
IgG; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Drug delivery systems...  
immunoconjugates; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Diagnosis...  
immunodiagnosis; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Drug delivery systems...  
immunotoxins; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Apoptosis...  
inducer; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Mitosis...  
inhibitors; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Fluorescent substances... Heavy metals...  
label; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Kidney,disease...  
lupus nephritis; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Proteins...  
MCP (membrane cofactor protein); unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Kidney,disease...  
 membranous glomerulonephritis; unconjugated and conjugated antibodies,  
 fragments or antibody fusion proteins for immunotherapy and  
 immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...  
 monoclonal; unconjugated and conjugated antibodies, fragments or  
 antibody fusion proteins for immunotherapy and immunodiagnosis of B  
 cell malignancies and autoimmune disease

Mucins...  
 MUC1; unconjugated and conjugated antibodies, fragments or antibody  
 fusion proteins for immunotherapy and immunodiagnosis of B cell  
 malignancies and autoimmune disease

Erythema...  
 multiforme; unconjugated and conjugated antibodies, fragments or  
 antibody fusion proteins for immunotherapy and immunodiagnosis of B  
 cell malignancies and autoimmune disease

Skin,neoplasm...  
 mycosis fungoides; unconjugated and conjugated antibodies, fragments or  
 antibody fusion proteins for immunotherapy and immunodiagnosis of B  
 cell malignancies and autoimmune disease

Inflammation... Kidney,disease...  
 nephritis, post-streptococcal; unconjugated and conjugated antibodies,  
 fragments or antibody fusion proteins for immunotherapy and  
 immunodiagnosis of B cell malignancies and autoimmune disease

Erythema...  
 nodosum; unconjugated and conjugated antibodies, fragments or antibody  
 fusion proteins for immunotherapy and immunodiagnosis of B cell  
 malignancies and autoimmune disease

Lymphoma...  
 non-Hodgkin's; unconjugated and conjugated antibodies, fragments or  
 antibody fusion proteins for immunotherapy and immunodiagnosis of B  
 cell malignancies and autoimmune disease

CAS REGISTRY NUMBERS:

55-86-7D analogs, unconjugated and conjugated antibodies, fragments or  
 antibody fusion proteins for immunotherapy and immunodiagnosis of B  
 cell malignancies and autoimmune disease

14596-37-3 15749-66-3 14391-96-9 14596-12-4 13981-25-4 15757-86-5  
 14265-71-5 14687-61-7 14158-27-1 10098-91-6 14119-15-4 14913-89-4  
 14981-64-7 15760-04-0 14158-31-7 10043-66-0 14191-64-1 14981-79-4  
 15765-31-8 15766-00-4 14391-19-6 13967-65-2 15840-13-8 14265-75-9  
 15765-78-3 14378-26-8 14158-35-1 10043-49-9 14391-11-8 15816-77-0  
 15092-94-1 15776-20-2 13981-38-9 14119-09-6 378253-43-1  
 378784-45-3 378784-00-0 15750-15-9 14914-68-2 14391-20-9  
 378782-88-8 14694-69-0 14265-85-1 15755-39-2 15904-62-8 14913-49-6  
 15623-45-7 14835-02-0 15706-52-2 15229-37-5 15756-41-9 17239-90-6  
 15750-24-0 14798-12-0 14391-32-3 15117-96-1 biological studies,  
 unconjugated and conjugated antibodies, fragments or antibody fusion  
 proteins for immunotherapy and immunodiagnosis of B cell malignancies  
 and autoimmune disease

12586-31-1 capture; unconjugated and conjugated antibodies, fragments or  
 antibody fusion proteins for immunotherapy and immunodiagnosis of B  
 cell malignancies and autoimmune disease

7440-42-8D compds., unconjugated and conjugated antibodies, fragments or  
 antibody fusion proteins for immunotherapy and immunodiagnosis of B  
 cell malignancies and autoimmune disease

7440-66-6D 7429-90-5D 7440-55-3D 7439-94-3D 7440-05-3D complexes,  
 unconjugated and conjugated antibodies, fragments or antibody fusion  
 proteins for immunotherapy and immunodiagnosis of B cell malignancies  
 and autoimmune disease

7440-06-4D coordination complexes and analogs, unconjugated and conjugated

antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease  
151-56-4D 13010-20-3D 15056-34-5D 59-30-3D 1605-68-1D 289-95-2D  
120-73-0D 60-34-4D 187888-07-9D 33069-62-4D 7689-03-4D 23214-92-8D  
derivs. and analogs, unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease  
329900-75-6 inhibitors; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease  
57-13-6D substituted derivs. and analogs, unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease  
127464-60-2 352423-07-5 50-18-0 33419-42-0 671-16-9 53-03-2 154-93-8  
59-05-2 11056-06-7 50-02-2 4346-18-3 83314-01-6 58-05-9 9001-99-4  
9003-98-9 62683-29-8 11096-26-7 9014-42-0 143011-72-7 83869-56-1  
67-43-6 60239-18-1 60239-22-7 56491-86-2 138612-85-8 4375-07-9  
57-22-7 75037-46-6 unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

6/7/19 (Item 12 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

139317445 CA: 139(21)317445r PATENT  
Remedies for pemphigus containing CD40l antagonist as the active ingredient  
INVENTOR(AUTHOR): Amagai, Masayuki; Nishikawa, Takeji  
LOCATION: Japan,  
ASSIGNEE: Keio University; Eisai Co., Ltd.  
PATENT: PCT International ; WO 200386463 A1 DATE: 20031023  
APPLICATION: WO 2003JP4219 (20030402) \*JP 2002101886 (20020403)  
PAGES: 22 pp. CODEN: PIXXD2 LANGUAGE: Japanese  
PATENT CLASSIFICATIONS:  
CLASS: A61K-045/00A; A61K-039/395B; A61P-017/00B; A61P-037/06B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG  
SECTION:  
CA201007 Pharmacology  
IDENTIFIERS: pemphigus vulgaris foliaceus CD40l receptor antagonist antiCD40L  
DESCRIPTORS:  
Glycoproteins...  
CD40-L (antigen CD40 ligand); remedies for pemphigus contg. CD40l antagonist as the active ingredient  
T cell(lymphocyte)...  
helper cell; remedies for pemphigus contg. CD40l antagonist as the active ingredient  
Skin,disease...  
pemphigus foliaceus; remedies for pemphigus contg. CD40l antagonist as the active ingredient  
Skin,disease...

pemphigus vulgaris; remedies for pemphigus contg. CD40l antagonist as the active ingredient  
Skin,disease...  
pemphigus; remedies for pemphigus contg. CD40l antagonist as the active ingredient  
CD40(antigen)... Human... Antigen-presenting cell...  
remedies for pemphigus contg. CD40l antagonist as the active ingredient  
CAS REGISTRY NUMBERS:  
252662-47-8D MR1 antibody, remedies for pemphigus contg. CD40l antagonist as the active ingredient

6/7/20 (Item 13 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

137228962 CA: 137(16)228962y PATENT  
CD4+CD25+ regulatory T cells from human blood  
INVENTOR(AUTHOR): Schuler, Gerold  
LOCATION: Germany,  
PATENT: European Pat. Appl. ; EP 1241249 A1 DATE: 20020918  
APPLICATION: EP 2001106033 (20010312)  
PAGES: 26 pp. CODEN: EPXXDW LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-005/06A; A61K-035/14B; G01N-033/50B; A61P-037/06B;  
A61P-037/04B  
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;  
SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR  
SECTION:  
CA209016 Biochemical Methods  
CA215XXX Immunochemistry  
IDENTIFIERS: CD4 CD25 regulatory T cell blood  
DESCRIPTORS:  
Antigens...  
alloantigens; CD4+CD25+ regulatory T cells from human blood  
Interferons...  
 $\alpha$ ; CD4+CD25+ regulatory T cells from human blood  
Antigens...  
autoantigens; CD4+CD25+ regulatory T cells from human blood  
Acrylic fibers,analysis... Adoptive immunotherapy... Animal tissue...  
Antigens... Apoptosis... Autoimmune disease... Blood... CD28(antigen)...  
CD2(antigen)... CD3(antigen)... CD4(antigen)... Cell... Composition...  
CTLA-4(antigen)... Dendritic cell... Drugs... Hepatitis... Human...  
Immunity... Interleukin 10... Interleukin 2 receptors... Interleukin 2...  
Interleukin 5... Interleukin 7... Interleukin 9... Magnetic separation...  
Molecules... Necrosis... Pathogen... RNA... T cell(lymphocyte)...  
Thyroglobulin... Transplant and Transplantation... Transplant rejection...  
Vitiligo...  
CD4+CD25+ regulatory T cells from human blood  
Glycoproteins...  
CD40-L (antigen CD40 ligand); CD4+CD25+ regulatory T cells from human blood  
Transplant and Transplantation...  
graft-vs.-host reaction; CD4+CD25+ regulatory T cells from human blood  
Adsorption...  
immunoadsorption; CD4+CD25+ regulatory T cells from human blood  
Antibodies...  
monoclonal; CD4+CD25+ regulatory T cells from human blood  
Skin,disease...  
pemphigus vulgaris; CD4+CD25+ regulatory T cells from human blood  
Thyroid gland,disease...



thyroiditis; CD4+CD25+ regulatory T cells from human blood  
CAS REGISTRY NUMBERS:  
7440-70-2 analysis, ionophor; CD4+CD25+ regulatory T cells from human  
blood  
9002-10-2 CD4+CD25+ regulatory T cells from human blood  
17673-25-5D esters, CD4+CD25+ regulatory T cells from human blood

6/7/21 (Item 14 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

136246408 CA: 136(16)246408f PATENT  
Combination therapy for treatment of autoimmune diseases using B cell  
depleting/immunoregulatory antibody combination.  
INVENTOR(AUTHOR): Hanna, Nabil  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals  
PATENT: PCT International ; WO 200222212 A2 DATE: 20020321  
APPLICATION: WO 2001US29026 (20010918) \*US PV257147 (20001222)  
PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61P-037/00; A61K-039/39  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA;  
CH; CN; CO; CU; CZ; EE; ES; FI; GB; GE; GM; HU; ID; IL; IN; KP; KR; LK; LR;  
MN; MW; MX; NO; NZ; PL; PT; RO; RU DESIGNATED REGIONAL: GH; GM; KE; LS; MW  
; MZ; SD; SL; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE;  
IT; MC; NL; PT; SE; TR; CG; CI; GA; GN; GW; ML; MR; NE; SN; TD; TG  
SECTION:  
CA215008 Immunochemistry  
IDENTIFIERS: autoimmune disease immunotherapy antibody B lymphocyte  
DESCRIPTORS:  
Immune complexes...  
-mediated diseases; combination therapy for treatment of autoimmune  
diseases using B cell depleting/immunoregulatory antibody combination  
Leukocyte...  
adhesion deficiency; combination therapy for treatment of autoimmune  
diseases using B cell depleting/immunoregulatory antibody combination  
Respiratory distress syndrome...  
adult; combination therapy for treatment of autoimmune diseases using B  
cell depleting/immunoregulatory antibody combination  
Nerve,disease...  
allergic neuritis; combination therapy for treatment of autoimmune  
diseases using B cell depleting/immunoregulatory antibody combination  
Encephalitis...  
allergic; combination therapy for treatment of autoimmune diseases  
using B cell depleting/immunoregulatory antibody combination  
Phospholipids,biological studies...  
antibodies to, antiphospholipid syndrome; combination therapy for  
treatment of autoimmune diseases using B cell  
depleting/immunoregulatory antibody combination  
Artery,disease...  
arteritis, giant cell; combination therapy for treatment of autoimmune  
diseases using B cell depleting/immunoregulatory antibody combination  
Antibodies...  
autoantibodies; combination therapy for treatment of autoimmune  
diseases using B cell depleting/immunoregulatory antibody combination  
Ovary,disease...  
autoimmune oophoritis; combination therapy for treatment of autoimmune  
diseases using B cell depleting/immunoregulatory antibody combination  
Platelet(blood)...

autoimmune thrombocytopenia; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Thyroid gland,disease...

autoimmune thyroiditis; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Skin,disease...

bullous pemphigoid; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CDw75; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CDw76; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CDw78; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CDw84; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD24; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD37; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Glycoproteins...

CD40-L (antigen CD40 ligand); combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD53; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD72; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD73; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD77; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD79a; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD81; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD83; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...

CD85; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Nervous system...

central, inflammation; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Antibodies...

chimeric, humanized; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Inflammation...  
 chronic; combination therapy for treatment of autoimmune diseases using  
 B cell depleting/immunoregulatory antibody combination

Intestine,disease...  
 colitis; combination therapy for treatment of autoimmune diseases using  
 B cell depleting/immunoregulatory antibody combination

Autoimmune disease... B cell(lymphocyte)... Antibodies... CD80(antigen)...  
 CD86(antigen)... CD19(antigen)... CD20(antigen)... CD22(antigen)...  
 CD40(antigen)... CD4(antigen)... Invariant chain(class II antigen)... Human  
 ... Psoriasis... Dermatitis... Respiratory distress syndrome... Meningitis  
 ... Encephalitis... Allergy... Eczema... Asthma... Atherosclerosis...  
 Rheumatoid arthritis... Diabetes mellitus... Multiple sclerosis...  
 Sjogren's syndrome... Tuberculosis... Sarcoidosis... Granulomatous disease  
 ... Multiple organ failure... Myasthenia gravis... Graves' disease...  
 Behcet's syndrome... Immunosuppressants... Immunotherapy...  
 combination therapy for treatment of autoimmune diseases using B cell  
 depleting/immunoregulatory antibody combination

Cytotoxic agents... Radionuclides,biological studies...  
 conjugates with antibody; combination therapy for treatment of  
 autoimmune diseases using B cell depleting/immunoregulatory antibody  
 combination

Anemia(disease)...  
 Coombs pos.; combination therapy for treatment of autoimmune diseases  
 using B cell depleting/immunoregulatory antibody combination

Intestine,disease...  
 Crohn's; combination therapy for treatment of autoimmune diseases using  
 B cell depleting/immunoregulatory antibody combination

Cryoglobulins...  
 cryoglobulinemia; combination therapy for treatment of autoimmune  
 diseases using B cell depleting/immunoregulatory antibody combination

Allergy...  
 delayed hypersensitivity; combination therapy for treatment of  
 autoimmune diseases using B cell depleting/immunoregulatory antibody  
 combination

Cell migration...  
 diapedesis, leukocyte; combination therapy for treatment of autoimmune  
 diseases using B cell depleting/immunoregulatory antibody combination

Endocrine system...  
 disease, autoimmune; combination therapy for treatment of autoimmune  
 diseases using B cell depleting/immunoregulatory antibody combination

Muscle,disease...  
 Eaton-Lambert syndrome; combination therapy for treatment of autoimmune  
 diseases using B cell depleting/immunoregulatory antibody combination

Proteins...  
 gene B29; combination therapy for treatment of autoimmune diseases  
 using B cell depleting/immunoregulatory antibody combination

Glycoproteins...  
 gene KAI1; combination therapy for treatment of autoimmune diseases  
 using B cell depleting/immunoregulatory antibody combination

Kidney,disease...  
 glomerulonephritis, anti-glomerular basement membrane; combination  
 therapy for treatment of autoimmune diseases using B cell  
 depleting/immunoregulatory antibody combination

Kidney,disease...  
 glomerulonephritis; combination therapy for treatment of autoimmune  
 diseases using B cell depleting/immunoregulatory antibody combination

Anemia(disease)...  
 hemolytic; combination therapy for treatment of autoimmune diseases  
 using B cell depleting/immunoregulatory antibody combination

Antibodies...  
 humanized; combination therapy for treatment of autoimmune diseases

using B cell depleting/immunoregulatory antibody combination  
 Purpura(disease)...  
     idiopathic thrombocytopenic; combination therapy for treatment of  
     autoimmune diseases using B cell depleting/immunoregulatory antibody  
     combination  
 Kidney,disease...  
     IgA nephropathy; combination therapy for treatment of autoimmune  
     diseases using B cell depleting/immunoregulatory antibody combination  
 Immunoglobulin receptors...  
     IgE type II; combination therapy for treatment of autoimmune diseases  
     using B cell depleting/immunoregulatory antibody combination  
 Kidney,disease...  
     immune complex nephritis; combination therapy for treatment of  
     autoimmune diseases using B cell depleting/immunoregulatory antibody  
     combination  
 T cell(lymphocyte)...  
     infiltration; combination therapy for treatment of autoimmune diseases  
     using B cell depleting/immunoregulatory antibody combination  
 Intestine,disease...  
     inflammatory; combination therapy for treatment of autoimmune diseases  
     using B cell depleting/immunoregulatory antibody combination  
 Drug delivery systems...  
     infusions; combination therapy for treatment of autoimmune diseases  
     using B cell depleting/immunoregulatory antibody combination  
 Drug delivery systems...  
     injections, i.v.; combination therapy for treatment of autoimmune  
     diseases using B cell depleting/immunoregulatory antibody combination  
 Diabetes mellitus...  
     insulin-dependent; combination therapy for treatment of autoimmune  
     diseases using B cell depleting/immunoregulatory antibody combination  
 Skin,disease...  
     pemphigus; combination therapy for treatment of autoimmune diseases  
     using B cell depleting/immunoregulatory antibody combination  
 Anemia(disease)...  
     pernicious anemia; combination therapy for treatment of autoimmune  
     diseases using B cell depleting/immunoregulatory antibody combination  
 Muscle,disease...  
     polymyositis; combination therapy for treatment of autoimmune diseases  
     using B cell depleting/immunoregulatory antibody combination  
 Nerve,disease...  
     polyneuropathy, IgM; combination therapy for treatment of autoimmune  
     diseases using B cell depleting/immunoregulatory antibody combination  
 Blood vessel,disease...  
     Raynaud's phenomenon; combination therapy for treatment of autoimmune  
     diseases using B cell depleting/immunoregulatory antibody combination  
 Arthritis...  
     Reiter's syndrome; combination therapy for treatment of autoimmune  
     diseases using B cell depleting/immunoregulatory antibody combination  
 Connective tissue...  
     scleroderma; combination therapy for treatment of autoimmune diseases  
     using B cell depleting/immunoregulatory antibody combination  
 Nervous system...  
     sclerosis; combination therapy for treatment of autoimmune diseases  
     using B cell depleting/immunoregulatory antibody combination  
 Muscle,disease...  
     stiff-man syndrome; combination therapy for treatment of autoimmune  
     diseases using B cell depleting/immunoregulatory antibody combination  
 CAS REGISTRY NUMBERS:  
 192391-48-3 79217-60-0 104987-11-3 174722-31-7 206181-63-7 82707-54-8  
     combination therapy for treatment of autoimmune diseases using B cell  
     depleting/immunoregulatory antibody combination

6/7/22 (Item 15 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

136101076 CA: 136(7)101076m PATENT  
Methods for abrogating a cellular immune response  
INVENTOR(AUTHOR): Albert, Matthew L.; Jegathesan, Mithila; Darnell,  
Robert B.  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20020004041 A1 DATE: 20020110  
APPLICATION: US 804584 (20010312) \*US 251896 (19990219) \*US 545958  
(20000505)  
PAGES: 35 pp., Cont.-in-part of U.S. Ser. No. 545,958. CODEN: USXXCO  
LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 424093210; A61K-048/00A; A61K-045/00B; A61K-031/739B;  
A61K-038/19B  
SECTION:  
CA215001 Immunochemistry  
IDENTIFIERS: dendritic cell maturation stimulatory mol tolerance,  
monoclonal antibody TNF superfamily ligand receptor  
DESCRIPTORS:  
Immune tolerance...  
anergy, T cell; dendritic cell maturation-stimulatory mols. for  
abrogating cellular immune response and inducing immune tolerance  
Transplant and Transplantation... Animal virus...  
antigen; dendritic cell maturation-stimulatory mols. for abrogating  
cellular immune response and inducing immune tolerance  
Antigens...  
autoantigens; dendritic cell maturation-stimulatory mols. for  
abrogating cellular immune response and inducing immune tolerance  
Chemokine receptors...  
 $\beta$  chemokine receptor CCR6, ligand; dendritic cell  
maturation-stimulatory mols. for abrogating cellular immune response  
and inducing immune tolerance  
Glycoproteins...  
CD40-L (antigen CD40 ligand); dendritic cell maturation-stimulatory  
mols. for abrogating cellular immune response and inducing immune  
tolerance  
Immunity...  
cell-mediated, redn.; dendritic cell maturation-stimulatory mols. for  
abrogating cellular immune response and inducing immune tolerance  
Infection...  
chronic; dendritic cell maturation-stimulatory mols. for abrogating  
cellular immune response and inducing immune tolerance  
DNA...  
CpG-contg.; dendritic cell maturation-stimulatory mols. for abrogating  
cellular immune response and inducing immune tolerance  
T cell(lymphocyte)...  
cytotoxic, redn.; dendritic cell maturation-stimulatory mols. for  
abrogating cellular immune response and inducing immune tolerance  
Transplant rejection... CD4-positive T cell... Dendritic cell... Antibodies  
... CD40(antigen)... Autoimmune disease... Psoriasis... Multiple sclerosis  
... Rheumatoid arthritis... Lupus erythematosus... Immunotherapy...  
Pathogen... Mycobacterium... Human immunodeficiency virus... Molecules...  
Epitopes... Chemotactic factors... Lipopolysaccharides... Monocyte...  
Mammalia... Apoptosis... Invariant chain(class II antigen)... Signal  
transduction,biological...  
dendritic cell maturation-stimulatory mols. for abrogating cellular

immune response and inducing immune tolerance

Cytokine receptors...

DR3 (death receptor 3); dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

T cell(lymphocyte)...

effector cell, redn.; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Proteins...

FK-binding; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

T cell(lymphocyte)...

helper cell/inducer, TH2, redn.; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Histocompatibility antigens...

HLA, HLA-DM; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Histocompatibility antigens...

HLA-A; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Histocompatibility antigens...

HLA-B; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Histocompatibility antigens...

HLA-C; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Histocompatibility antigens...

HLA-DR; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Immune tolerance...

induction; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Diabetes mellitus...

insulin-dependent; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

T cell(lymphocyte)...

killer cell, redn.; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Histocompatibility antigens...

MHC (major histocompatibility complex), class I; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Histocompatibility antigens...

MHC (major histocompatibility complex), class II; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Culture media...

monocyte-conditioned; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Cytokine receptors...

OX40 ligand; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Cytokines...

OX40; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Skin,disease...

pemphigus vulgaris; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Mononuclear cell(leukocyte)...

peripheral blood; dendritic cell maturation-stimulatory mols. for abrogating cellular immune response and inducing immune tolerance

Blood...  
 peripheral mononuclear cells; dendritic cell maturation-stimulatory  
 mols. for abrogating cellular immune response and inducing immune  
 tolerance  
 CD8-positive T cell...  
 redn.; dendritic cell maturation-stimulatory mols. for abrogating  
 cellular immune response and inducing immune tolerance  
 Chemokines...  
 SLC (secondary lymphoid tissue chemokine); dendritic cell  
 maturation-stimulatory mols. for abrogating cellular immune response  
 and inducing immune tolerance  
 Tumor necrosis factors... Tumor necrosis factor receptors...  
 superfamily; dendritic cell maturation-stimulatory mols. for abrogating  
 cellular immune response and inducing immune tolerance  
 Antigens...  
 tumor-assocd.; dendritic cell maturation-stimulatory mols. for  
 abrogating cellular immune response and inducing immune tolerance  
 Cytokines...  
 TWEAK; dendritic cell maturation-stimulatory mols. for abrogating  
 cellular immune response and inducing immune tolerance  
 CAS REGISTRY NUMBERS:  
 147171-40-2 antagonists; dendritic cell maturation-stimulatory mols. for  
 abrogating cellular immune response and inducing immune tolerance  
 9001-92-7 cathepsin D-alternative; dendritic cell maturation-stimulatory  
 mols. for abrogating cellular immune response and inducing immune  
 tolerance  
 363-24-6 9025-26-7 104987-11-3 53123-88-9 207621-35-0 dendritic cell  
 maturation-stimulatory mols. for abrogating cellular immune response  
 and inducing immune tolerance  
 2382-65-2D derivs., DNA contg.; dendritic cell maturation-stimulatory  
 mols. for abrogating cellular immune response and inducing immune  
 tolerance  
 9004-08-4 inhibitors; dendritic cell maturation-stimulatory mols. for  
 abrogating cellular immune response and inducing immune tolerance

6/7/23 (Item 16 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2008 American Chemical Society. All rts. reserv.

136052724 CA: 136(4)52724k PATENT  
 Methods for regulating a cell-mediated immune response by blocking  
 lymphocytic signals and by blocking LFA-1 mediated adhesion  
 INVENTOR(AUTHOR): Townsend, Robert M.; Todderud, Charles Gordon; Peach,  
 Robert J.  
 LOCATION: USA  
 ASSIGNEE: Bristol-Myers Squibb Company  
 PATENT: PCT International ; WO 200195928 A2 DATE: 20011220  
 APPLICATION: WO 2001US18619 (20010608) \*US PV210671 (20000609)  
 PAGES: 75 pp. CODEN: PIXXD2 LANGUAGE: English  
 PATENT CLASSIFICATIONS:  
 CLASS: A61K-038/17A; A61K-039/395B; A61P-037/00B; C07K-014/705B;  
 C07K-016/28B; A61K-039/395B; A61K-038/17B  
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
 CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
 GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
 LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;  
 SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG;  
 KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ  
 ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC;  
 NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

IDENTIFIERS: lymphocytic signal blocker cellular immune response, immunol  
disease allograft rejection antibody CD28, soluble CD40 CD154 B7 CTLA4  
LFA1

DESCRIPTORS:

Transplant rejection...

allotransplant; cell adhesion-blocking and lymphocytic signal-blocking  
agents for regulating cellular immunity and treating immunol. diseases  
and allograft rejection

Actinins...

$\alpha$ -; cell adhesion-blocking and lymphocytic signal-blocking agents  
for regulating cellular immunity and treating immunol. diseases and  
allograft rejection

Integrins...

antigens CD11a; cell adhesion-blocking and lymphocytic signal-blocking  
agents for regulating cellular immunity and treating immunol. diseases  
and allograft rejection

Stomach,disease...

atrophic gastritis, autoimmune; cell adhesion-blocking and lymphocytic  
signal-blocking agents for regulating cellular immunity and treating  
immunol. diseases and allograft rejection

Stomach,disease...

autoimmune gastritis, atrophic; cell adhesion-blocking and lymphocytic  
signal-blocking agents for regulating cellular immunity and treating  
immunol. diseases and allograft rejection

Anemia(disease)...

autoimmune hemolytic anemia; cell adhesion-blocking and lymphocytic  
signal-blocking agents for regulating cellular immunity and treating  
immunol. diseases and allograft rejection

Thyroid gland,disease...

autoimmune thyroiditis; cell adhesion-blocking and lymphocytic  
signal-blocking agents for regulating cellular immunity and treating  
immunol. diseases and allograft rejection

Eye,disease...

autoimmune uveitis; cell adhesion-blocking and lymphocytic  
signal-blocking agents for regulating cellular immunity and treating  
immunol. diseases and allograft rejection

Integrins...

$\beta$ 2; cell adhesion-blocking and lymphocytic signal-blocking agents  
for regulating cellular immunity and treating immunol. diseases and  
allograft rejection

Health products...

biologicals; cell adhesion-blocking and lymphocytic signal-blocking  
agents for regulating cellular immunity and treating immunol. diseases  
and allograft rejection

Cell adhesion molecules...

blocker; cell adhesion-blocking and lymphocytic signal-blocking agents  
for regulating cellular immunity and treating immunol. diseases and  
allograft rejection

Tumor necrosis factors...

blockers or antagonists; cell adhesion-blocking and lymphocytic  
signal-blocking agents for regulating cellular immunity and treating  
immunol. diseases and allograft rejection

Glycoproteins...

CD40-L (antigen CD40 ligand); cell adhesion-blocking and lymphocytic  
signal-blocking agents for regulating cellular immunity and treating  
immunol. diseases and allograft rejection

Transplant rejection... Ligands... CD28(antigen)... CD40(antigen)...

CD80(antigen)... CTLA-4(antigen)... LFA-1(antigen)... Filamin... Rodentia

... Antibodies... Fusion proteins(chimeric proteins)... Psoriasis... Lupus



erythematosus... Graves' disease... Autoimmune disease... Addison's disease  
 ... Diabetes mellitus... Myasthenia gravis... Multiple sclerosis...  
 Sjogren's syndrome... Rheumatic diseases... Rheumatoid arthritis... Human  
 ... Monkey... Ape... Dog(Canis familiaris)... Cat(Felis catus)... Cattle...  
 Horse(Equus caballus)... Rabbit... Mouse... Rat... Immunosuppressants...  
 Corticosteroids,biological studies... Drugs... Molecular cloning... DNA  
 sequences... Protein sequences...  
     cell adhesion-blocking and lymphocytic signal-blocking agents for  
     regulating cellular immunity and treating immunol. diseases and  
     allograft rejection  
 Immunity...  
     cell-mediated; cell adhesion-blocking and lymphocytic signal-blocking  
     agents for regulating cellular immunity and treating immunol. diseases  
     and allograft rejection  
 Immunoglobulins...  
     chimeric CTLA4; cell adhesion-blocking and lymphocytic signal-blocking  
     agents for regulating cellular immunity and treating immunol. diseases  
     and allograft rejection  
 Intestine,disease...  
     Crohn's; cell adhesion-blocking and lymphocytic signal-blocking agents  
     for regulating cellular immunity and treating immunol. diseases and  
     allograft rejection  
 Integrins...  
     cytohesin 1; cell adhesion-blocking and lymphocytic signal-blocking  
     agents for regulating cellular immunity and treating immunol. diseases  
     and allograft rejection  
 Immunity...  
     disorder; cell adhesion-blocking and lymphocytic signal-blocking agents  
     for regulating cellular immunity and treating immunol. diseases and  
     allograft rejection  
 Kidney,disease...  
     Goodpasture's syndrome; cell adhesion-blocking and lymphocytic  
     signal-blocking agents for regulating cellular immunity and treating  
     immunol. diseases and allograft rejection  
 Transplant and Transplantation...  
     graft-vs.-host reaction; cell adhesion-blocking and lymphocytic  
     signal-blocking agents for regulating cellular immunity and treating  
     immunol. diseases and allograft rejection  
 Transplant and Transplantation...  
     heart; cell adhesion-blocking and lymphocytic signal-blocking agents  
     for regulating cellular immunity and treating immunol. diseases and  
     allograft rejection  
 Cell adhesion molecules...  
     ICAM-1 (intercellular adhesion mol. 1); cell adhesion-blocking and  
     lymphocytic signal-blocking agents for regulating cellular immunity and  
     treating immunol. diseases and allograft rejection  
 Cell adhesion molecules...  
     ICAM-2 (intercellular adhesion mol. 2); cell adhesion-blocking and  
     lymphocytic signal-blocking agents for regulating cellular immunity and  
     treating immunol. diseases and allograft rejection  
 Cell adhesion molecules...  
     ICAM-3 (intercellular adhesion mol. 3); cell adhesion-blocking and  
     lymphocytic signal-blocking agents for regulating cellular immunity and  
     treating immunol. diseases and allograft rejection  
 Cytokines...  
     inflammatory; cell adhesion-blocking and lymphocytic signal-blocking  
     agents for regulating cellular immunity and treating immunol. diseases  
     and allograft rejection  
 Diabetes mellitus...  
     insulin-dependent; cell adhesion-blocking and lymphocytic  
     signal-blocking agents for regulating cellular immunity and treating

immunol. diseases and allograft rejection

Drug delivery systems...

- local; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Signal transduction,biological...

- lymphocytic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Connective tissue...

- mixed connective tissue disease; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Antibodies...

- monoclonal; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Hypothyroidism...

- myxedema; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Kidney,disease...

- nephritis, lupus; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Anti-inflammatory agents...

- nonsteroidal; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Skin,disease...

- pemphigus; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Anemia(disease)...

- pernicious anemia; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Muscle,disease...

- polymyositis; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Biliary tract...

- primary biliary cirrhosis; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Connective tissue...

- scleroderma; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Lymphocyte...

- signal; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Transplant and Transplantation...

- skin; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Antigens...

- surface; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Eye,disease...

sympathetic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Drug delivery systems...

systemic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Leukemia...

T-cell, acute; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Lymphoma...

T-cell; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Disease,animal...

testicular angiocentric T cell lymphoma; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Platelet(blood)...

thrombocytopenia, idiopathic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Skin... Heart...

transplant; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Intestine,disease...

ulcerative colitis; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Blood vessel,disease...

vasculitis, benign lymphocytic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Hepatitis...

viral, chronic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

CAS REGISTRY NUMBERS:

382707-61-1P 382707-62-2P amino acid sequence; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

79217-60-0 53-03-2 446-86-6 59-05-2 170277-31-3 118-42-3 599-79-1 185243-69-0 143090-92-0 cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

329900-75-6 inhibitors; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

382707-60-0P 382707-63-3P nucleotide sequence; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

7440-57-5D salts, cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

382711-44-6 382711-45-7 382711-46-8 382711-47-9 382711-48-0 unclaimed sequence; methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking LFA-1 mediated adhesion

6/7/24 (Item 17 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

135370653 CA: 135(26)370653a PATENT  
Compositions and methods for achieving immune suppression  
INVENTOR(AUTHOR): Strom, Terry B.; Maslinski, Wlodzimierz; Zheng, Xin  
Xiao; Kim, Yon Su; Lacraz, Sylvie Ferrari  
LOCATION: USA  
ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.  
PATENT: PCT International ; WO 200187330 A2 DATE: 20011122  
APPLICATION: WO 2001US15578 (20010514) \*US PV203801 (20000512)  
PAGES: 42 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-038/20A; A61K-038/17B; A61K-039/395B; A61P-037/06B;  
C07K-014/54B; C07K-014/705B; A61K-038/20B; A61K-038/17B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;  
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;  
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;  
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG  
SECTION:  
CA215005 Immunochemistry  
CA203XXX Biochemical Genetics  
IDENTIFIERS: interleukin 15 antibody costimulatory signal  
immunosuppression, immune tolerance mutant IL15 B7 antigen, autoimmune  
disease chimeric CTLA4 Ig IL15  
DESCRIPTORS:  
Thyroid gland,disease...  
autoimmune thyroiditis; interleukin 15 receptor-targeting agent and  
costimulatory signal-inhibiting agent for diagnosis and treatment of  
immunol. diseases or autoimmune diseases  
Thyroid gland,disease...  
autoimmune; interleukin 15 receptor-targeting agent and costimulatory  
signal-inhibiting agent for diagnosis and treatment of immunol.  
diseases or autoimmune diseases  
Skin,disease...  
Brazilian pemphigus; interleukin 15 receptor-targeting agent and  
costimulatory signal-inhibiting agent for diagnosis and treatment of  
immunol. diseases or autoimmune diseases  
Glycoproteins,specific or class...  
CD40-L (antigen CD40 ligand); interleukin 15 receptor-targeting agent  
and costimulatory signal-inhibiting agent for diagnosis and treatment  
of immunol. diseases or autoimmune diseases  
Nervous system...  
central, disease, autoimmune; interleukin 15 receptor-targeting agent  
and costimulatory signal-inhibiting agent for diagnosis and treatment  
of immunol. diseases or autoimmune diseases  
CTLA-4(antigen)...  
chimeric; interleukin 15 receptor-targeting agent and costimulatory  
signal-inhibiting agent for diagnosis and treatment of immunol.  
diseases or autoimmune diseases  
Signal transduction,biological...  
costimulatory mol. inhibitor; interleukin 15 receptor-targeting agent  
and costimulatory signal-inhibiting agent for diagnosis and treatment  
of immunol. diseases or autoimmune diseases  
Immunity...

disorder; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Immunoglobulins...  
fragments; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Immunoglobulins...  
G, Fc; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Intestine,disease...  
inflammatory; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Blood vessel,disease...  
injury; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Diabetes mellitus...  
insulin-dependent; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Immunosuppression... Antibodies... T cell(lymphocyte)... Antigen-presenting cell... CD80(antigen)... CD86(antigen)... DNA sequences... Protein sequences... Molecular cloning... Fusion proteins(chimeric proteins)... Immunoglobulins... CD28(antigen)... CD40(antigen)... Autoimmune disease... Rheumatic diseases... Sjogren's syndrome... Dermatomyositis... Behcet's syndrome... Rheumatoid arthritis... Graves' disease... Multiple sclerosis ... Myasthenia gravis... Encephalomyelitis... Psoriasis... AIDS(disease)...

Transplant rejection... Neoplasm... Immunosuppressants...  
interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Interleukin receptors...  
interleukin 15; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Connective tissue...  
mixed connective tissue disease; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Interleukin 15...  
mutant; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Diabetes mellitus...  
non-insulin-dependent; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Skin,disease...  
pemphigus foliaceus; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Skin,disease...  
pemphigus vegetans; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Skin,disease...  
pemphigus vulgaris; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of

immunol. diseases or autoimmune diseases  
Skin,disease...  
pemphigus; interleukin 15 receptor-targeting agent and costimulatory  
signal-inhibiting agent for diagnosis and treatment of immunol.  
diseases or autoimmune diseases  
Muscle,disease...  
polymyositis; interleukin 15 receptor-targeting agent and costimulatory  
signal-inhibiting agent for diagnosis and treatment of immunol.  
diseases or autoimmune diseases  
Arthritis...  
Reiter's syndrome; interleukin 15 receptor-targeting agent and  
costimulatory signal-inhibiting agent for diagnosis and treatment of  
immunol. diseases or autoimmune diseases  
Connective tissue...  
scleroderma; interleukin 15 receptor-targeting agent and costimulatory  
signal-inhibiting agent for diagnosis and treatment of immunol.  
diseases or autoimmune diseases  
Lupus erythematosus...  
systemic; interleukin 15 receptor-targeting agent and costimulatory  
signal-inhibiting agent for diagnosis and treatment of immunol.  
diseases or autoimmune diseases  
CAS REGISTRY NUMBERS:  
199129-26-5 172075-43-3 amino acid sequence; interleukin 15  
receptor-targeting agent and costimulatory signal-inhibiting agent for  
diagnosis and treatment of immunol. diseases or autoimmune diseases  
374585-67-8 172075-42-2 nucleotide sequence; interleukin 15  
receptor-targeting agent and costimulatory signal-inhibiting agent for  
diagnosis and treatment of immunol. diseases or autoimmune diseases  
288797-03-5 288797-02-4 288797-04-6 unclaimed nucleotide sequence;  
compsn. and methods for achieving immune suppression

6/7/25 (Item 18 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

126017804 CA: 126(2)17804h PATENT  
Human antibodies derived from immunized xenomice  
INVENTOR(AUTHOR): Kucherlapati, Raju; Jakobovits, Aya; Klapholz, Sue;  
Brenner, Daniel G.; Capon, Daniel J.  
LOCATION: USA  
ASSIGNEE: Cell Genesys, Inc.  
PATENT: PCT International ; WO 9634096 A1 DATE: 19961031  
APPLICATION: WO 95US5500 (19950428)  
PAGES: 64 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-015/00A  
DESIGNATED COUNTRIES: AU; CA; FI; HU; JP; KR; NO; NZ  
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;  
NL; PT; SE  
SECTION:  
CA215003 Immunochemistry  
IDENTIFIERS: human antibody Ig xenomice therapeutic  
DESCRIPTORS:  
Proteins(specific proteins and subclasses)...  
amadori; human antibodies derived from immunized xenomice  
Dermatophagoides... Leukocyte...  
antigen; human antibodies derived from immunized xenomice  
Antigens...  
A7; human antibodies derived from immunized xenomice  
Interferon receptors...

$\beta$ ; human antibodies derived from immunized xenomice  
Antigens...  
B7.3; human antibodies derived from immunized xenomice  
CD antigens...  
CDw52; human antibodies derived from immunized xenomice  
CD antigens...  
CD27; human antibodies derived from immunized xenomice  
Antigens...  
CD29 ligand; human antibodies derived from immunized xenomice  
Antigens...  
CD30 ligand; human antibodies derived from immunized xenomice  
CD antigens...  
CD6; human antibodies derived from immunized xenomice  
CD antigens...  
CD72; human antibodies derived from immunized xenomice  
Fc receptors...  
E; human antibodies derived from immunized xenomice  
Sialoglycoproteins...  
endosialins; human antibodies derived from immunized xenomice  
Glycoproteins(specific proteins and subclasses)...  
gcIII; human antibodies derived from immunized xenomice  
Lipids,biological studies...  
glycated; human antibodies derived from immunized xenomice  
Glycoproteins(specific proteins and subclasses)...  
gp39; human antibodies derived from immunized xenomice  
Cytokines...  
Gro $\alpha$ ; human antibodies derived from immunized xenomice  
Cytokines...  
Gro $\beta$ ; human antibodies derived from immunized xenomice  
Myelin...  
growth inhibitor assocd. with; human antibodies derived from immunized xenomice  
Thyroid diseases...  
Hashimoto's thyroiditis; human antibodies derived from immunized xenomice  
Surface antigens...  
hepatitis virus; human antibodies derived from immunized xenomice  
Adult respiratory distress syndrome... Allergens... Animal cell line...  
Animal cells... Antibodies... Antigens... Asthma... Autoimmune diseases...  
B cell(lymphocyte)... Behcet's syndrome... Cachexia... Carcinoembryonic antigen...  
CD11a(antigen)... CD11b(antigen)... CD11c(antigen)...  
CD14(antigen)... CD19(antigen)... CD20(antigen)... CD22(antigen)...  
CD28(antigen)... CD2(antigen)... CD30(antigen)... CD3(antigen)... CD40 ligand...  
CD40(antigen)... CD44(antigen)... CD45(antigen)... CD4(antigen)...  
... CD56(antigen)... CD5(antigen)... CD69(antigen)... CD7(antigen)...  
CD80(antigen)... CD86(antigen)... CD8(antigen)... Cell adhesion molecules...  
... Chemokines... Cholesteryl ester transfer protein... Class I MHC antigens...  
Class II MHC antigens... Coagulation factors(blood)...  
CTLA-4(antigen)... Cytomegalovirus... Dermatomyositis... Diagnosis... E glycoprotein(envelope glycoprotein)...  
Endotoxins... Enzymes,biological studies... Eosinophil cationic protein...  
Epidermal growth factor receptors... Erythropoietin receptors... E-selectin...  
Fas antigen... Fc receptors... Fc $\epsilon$ RI receptors... Fc $\epsilon$ RII receptors... Fibrinogens...  
Fibrins... Fibroblast growth factor receptors... Glomerulonephritis...  
Glycoprotein B... Glycoprotein H... Graft-vs.-host reaction... Granulocyte colony-stimulating factor receptors...  
Graves' disease... Growth factor receptors... Growth factors(animal)... Hematopoietin receptors...  
Hepatitis virus... Histocompatibility antigens... Human herpesvirus 3... Human herpesvirus 4...  
Human herpesvirus... Human immunodeficiency virus 1... Human papillomavirus...  
ICAM-1(cell adhesion molecule)... ICAM-2(cell adhesion molecule)... IgE... Immunoglobulins...  
Insulin-dependent diabetes

mellitus... Integrin  $\alpha 1\beta 1$ ... Integrin  $\alpha 2\beta 1$ ...  
 Integrin  $\alpha 3\beta 1$ ... Integrin  $\alpha 4\beta 1$ ... Integrin  
 $\alpha 5\beta 1$ ... Integrin  $\alpha 6\beta 1$ ... Integrin  $\beta 1$ ... Integrin  
 $\beta 2$ ... Interferon receptors... Interferon  $\alpha$  receptors...  
 Interferon  $\gamma$  receptors... Interferon  $\gamma$ ... Interleukin receptors  
 ... Interleukin 1 receptors... Interleukin 10... Interleukin 11...  
 Interleukin 12... Interleukin 13... Interleukin 15... Interleukin 1...  
 Interleukin 2 receptors... Interleukin 2... Interleukin 3 receptors...  
 Interleukin 3... Interleukin 4 receptors... Interleukin 4... Interleukin 5  
 receptors... Interleukin 5... Interleukin 6 receptors... Interleukin 6...  
 Interleukin 7 receptors... Interleukin 7... Interleukin 8 receptors...  
 Interleukin 8... Interleukin 9... Interleukins... Ley antigen...  
 LFA-1(antigen)... LFA-3(antigen)... L-selectin... Macrophage inflammatory  
 protein 1 $\alpha$ ... Mac-1 antigen... Major basic protein...  
 Metastasis(tumor)... Monoclonal antibodies... Monocyte chemoattractant  
 protein-1... Mucins... Multiple myeloma... Multiple sclerosis... Myasthenia  
 gravis... Neutrophil-activating peptide-2... Osteopontin... Osteoporosis...  
 Oxidized low-density lipoproteins... Paget's disease of bone...  
 Platelet-derived growth factor receptors... Platelet-derived growth factors  
 ... Polymyositis... Pseudomonas... Psoriasis... p150,95 antigen...  
 P-glycoproteins... P-selectin... RANTES(chemokine)... Renal cell carcinoma  
 ... Reperfusion injury... Respiratory syncytial virus... Rh blood groups...  
 Rheumatoid arthritis... Scleroderma... Septic shock... Sjogren's syndrome  
 ... Systemic lupus erythematosus... TCR(T-cell receptors)... Tetanus toxin  
 ... Therapy... Thyrotropin receptors... Toxins... Transforming growth  
 factor  $\beta$  receptors... Transforming growth factors  $\beta$ ... Tumor  
 necrosis factor receptors... Tumor necrosis factor  $\alpha$ ...  
 Tumor-associated antigen... Type IV collagen... VCAM-1(cell adhesion  
 molecule)...  
     human antibodies derived from immunized xenomice  
 Parathyroid hormone receptors...  
     humoral hypercalcemic factor; human antibodies derived from immunized  
     xenomice  
 Genes(animal)...  
     Ig.; human antibodies derived from immunized xenomice  
 Interleukin receptors...  
     interleukin 10 receptors; human antibodies derived from immunized  
     xenomice  
 Interleukin receptors...  
     interleukin 11 receptors; human antibodies derived from immunized  
     xenomice  
 Interleukin receptors...  
     interleukin 13 receptors; human antibodies derived from immunized  
     xenomice  
 Interleukins... Receptors...  
     interleukin 14; human antibodies derived from immunized xenomice  
 Interleukin receptors...  
     interleukin 15 receptors; human antibodies derived from immunized  
     xenomice  
 Interleukin receptors...  
     interleukin 9 receptors; human antibodies derived from immunized  
     xenomice  
 Lewis blood groups...  
     Leb, synthetic; human antibodies derived from immunized xenomice  
 Selectins...  
     ligands; human antibodies derived from immunized xenomice  
 Proteins(specific proteins and subclasses)...  
     LMP-1; human antibodies derived from immunized xenomice  
 Membrane proteins...  
     LMP-2 (latent-infection membrane protein 2); human antibodies derived  
     from immunized xenomice



Allergens...  
     Lol p I (Lolium perenne, I); human antibodies derived from immunized xenomice  
 Connective tissue diseases...  
     mixed; human antibodies derived from immunized xenomice  
 Skin diseases...  
     Paget disease; human antibodies derived from immunized xenomice  
 Breast diseases... Reproductive tract diseases...  
     Paget; human antibodies derived from immunized xenomice  
 Antibodies...  
     pANCA or perinuclear antineutrophil cytoplasm antibodies; human antibodies derived from immunized xenomice  
 Skin diseases...  
     pemphigus; human antibodies derived from immunized xenomice  
 Chemokines...  
     PF4; human antibodies derived from immunized xenomice  
 c-erbB2 gene(animal)...  
     products; human antibodies derived from immunized xenomice  
 Virus...  
     protein; human antibodies derived from immunized xenomice  
 IgE... Interleukin 11... Interleukin 12... Interleukin 13... Interleukin 15  
     ... Interleukin 9...  
     receptors; human antibodies derived from immunized xenomice  
 DNA...  
     recombinant; human antibodies derived from immunized xenomice  
 Arthritis... Conjunctivitis... Urinary tract diseases...  
     Reiter's syndrome; human antibodies derived from immunized xenomice  
 Transplant(organ)...  
     rejection; human antibodies derived from immunized xenomice  
 Ischemia...  
     reperfusion; human antibodies derived from immunized xenomice  
 Ligands...  
     selectin; human antibodies derived from immunized xenomice  
 Venoms...  
     snake; human antibodies derived from immunized xenomice  
 Proteins(specific proteins and subclasses)...  
     uropontins; human antibodies derived from immunized xenomice  
 Receptors...  
     vascular endothelial growth factor; human antibodies derived from immunized xenomice  
 Bee... Snake...  
     venom; human antibodies derived from immunized xenomice  
 Proteins (general),biological studies...  
     viral; human antibodies derived from immunized xenomice  
 Mouse...  
     xeno-; human antibodies derived from immunized xenomice  
 Interleukin receptors...  
     12; human antibodies derived from immunized xenomice  
 CAS REGISTRY NUMBERS:  
 90027-15-3 90245-82-3 90546-31-3 196000-12-3 532375-95-3 620103-71-3  
     620315-43-3 622295-09-3 800435-34-3 802954-38-3 802955-41-3  
     816697-07-3 829868-98-3 924482-21-3 986038-40-3 1162437-33-3  
     1274646-02-3 human antibodies derived from immunized xenomice  
 90026-46-3 proteins related to; human antibodies derived from immunized xenomice  
 ? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR -

CD154 OR GP39 OR CD154)  
S4 1 RD S3 (unique items)  
S5 37 (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR  
CD154)  
S6 25 RD S5 (unique items)  
? t s6/3/all

6/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0020104725 BIOSIS NO.: 200800151664  
T-B cell interaction is crucial for the induction of desmoglein 3-specific  
IgG autoantibodies in an HLA-class II transgenic mouse model of  
pemphigus vulgaris  
AUTHOR: Eming R (Reprint); Hertl M; Schmidt J; Podstawa E; Feliciani C;  
Sonderstrup G  
AUTHOR ADDRESS: Univ Marburg, Marburg, Germany\*\*Germany  
JOURNAL: Journal of Investigative Dermatology 127 (Suppl. 2): pS66 OCT  
2007 2007  
CONFERENCE/MEETING: 37th Annual Meeting of the  
European-Society-for-Dermatological-Research Zurich, SWITZERLAND  
September 05 -08, 2007; 20070905  
SPONSOR: European Soc Dermatol Res  
ISSN: 0022-202X  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

6/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019927481 BIOSIS NO.: 200700587222  
Increased serum levels of circulating CD40 ligand in patients  
with bullous pemphigoid: Preliminary results  
AUTHOR: Watanabe R (Reprint); Ishiura N; Nakashima H; Yazawa N; Kuwano Y;  
Tada Y; Okochi H; Fujimoto M; Tamaki K  
AUTHOR ADDRESS: Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, 13-1  
Takaramachi, Kanazawa, Ishikawa 9208641, Japan\*\*Japan  
AUTHOR E-MAIL ADDRESS: fujimoto-m@umin.ac.jp  
JOURNAL: Dermatology (Basel) 215 (3): p180-186 2007 2007  
ITEM IDENTIFIER: doi:10.1159/000106573  
ISSN: 1018-8665  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

6/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

0019830322 BIOSIS NO.: 200700490063  
The CD40/CD40 ligand system is involved in the pathogenesis of  
pemphigus  
AUTHOR: Caproni Marzia; Antiga Emiliano; Torchia Daniele; Volpi Walter; del  
Bianco Elena; Cappetti Alessio; Feliciani Claudio; Fabbri Paolo (Reprint)  
AUTHOR ADDRESS: Via Pergola, 58-60, I-50121 Florence, Italy\*\*Italy  
AUTHOR E-MAIL ADDRESS: fabbri@unifi.it

JOURNAL: Clinical Immunology (Orlando) 124 (1): p22-25 JUL 2007 2007  
ITEM IDENTIFIER: doi:10.1016/j.clim.2007.04.007  
ISSN: 1521-6616  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

6/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

19097585 BIOSIS NO.: 200600442980  
Tolerance induction by the blockade of CD40/CD154 interaction in  
pemphigus vulgaris mouse model  
AUTHOR: Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki;  
Iwasaki Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji; Amagai  
Masayuki (Reprint)  
AUTHOR ADDRESS: Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35  
Shinanomachi, Tokyo 1608582, Japan\*\*Japan  
AUTHOR E-MAIL ADDRESS: amagai@sc.itc.keio.ac.jp  
JOURNAL: Journal of Investigative Dermatology 126 (1): p105-113 JAN 2006  
2006  
ISSN: 0022-202X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

6/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

19097571 BIOSIS NO.: 200600442966  
Inhibition of pemphigus vulgaris by targeting of the CD40-CD154  
co-stimulatory pathway: A step toward antigen-specific therapy?  
AUTHOR: Liu Zhi (Reprint); Li Ning; Diaz Luis A  
AUTHOR ADDRESS: Univ N Carolina, Dept Dermatol, 3100 Thuston Bowles, Chapel  
Hill, NC 27599 USA\*\*USA  
AUTHOR E-MAIL ADDRESS: zhiliu@med.unc.edu  
JOURNAL: Journal of Investigative Dermatology 126 (1): p11-13 JAN 2006  
2006  
ISSN: 0022-202X  
DOCUMENT TYPE: Article; Editorial  
RECORD TYPE: Citation  
LANGUAGE: English

6/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

16901534 BIOSIS NO.: 200200495045  
Blockade of CD40/CD40L interaction has therapeutic benefits in the  
pemphigus vulgaris mouse model  
AUTHOR: Aoki M (Reprint); Tsunoda K (Reprint); Ota T (Reprint); Iwasaki T;  
Tanaka S; Koyasu S; Amagai M (Reprint); Nishikawa T (Reprint)  
AUTHOR ADDRESS: Dermatology, Keio University of School of Medicine, Tokyo,  
Japan\*\*Japan  
JOURNAL: Journal of Investigative Dermatology 119 (1): p317 July, 2002  
2002

MEDIUM: print  
CONFERENCE/MEETING: 63rd Annual Meeting of the Society for Investigative Dermatology Los Angeles, California, USA May 15-18, 2002; 20020515  
ISSN: 0022-202X  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

6/3/7 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081248610 EMBASE No: 2006310874  
B cells move to centre stage: Novel opportunities for autoimmune disease treatment  
Browning J.L.  
Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge, MA 02445, United States  
AUTHOR EMAIL: Jeff.Browning@biogenidec.com  
CORRESP. AUTHOR: Browning J.L.  
CORRESP. AUTHOR AFFIL: Department of Immunobiology USA, Biogen Idec, 12 Cambridge Center, Cambridge, MA 02445, United States  
CORRESP. AUTHOR EMAIL: Jeff.Browning@biogenidec.com

Nature Reviews Drug Discovery ( Nat. Rev. Drug Discov. ) (United Kingdom)  
July 1, 2006, 5/7 (564-576)  
CODEN: NRDDA ISSN: 14741776 eISSN: 14741784  
PUBLISHER ITEM IDENTIFIER: N2085  
DOI: 10.1038/nrd2085  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 173

6/3/8 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

148306456 CA: 148(14)306456e PATENT  
Methods of identifying a marker of regulatory CD4+ T cells  
INVENTOR(AUTHOR): Dromey, James A.; Mannering, Stuart I.; Harrison, Leonard C.  
LOCATION: Australia  
ASSIGNEE: The Walter and Eliza Hall Institute of Medical Research  
PATENT: PCT International ; WO 200828229 A1 DATE: 20080313  
APPLICATION: WO 2007AU1302 (20070905) \*US 2006PV842548 (20060905)  
PAGES: 78pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
IPC/8 + Level Value Position Status Version Action Source Office:  
C12N-0005/08 A I F B 20060101 H AU  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/9 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

148055086 CA: 148(3)55086n PATENT  
Preparation of pyrrolopyrimidine compounds as protein kinase inhibitors  
INVENTOR(AUTHOR): Brain, Christopher Thomas; Thoma, Gebhard; Sung, Moo Je  
LOCATION: Switz.  
ASSIGNEE: Novartis A.-G.; Novartis Pharma G.m.b.H.  
PATENT: PCT International ; WO 2007140222 A2 DATE: 20071206  
APPLICATION: WO 2007US69595 (20070524) \*US 2006PV808605 (20060526)  
PAGES: 213pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;  
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;  
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ;  
NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL;  
SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/10 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

147534655 CA: 147(26)534655d PATENT  
Use of a compound with receptor activator of nuclear factor-kB ligand  
(RANKL) activity  
INVENTOR(AUTHOR): Penninger, Josef; Loser, Karin; Beissert, Stefan  
LOCATION: Austria  
ASSIGNEE: Imba-Institut Fuer Molekulare Biotechnologie GmbH  
PATENT: PCT International ; WO 2007128564 A2 DATE: 20071115  
APPLICATION: WO 2007EP4045 (20070508) \*EP 2006450071 (20060508)  
PAGES: 44pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
IPCR/8 + Level Value Position Status Version Action Source Office:  
A61K-0031/00 A I F B 20060101 H EP  
A61P-0037/00 A I L B 20060101 H EP  
A61P-0017/00 A I L B 20060101 H EP  
A61K-0038/20 A I L B 20060101 H EP  
A61K-0038/16 A I L B 20060101 H EP  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;  
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;  
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;  
NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;  
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/11 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146006355 CA: 146(1)6355z PATENT

Biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

INVENTOR(AUTHOR): Aukerman, Sharon Lea; Jallal, Bahija; Luqman, Mohammad

LOCATION: USA

ASSIGNEE: Novartis AG; Xoma Technology

PATENT: PCT International ; WO 2006125117 A2 DATE: 20061123

APPLICATION: WO 2006US19325 (20060518) \*US 2005PV682575 (20050518) \*US 2005PV749336 (20051209)

PAGES: 145pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

G01N-0033/564 A I F B 20060101 H EP

G01N-0033/68 A I L B 20060101 H EP

A61P-0037/00 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/12 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

145055995 CA: 145(4)55995w PATENT

Modulation of Fc gamma receptors for optimizing immunotherapy

INVENTOR(AUTHOR): Boruchov, Adam; Young, James W.

LOCATION: USA

ASSIGNEE: Memorial Sloan-Kettering Cancer Center

PATENT: European Pat. Appl. ; EP 1674479 A1 DATE: 20060628

APPLICATION: EP 2005250446 (20050128) \*US 2004PV638422 (20041222) \*US 2004PV640685 (20041230) \*US 2005PV647616 (20050127)

PAGES: 77 pp. CODEN: EPXXDW LANGUAGE: English

DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR; BG; CZ; EE; HU; PL; SK; BA; HR; IS; YU

6/3/13 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

143241985 CA: 143(14)241985b PATENT

Inhibition of T cell activation in the treatment of immunological disease by blocking class II MHC antigen function

INVENTOR(AUTHOR): Chung, Yong-Hoon; Cho, Hoon-Sik; Park, Hong-Gyu; Yi, Ki-Wan

LOCATION: S. Korea

ASSIGNEE: Medexgen Inc.

PATENT: PCT International ; WO 200577415 A1 DATE: 20050825

APPLICATION: WO 2005KR457 (20050218) \*KR 10835 (20040218)

PAGES: 141 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/14 (Item 7 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142480770 CA: 142(26)480770p PATENT

Antagonistic monoclonal antibodies and derivatives specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror, Isabel

LOCATION: USA

ASSIGNEE: Chiron Corporation

PATENT: PCT International ; WO 200544306 A2 DATE: 20050519

APPLICATION: WO 2004US36957 (20041104) \*US 2003PV517337 (20031104) \*US 2003PV525579 (20031126) \*US 2004PV565710 (20040427)

PAGES: 114 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/15 (Item 8 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142409698 CA: 142(22)409698r PATENT

Vaccines for cancer, autoimmune disease and infections

INVENTOR(AUTHOR): Molldrem, Jeffrey

LOCATION: USA

ASSIGNEE: Board of Regents, the University of Texas System

PATENT: PCT International ; WO 200535714 A2 DATE: 20050421

APPLICATION: WO 2004US27792 (20040826) \*US 2003PV498238 (20030826)

PAGES: 235 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;

GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ;  
VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA  
; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;  
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;  
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;  
SN; TD; TG

6/3/16 (Item 9 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

142334937 CA: 142(18)334937g PATENT  
Regulatory leukocytes repressing B cell autoantibody secretion  
INVENTOR(AUTHOR): Vilen, Barbara J.; Kilmon, Michelle; Rutan, Jennifer A.  
LOCATION: USA  
ASSIGNEE: University of North Carolina At Chapel Hill  
PATENT: PCT International ; WO 200527841 A2 DATE: 20050331  
APPLICATION: WO 2004US30325 (20040916) \*US 2003PV503534 (20030916)  
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;  
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;  
NE; SN; TD; TG

6/3/17 (Item 10 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

142259982 CA: 142(14)259982n PATENT  
Compositions comprising autoantigen and antigen-specific multivalent  
antibody for treating cancer, infection and autoimmune disease  
INVENTOR(AUTHOR): Barabas, Arpad Z.  
LOCATION: Can.,  
ASSIGNEE: The Governors of the University of Calgary  
PATENT: PCT International ; WO 200516379 A1 DATE: 20050224  
APPLICATION: WO 2004CA1494 (20040812) \*US 2003PV495804 (20030815)  
PAGES: 104 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/395A; A61K-039/00B; A61P-037/00B; A61P-037/02B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;  
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;  
NE; SN; TD; TG



6/3/18 (Item 11 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

141122334 CA: 141(8)122334n PATENT  
Immunotherapy of B cell malignancies and autoimmune disease using  
unconjugated and conjugated antibodies, fragments or fusion proteins  
INVENTOR(AUTHOR): Goldenberg, David M.; Hansen, Hans  
LOCATION: USA  
ASSIGNEE: Immunomedics, Inc.; Mccall, John Douglas  
PATENT: PCT International ; WO 200458298 A1 DATE: 20040715  
APPLICATION: WO 2003GB5700 (20031231) \*US PV437145 (20021231)  
PAGES: 49 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/00A; A61K-041/00B; A61K-051/10B; A61K-039/395B;  
A61P-005/00B; A61P-037/06B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT;  
RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ;  
VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; SD  
; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG;  
CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO;  
SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD;  
TG

6/3/19 (Item 12 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

139317445 CA: 139(21)317445r PATENT  
Remedies for pemphigus containing CD40l antagonist as the active  
ingredient  
INVENTOR(AUTHOR): Amagai, Masayuki; Nishikawa, Takeji  
LOCATION: Japan,  
ASSIGNEE: Keio University; Eisai Co., Ltd.  
PATENT: PCT International ; WO 200386463 A1 DATE: 20031023  
APPLICATION: WO 2003JP4219 (20030402) \*JP 2002101886 (20020403)  
PAGES: 22 pp. CODEN: PIXXD2 LANGUAGE: Japanese  
PATENT CLASSIFICATIONS:  
CLASS: A61K-045/00A; A61K-039/395B; A61P-017/00B; A61P-037/06B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC;  
SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE  
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;  
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;  
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/20 (Item 13 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

137228962 CA: 137(16)228962y PATENT

CD4+CD25+ regulatory T cells from human blood  
INVENTOR(AUTHOR): Schuler, Gerold  
LOCATION: Germany,  
PATENT: European Pat. Appl. ; EP 1241249 A1 DATE: 20020918  
APPLICATION: EP 2001106033 (20010312)  
PAGES: 26 pp. CODEN: EPXXDW LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-005/06A; A61K-035/14B; G01N-033/50B; A61P-037/06B;  
A61P-037/04B  
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;  
SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR

6/3/21 (Item 14 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

136246408 CA: 136(16)246408f PATENT  
Combination therapy for treatment of autoimmune diseases using B cell  
depleting/immunoregulatory antibody combination.  
INVENTOR(AUTHOR): Hanna, Nabil  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals  
PATENT: PCT International ; WO 200222212 A2 DATE: 20020321  
APPLICATION: WO 2001US29026 (20010918) \*US PV257147 (20001222)  
PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61P-037/00; A61K-039/39  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA;  
CH; CN; CO; CU; CZ; EE; ES; FI; GB; GE; GM; HU; ID; IL; IN; KP; KR; LK; LR;  
MN; MW; MX; NO; NZ; PL; PT; RO; RU DESIGNATED REGIONAL: GH; GM; KE; LS; MW  
; MZ; SD; SL; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE;  
IT; MC; NL; PT; SE; TR; CG; CI; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/22 (Item 15 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

136101076 CA: 136(7)101076m PATENT  
Methods for abrogating a cellular immune response  
INVENTOR(AUTHOR): Albert, Matthew L.; Jegathesan, Mithila; Darnell,  
Robert B.  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20020004041 A1 DATE: 20020110  
APPLICATION: US 804584 (20010312) \*US 251896 (19990219) \*US 545958  
(20000505)  
PAGES: 35 pp., Cont.-in-part of U.S. Ser. No. 545,958. CODEN: USXXCO  
LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 424093210; A61K-048/00A; A61K-045/00B; A61K-031/739B;  
A61K-038/19B

6/3/23 (Item 16 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

136052724 CA: 136(4)52724k PATENT  
Methods for regulating a cell-mediated immune response by blocking  
lymphocytic signals and by blocking LFA-1 mediated adhesion

INVENTOR(AUTHOR): Townsend, Robert M.; Todderud, Charles Gordon; Peach, Robert J.

LOCATION: USA

ASSIGNEE: Bristol-Myers Squibb Company

PATENT: PCT International ; WO 200195928 A2 DATE: 20011220

APPLICATION: WO 2001US18619 (20010608) \*US PV210671 (20000609)

PAGES: 75 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-038/17A; A61K-039/395B; A61P-037/00B; C07K-014/705B; C07K-016/28B; A61K-039/395B; A61K-038/17B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/24 (Item 17 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

135370653 CA: 135(26)370653a PATENT

Compositions and methods for achieving immune suppression

INVENTOR(AUTHOR): Strom, Terry B.; Maslinski, Wlodzimierz; Zheng, Xin Xiao; Kim, Yon Su; Lacraz, Sylvie Ferrari

LOCATION: USA

ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.

PATENT: PCT International ; WO 200187330 A2 DATE: 20011122

APPLICATION: WO 2001US15578 (20010514) \*US PV203801 (20000512)

PAGES: 42 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-038/20A; A61K-038/17B; A61K-039/395B; A61P-037/06B; C07K-014/54B; C07K-014/705B; A61K-038/20B; A61K-038/17B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/25 (Item 18 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

126017804 CA: 126(2)17804h PATENT

Human antibodies derived from immunized xenomice

INVENTOR(AUTHOR): Kucherlapati, Raju; Jakobovits, Aya; Klapholz, Sue; Brenner, Daniel G.; Capon, Daniel J.

LOCATION: USA

ASSIGNEE: Cell Genesys, Inc.

PATENT: PCT International ; WO 9634096 A1 DATE: 19961031

APPLICATION: WO 95US5500 (19950428)

PAGES: 64 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-015/00A

DESIGNATED COUNTRIES: AU; CA; FI; HU; JP; KR; NO; NZ  
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;  
NL; PT; SE  
? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)

? t s6/kwic/all  
>>>KWIC option is not available in file(s): 399

6/KWIC/1 (Item 1 from file: 5)  
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...of desmoglein 3-specific IgG autoantibodies in an HLA-class II  
transgenic mouse model of pemphigus vulgaris

DESCRIPTORS:

DISEASES: \*\*\*pemphigus\*\*\* vulgaris...  
MESH TERMS: Pemphigus (MeSH)  
CHEMICALS & BIOCHEMICALS: ...anti- \*\*\*CD40L\*\*\* antibody...

6/KWIC/2 (Item 2 from file: 5)  
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Increased serum levels of circulating CD40 ligand in patients  
with bullous pemphigoid: Preliminary results

...ABSTRACT: cells and autoantibodies are induced. Recent studies have  
indicated the importance of the CD40 and CD40 ligand (CD40L)  
receptor-ligand pair in the immunopathogenesis of autoimmune  
diseases. \*\*\*CD40L\*\*\* circulates in soluble form, and some reports  
suggest that serum soluble CD40L (sCD40L) levels are increased in  
various autoimmune diseases. Objectives: To determine serum sCD40L levels  
in patients with pemphigus vulgaris (PV) and bullous pemphigoid  
(BP), and to determine their correlation with clinical findings and...

DESCRIPTORS:

DISEASES: \*\*\*pemphigus\*\*\* vulgaris...  
MESH TERMS: \*\*\*Pemphigus\*\*\* (MeSH...  
CHEMICALS & BIOCHEMICALS: CD40 ligand

6/KWIC/3 (Item 3 from file: 5)  
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

The CD40/CD40 ligand system is involved in the pathogenesis of  
pemphigus

ABSTRACT: The CD40/CD40 ligand (CD40L) system has never  
been investigated in autoimmune bullous diseases belonging to the  
\*\*\*pemphigus\*\*\* group in humans. Skin biopsy specimens from 21 patients  
with pemphigus vulgaris, 10 with pemphigus foliaceus and  
healthy volunteers were studied by immunohistochemistry (for CD40 and  
CD40L) and reversal transcriptase polymerase-chain reaction (for

CD40L), while sera were analyzed by enzyme-linked immunosorbent assay for soluble \*\*\*CD40L\*\*\*. In all \*\*\*pemphigus\*\*\* specimens, the basal and suprabasal layers of the epidermis and perivascular infiltrating cells were CD40+. \*\*\*CD40L\*\*\*+ cells moderately infiltrated the perivascular and interstitial dermis of \*\*\*pemphigus\*\*\* specimens. CD40L mRNA was strongly evident in all pemphigus samples while no signal was detected in the healthy controls. The expression of soluble CD40L was significantly greater in pemphigus sera than in controls. We showed here that the CD40/ \*\*\*CD40L\*\*\* system is upregulated both in lesional skin and in serum of patients with \*\*\*pemphigus\*\*\*. (c) 2007 Elsevier Inc. All rights reserved.

DESCRIPTORS:

DISEASES: \*\*\*pemphigus\*\*\* vulgaris...

MESH TERMS: Pemphigus (MeSH)

CHEMICALS & BIOCHEMICALS: ... \*\*\*CD40\*\*\* \*\*\*ligand\*\*\*

MISCELLANEOUS TERMS: CD40 ligand system

CONCEPT CODES:

6/KWIC/4 (Item 4 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model

ABSTRACT: Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by IgG autoantibodies against desmoglein 3 (Dsg3...

...from Dsg3(-/-) mice. The purpose of this study was to determine the role of CD40/CD154 interaction in the pathogenic antibody production and development of the disease in PV model mice. When anti- \*\*\*CD154\*\*\* monoclonal antibody (mAb) was administered to recipient mice prior to adoptive transfer, anti-CD154 mAb almost completely blocked the anti- Dsg3 IgG production and prevented blister formation. The blockade of CD40/CD154 interaction induced tolerance against Dsg3 as the suppression of antibody production was observed through day...

...Dsg3(-/-) splenocytes. Furthermore, the tolerance to Dsg3 was transferable because cotransfer of splenocytes from anti-CD154 mAb-treated mice and naive Dsg3(-/-) splenocytes significantly suppressed anti- Dsg3 IgG production in recipient mice. In contrast, when anti-CD154 mAb was injected after the mice had developed the PV phenotype, no significant suppression of the production of anti- Dsg3 IgG was observed. These findings indicate that the CD40/ \*\*\*CD154\*\*\* interaction is essential for the induction of pathogenic anti- Dsg3 IgG antibodies and that antigen-specific immune-regulatory cells induced by anti-CD154 mAb would hold a therapeutic option for autoimmune diseases.

...REGISTRY NUMBERS: anti- \*\*\*CD154\*\*\*

DESCRIPTORS:

DISEASES: \*\*\*pemphigus\*\*\* vulgaris...

MESH TERMS: Pemphigus (MeSH)

CHEMICALS & BIOCHEMICALS: ... \*\*\*CD154\*\*\* ; ...

...anti- \*\*\*CD154\*\*\* ;

6/KWIC/5 (Item 5 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Inhibition of pemphigus vulgaris by targeting of the CD40-CD154  
co-stimulatory pathway: A step toward antigen-specific therapy?

DESCRIPTORS:

...DISEASES: \*\*\*pemphigus\*\*\* vulgaris  
...MESH TERMS: \*\*\*Pemphigus\*\*\* (MeSH  
CHEMICALS & BIOCHEMICALS: ... \*\*\*CD154\*\*\* --

6/KWIC/6 (Item 6 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Blockade of CD40/CD40L interaction has therapeutic benefits in the  
pemphigus vulgaris mouse model

DESCRIPTORS:

DISEASES: \*\*\*pemphigus\*\*\* vulgaris...  
MESH TERMS: Pemphigus (MeSH)  
CHEMICALS & BIOCHEMICALS: ... \*\*\*CD40L\*\*\* { \*\*\*CD40\*\*\* \*\*\*ligand\*\*\* };  
MISCELLANEOUS TERMS: CD40/CD40L interaction {CD40/CD40  
\*\*\*ligand\*\*\* interaction...  
CONCEPT CODES:

6/KWIC/7 (Item 1 from file: 73)

DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

DRUG DESCRIPTORS:

...endogenous compound--ec; belimumab--drug therapy--dt; belimumab  
--pharmacology--pd; CD19 antigen--endogenous compound--ec; CD40  
ligand monoclonal antibody--drug therapy--dt; CD40 ligand  
monoclonal antibody--pharmacology--pd; complement component C3d receptor  
--endogenous compound--ec; epratuzumab--drug therapy--dt...

MEDICAL DESCRIPTORS:

...differentiation; lymphocyte function; monkey; mouse; myelo optic  
neuropathy--drug therapy--dt; myositis--drug therapy--dt; nonhuman;  
pemphigus vulgaris--drug therapy--dt; polyneuropathy--drug therapy  
--dt; priority journal; review; rheumatoid arthritis--drug therapy...  
? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)

? s (pemphigus) (20n) (inhibit? or suppress? or treat? or therap?) (20n) (cd4? or  
t(w)cell? or t(w)lymphocyte?)  
>>>File 5 processing for CELL? stopped at CELLULLASE  
Processing  
Processing  
Processing  
Processing  
Processing  
18072 PEMPHIGUS  
5242236 INHIBIT?  
1100686 SUPPRESS?  
8765477 TREAT?  
8195076 THERAP?  
376008 CD4?

2212549 T  
 13302071 CELL?  
 815677 T(W)CELL?  
 2212549 T  
 1329311 LYMPHOCYTE?  
 542775 T(W)LYMPHOCYTE?  
 S7 185 (PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR  
 THERAP?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?)  
 ? rd s7  
 S8 139 RD S7 (unique items)  
 ? t s8/e/all  
 >>>'E' not a valid format name  
 ? t s8/3/all

8/3/1 (Item 1 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2008 The Thomson Corporation. All rts. reserv.

0020104728 BIOSIS NO.: 200800151667  
 Suppressive effects of CD4+ CD25+ regulatory T  
 cells on the development of phenotypes in a mouse model of  
 pemphigus vulgaris  
 AUTHOR: Yokoyama T (Reprint); Matsuda S; Takae Y; Amagai M; Koyasu S  
 AUTHOR ADDRESS: Keio Univ, Sch Med, Tokyo, Japan\*\*Japan  
 JOURNAL: Journal of Investigative Dermatology 127 (Suppl. 2): pS66 OCT  
 2007 2007  
 CONFERENCE/MEETING: 37th Annual Meeting of the  
 European-Society-for-Dermatological-Research Zurich, SWITZERLAND  
 September 05 -08, 2007; 20070905  
 SPONSOR: European Soc Dermatol Res  
 ISSN: 0022-202X  
 DOCUMENT TYPE: Meeting; Meeting Abstract  
 RECORD TYPE: Citation  
 LANGUAGE: English

8/3/2 (Item 2 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2008 The Thomson Corporation. All rts. reserv.

0019485081 BIOSIS NO.: 200700144822  
 Study of the B- and T-lymphocyte responses in pemphigus  
 patients treated by anti-CD20 immunotherapy (rituximab)  
 AUTHOR: Musette P (Reprint); Mouquet H; Jacquot S; Gilbert D; Gougeon M L;  
 Roujeau J C; D'Incan M; Bedane C; Tron F; Joly P  
 AUTHOR ADDRESS: CHU Rouen, Serv Dermatol, Rouen, France\*\*France  
 JOURNAL: Journal of Investigative Dermatology 126 (Suppl. 3): p23 AUG 2006  
 2006  
 CONFERENCE/MEETING: 36th Annual Meeting of the  
 European-Society-of-Dermatology-Research (ESDR) Paris, FRANCE September  
 06 -07, 2006; 20060906  
 SPONSOR: European Soc Dermatol Res  
 ISSN: 0022-202X  
 DOCUMENT TYPE: Meeting; Meeting Abstract  
 RECORD TYPE: Citation  
 LANGUAGE: English

8/3/3 (Item 3 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2008 The Thomson Corporation. All rts. reserv.

19097571 BIOSIS NO.: 200600442966  
Inhibition of pemphigus vulgaris by targeting of the CD40  
-CD154 co-stimulatory pathway: A step toward antigen-specific  
therapy?  
AUTHOR: Liu Zhi (Reprint); Li Ning; Diaz Luis A  
AUTHOR ADDRESS: Univ N Carolina, Dept Dermatol, 3100 Thuston Bowles, Chapel  
Hill, NC 27599 USA\*\*USA  
AUTHOR E-MAIL ADDRESS: zhiliu@med.unc.edu  
JOURNAL: Journal of Investigative Dermatology 126 (1): p11-13 JAN 2006  
2006  
ISSN: 0022-202X  
DOCUMENT TYPE: Article; Editorial  
RECORD TYPE: Citation  
LANGUAGE: English

8/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18008306 BIOSIS NO.: 200400379095  
Mechanism of action of extracorporeal photochemotherapy in chronic  
graft-versus-host disease  
AUTHOR: Fimiani M (Reprint); Di Renzo M; Rubegni P  
AUTHOR ADDRESS: Policlin ScotteIst Sci Dermatol, Univ Siena, I-53100,  
Siena, Italy\*\*Italy  
AUTHOR E-MAIL ADDRESS: fimiani@unisi.it  
JOURNAL: British Journal of Dermatology 150 (6): p1055-1060 June 2004 2004  
MEDIUM: print  
ISSN: 0007-0963  
DOCUMENT TYPE: Article; Literature Review  
RECORD TYPE: Abstract  
LANGUAGE: English

8/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

16901534 BIOSIS NO.: 200200495045  
Blockade of CD40/CD40L interaction has therapeutic  
benefits in the pemphigus vulgaris mouse model  
AUTHOR: Aoki M (Reprint); Tsunoda K (Reprint); Ota T (Reprint); Iwasaki T;  
Tanaka S; Koyasu S; Amagai M (Reprint); Nishikawa T (Reprint)  
AUTHOR ADDRESS: Dermatology, Keio University of School of Medicine, Tokyo,  
Japan\*\*Japan  
JOURNAL: Journal of Investigative Dermatology 119 (1): p317 July, 2002  
2002  
MEDIUM: print  
CONFERENCE/MEETING: 63rd Annual Meeting of the Society for Investigative  
Dermatology Los Angeles, California, USA May 15-18, 2002; 20020515  
ISSN: 0022-202X  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

8/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.



16399955 BIOSIS NO.: 200100571794

Induction of apoptosis, depletion of glutathione, and DNA damage by  
extracorporeal photochemotherapy and psoralen with exposure to UV light  
in vitro

AUTHOR: Efferth Thomas (Reprint); Fabry Ursula; Osieka Rainhardt

AUTHOR ADDRESS: Virtual Campus Rhineland-Palatinate, 55033, Mainz, Germany  
\*\*Germany

JOURNAL: Anticancer Research 21 (4A): p2777-2784 July-August, 2001 2001

MEDIUM: print

ISSN: 0250-7005

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

8/3/7 (Item 7 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

15406625 BIOSIS NO.: 200000124938

The use of chlorambucil with prednisone in the treatment of pemphigus

AUTHOR: Shah Neha; Green Andy R; Elgart George W; Kerdel Francisco  
(Reprint)

AUTHOR ADDRESS: Department of Dermatology and Cutaneous Surgery, University  
of Miami School of Medicine, Miami, FL, 33101, USA\*\*USA

JOURNAL: Journal of the American Academy of Dermatology 42 (1 Part 1): p  
85-88 Jan., 2000 2000

MEDIUM: print

ISSN: 0190-9622

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

8/3/8 (Item 8 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

15311192 BIOSIS NO.: 200000029505

Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte  
death in paraneoplastic pemphigus

AUTHOR: Reich K (Reprint); Brinck U; Letschert M; Blaschke V; Dames K;  
Braess J; Woermann B; Ruenger T M; Neumann C

AUTHOR ADDRESS: Department of Dermatology, Georg-August-University, von  
Siebold Strasse 3, D-37075, Goettingen, Germany\*\*Germany

JOURNAL: British Journal of Dermatology 141 (4): p739-746 Oct., 1999 1999

MEDIUM: print

ISSN: 0007-0963

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

8/3/9 (Item 9 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

14702756 BIOSIS NO.: 199800497003

CD44 variant isoform expression in a variety of skin-associated autoimmune  
diseases

AUTHOR: Seiter Simone (Reprint); Schadendorf Dirk; Tilgen Wolfgang  
(Reprint); Zoeller Margot  
AUTHOR ADDRESS: Dep. Dermatol., Univ. Homburg, Homburg, Germany\*\*Germany  
JOURNAL: Clinical Immunology and Immunopathology 89 (1): p79-93 Oct., 1998  
1998  
MEDIUM: print  
ISSN: 0090-1229  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

8/3/10 (Item 10 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

14434848 BIOSIS NO.: 199800229095  
Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3  
specific T cell responses in pemphigus vulgaris patients and normals  
AUTHOR: Hertl Michael; Karr Robert W; Amagai Masayuki; Katz Stephen I  
AUTHOR ADDRESS: Hautklin., Universitaetsklinikum der RWTH, Pauwelsstr. 30,  
D-52072 Aachen, Germany\*\*Germany  
JOURNAL: Journal of Investigative Dermatology 110 (4): p388-392 April,  
1998 1998  
MEDIUM: print  
ISSN: 0022-202X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

8/3/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13356778 BIOSIS NO.: 199698824611  
Therapeutic experience with extracorporeal photophoresis. Technical  
aspects, monitoring and clinical results in 41 patients  
AUTHOR: Owsianowski M; Garbe C; Ramaker J; Orfanos C E; Gollnick H  
(Reprint)  
AUTHOR ADDRESS: Universitaetsklin. Dermatol. Venerol., Otto-von-Guericke  
Univ., Leipzigstr. 44, D-39120 Magdeburg, Germany\*\*Germany  
JOURNAL: Hautarzt 47 (2): p114-123 1996 1996  
ISSN: 0017-8470  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: German

8/3/12 (Item 12 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13328645 BIOSIS NO.: 199698796478  
Investigation of phenotype and T-cell functions in  
pemphigus vulgaris patients treated with Sandimmun and  
glucocorticoids  
AUTHOR: Matushevskaya E V (Reprint); Svirshchevskaya E V; Kubanova A A;  
Samsonov V A; Khapilova V I  
AUTHOR ADDRESS: Dep. Skin Vener. Dis., Mosc. State Med. Univ., Moscow,  
Russia\*\*Russia

JOURNAL: Vestnik Dermatologii i Venerologii 0 (6): p6-11 1995 1995  
ISSN: 0042-4609  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: Russian

8/3/13 (Item 13 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13236989 BIOSIS NO.: 199698704822  
Long-term interferon-alpha therapy induces autoantibodies against epidermis  
AUTHOR: Fleischmann M; Celerier P; Bernard P; Litoux P; Dreno B (Reprint)  
AUTHOR ADDRESS: Dep. Dermatol., Hotel-Dieu, Pl. A. Ricordeau, F-44035  
Nantes Cedex 01, France\*\*France  
JOURNAL: Dermatology (Basel) 192 (1): p50-55 1996 1996  
ISSN: 1018-8665  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

8/3/14 (Item 14 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

12658117 BIOSIS NO.: 199598125950  
Review of immunomodulation by photopheresis: Treatment of cutaneous T-cell  
lymphoma, autoimmune disease, and allograft rejection  
AUTHOR: Wolfe Jonathan T; Lessin Stuart R; Singh Anjali H; Rook Alain H  
(Reprint)  
AUTHOR ADDRESS: Dep. Dermatol., Hosp. Univ. Pennsylvania, 3400 Spruce St.,  
Philadelphia, PA 19104, USA\*\*USA  
JOURNAL: Artificial Organs 18 (12): p888-897 1994 1994  
ISSN: 0160-564X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

8/3/15 (Item 15 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

11844356 BIOSIS NO.: 199396008772  
Parenteral administration of 8-methoxypsoralen in photopheresis  
AUTHOR: Knobler Robert M (Reprint); Trautinger Franz; Graninger Winfried;  
Macheiner Walter; Gruenwald Christian; Neumann Reinhard; Ramer Wolfgang  
AUTHOR ADDRESS: Dep. Dermatology, Univ. Vienna Med. Sch., Alserstrasse 4,  
A-1090 Vienna, Austria\*\*Austria  
JOURNAL: Journal of the American Academy of Dermatology 28 (4): p580-584  
1993  
ISSN: 0190-9622  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

8/3/16 (Item 16 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

11133059 BIOSIS NO.: 199243101650  
PHOTOPHERESIS A CLINICALLY RELEVANT IMMUNOBIOLOGIC RESPONSE MODIFIER  
BOOK TITLE: EDELSON, R. L. (ED.). ANNALS OF THE NEW YORK ACADEMY OF  
SCIENCES, VOL. 636. ANTIGEN AND CLONE-SPECIFIC IMMUNOREGULATION; MEETING,  
NEW YORK, NEW YORK, USA, OCTOBER 22-24, 1990. XII+410P. NEW YORK ACADEMY  
OF SCIENCES: NEW YORK, NEW YORK, USA. ILLUS  
AUTHOR: EDELSON R L (Reprint)  
AUTHOR ADDRESS: DEP DERMATOLOGY, YALE UNIV SCH MED, 333 CEDAR STREET, 500  
LCI, PO BOX 3333, NEW HAVEN, CONN 06510-8059, USA\*\*USA  
SERIES TITLE: Annals of the New York Academy of Sciences p154-164 1991  
ISSN: 007-8923 ISBN: 0-89766-688-7 (PAPER); 0-89766-687-9 (CLOTH)  
DOCUMENT TYPE: Book; Meeting  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

8/3/17 (Item 17 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

08926693 BIOSIS NO.: 198835023798  
A MOLECULAR BASIS FOR MHC CLASS II-ASSOCIATED AUTOIMMUNITY  
AUTHOR: TODD J A (Reprint); ACHA-ORBEA H; BELL J I; CHAO N; FRONEK Z; JACOB  
C O; MCDERMOTT M; SINHA A A; TIMMERMAN L; ET AL  
AUTHOR ADDRESS: DEP MED MICROBIOL, STANFORD UNIV, STANFORD, CALIF 94305,  
USA\*\*USA  
JOURNAL: Science (Washington D C) 240 (4855): p1003-1009 1988  
ISSN: 0036-8075  
DOCUMENT TYPE: Article  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

8/3/18 (Item 18 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

08744158 BIOSIS NO.: 198784098307  
T AND B-LYMPHOCYTES IN PEMPHIGUS VULGARIS A CLINICO-IMMUNOLOGICAL FOLLOW-UP  
STUDY OF FIFTY PATIENTS WITH PEMPHIGUS VULGARIS  
AUTHOR: MASHKILLEYSON N (Reprint)  
AUTHOR ADDRESS: DEP DERMATOL, HELSINKI UNIV CENTRAL HOSP, SNELLMANINKATU  
14, SF-00170 HELSINKI 17, FINLAND\*\*FINLAND  
JOURNAL: Acta Dermato-Venereologica 67 (3): p218-224 1987  
ISSN: 0001-5555  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

8/3/19 (Item 19 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

08663040 BIOSIS NO.: 198784017189  
PHOTOPHERESIS EXTRACORPOREAL IRRADIATION OF 8 MOP CONTAINING BLOOD A NEW  
THERAPEUTIC MODALITY  
AUTHOR: KNOBLER R M (Reprint)  
AUTHOR ADDRESS: DEP DERMATOL II, UNIV VIENNA, ALSERSTRASSE 4, A-1090

VIENNA, AUSTRIA\*\*AUSTRIA  
JOURNAL: Blut 54 (4): p247-250 1987  
ISSN: 0006-5242  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

8/3/20 (Item 20 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

08118527 BIOSIS NO.: 198681082418  
CUTANEOUS IMMUNOLOGICAL STUDIES IN DIAGNOSIS OF ACUTE GRAFT-VS.-HOST  
DISEASE  
AUTHOR: DRENO B (Reprint); MILPIED N; HAROUSSEAU J L; STADLER J F; BUREAU B  
; MILPIED B; BARRIERE H  
AUTHOR ADDRESS: CLIN DERMATOL, HOTEL DIEU 44035, NANTES CEDEX, FR\*\*FRANCE  
JOURNAL: British Journal of Dermatology 114 (1): p7-16 1986  
ISSN: 0007-0963  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

8/3/21 (Item 21 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

08060161 BIOSIS NO.: 198681024052  
IMMUNOLOGICAL STUDIES IN SOME BULLOUS DISEASE  
AUTHOR: LEON M (Reprint); VULCAN V; ALECU M; OANA A  
AUTHOR ADDRESS: CENTRUL DERMATO-VENEROLOGIC, BUCURESTI\*\*HUNGARY  
JOURNAL: Revista de Medicina Interna Neurologie Psihiatrie Neurochirurgie  
Dermato-Venerologie Serie Dermato-Venerologia 30 (2): p81-92 1985  
ISSN: 0377-4988  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ROMANIAN

8/3/22 (Item 22 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

06996601 BIOSIS NO.: 198376088036  
PRODUCTION OF PEMPHIGUS ANTIBODY IN-VITRO AND ANALYSIS OF T CELL SUBSETS  
AUTHOR: AHMED A R (Reprint); MURAHATA R I; SCHROFF R W; STEVENS R M; SAXON  
A S  
AUTHOR ADDRESS: DIVISION OF DERMATOLOGY, DEPARTMENT OF MEDICINE, UCLA  
SCHOOL OF MEDICINE, LOS ANGELES, CALIFORNIA 90024, USA\*\*USA  
JOURNAL: Journal of Clinical Immunology 3 (3): p241-252 1983  
ISSN: 0271-9142  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

8/3/23 (Item 23 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

06199421 BIOSIS NO.: 198171018380  
IMMUNOLOGICAL STUDY OF KERATO ACANTHOMAS  
AUTHOR: TOSCA A (Reprint); VARELZIDIS A; AVGERINOU G; HATZIS J; PERISSIOS A  
; NICOLIS G  
AUTHOR ADDRESS: UNIV ATHENS, SCH MED, DEP DERMATOL, "A SYGROS" HOSP, I  
DRAGOUMI 5 ATHENS, GREECE\*\*GREECE  
JOURNAL: Archives of Dermatological Research 268 (2): p149-156 1980  
ISSN: 0340-3696  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

8/3/24 (Item 24 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

06163921 BIOSIS NO.: 198121047884  
SUPPRESSOR T CELL FUNCTION IS PRESERVED IN  
PEMPHIGUS AND PEMPHIGOID  
AUTHOR: KING A J (Reprint); LOPATIN D E; VOORHEES J J; DIAZ L A; SCHWARTZ S  
A  
AUTHOR ADDRESS: DEP OF DERMATOL, DENTAL RES INST, UNIV OF MICHIGAN, ANN  
ARBOR, MICHIGAN, USA\*\*USA  
JOURNAL: Clinical Research 29 (2): p283A 1981  
CONFERENCE/MEETING: 38TH ANNUAL NATIONAL MEETING OF THE AMERICAN FEDERATION  
FOR CLINICAL RESEARCH, SAN FRANCISCO, CALIF., USA, APRIL 25-27, 1981. CLIN  
RES.  
ISSN: 0009-9279  
DOCUMENT TYPE: Meeting  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

8/3/25 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0082112095 EMBASE No: 2007548047  
The selective immunotherapy of pemphigus  
Bystryn J.C.; Czernik A. // Bystryn J.C.  
Ronald O. Perelman Department of Dermatology, New York University School  
of Medicine, New York, NY, United States // NYU Medical Center, 560 1st  
Avenue, New York, NY 10016, United States  
AUTHOR EMAIL: bystryn@nyu.edu; bystryn@nyu.edu  
CORRESP. AUTHOR: Bystryn J.C.  
CORRESP. AUTHOR AFFIL: NYU Medical Center, 560 1st Avenue, New York, NY  
10016, United States  
CORRESP. AUTHOR EMAIL: bystryn@nyu.edu

Giornale Italiano di Dermatologia e Venereologia ( G. Ital. Dermatol.  
Venereol. ) (Italy) August 1, 2007, 142/4 (381-390)  
CODEN: GIDVD ISSN: 00264741  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English; Italian  
NUMBER OF REFERENCES: 63

8/3/26 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081949325 EMBASE No: 2007383664

Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone

Scheinfeld N. // Scheinfeld N.

Department of Dermatology, St. Luke's-Roosevelt, New York, NY USA //

Department of Dermatology, St. Luke's-Roosevelt, 1090 Amsterdam Ave, New York, NY 10025, United States

AUTHOR EMAIL: NSS32@columbia.edu; NSS32@columbia.edu

CORRESP. AUTHOR: Scheinfeld N.

CORRESP. AUTHOR AFFIL: Department of Dermatology, St. Luke's-Roosevelt, 1090 Amsterdam Ave, New York, NY 10025, United States

CORRESP. AUTHOR EMAIL: NSS32@columbia.edu

Journal of Dermatological Treatment ( J. Dermatol. Treat. ) (United Kingdom) September 5, 2007, 18/4 (243-245)

CODEN: JDTR ISSN: 09546634 eISSN: 14711753

PUBLISHER ITEM IDENTIFIER: 779333677

DOI: 10.1080/09546630701287324

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 9

8/3/27 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081810060 EMBASE No: 2007244126

Role of regulatory T cells in the development of skin diseases

Lima H.C. // Lima H.C. // Lima H.C.

Department of Pathology, Universidade Federal do Parana - UFPR, Curitiba

(PR), Brazil // Service of Dermatology and Research Nucleus in

Immunodermatology and Clinical Immunology, Universidade Federal do Parana

- UFPR, Curitiba (PR), Brazil // Rua XV de Novembro, 1206, 80060-000 -

Curitiba - PR

AUTHOR EMAIL: hclima@ufpr.br; hclima@ufpr.br; hclima@ufpr.br

CORRESP. AUTHOR: Lima H.C.

CORRESP. AUTHOR AFFIL: Rua XV de Novembro, 1206, 80060-000 - Curitiba - PR

CORRESP. AUTHOR EMAIL: hclima@ufpr.br

Anais Brasileiros de Dermatologia ( An. Bras. Dermatol. ) (Brazil) May 1, 2006, 81/3 (269-281)

CODEN: ABDEB ISSN: 03650596 eISSN: 18064841

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English; Portuguese

NUMBER OF REFERENCES: 121

8/3/28 (Item 4 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081779408 EMBASE No: 2007213412

Therapy of autoimmune bullous diseases

Mutasim D.F.

Department of Dermatology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0592, United States

AUTHOR EMAIL: diya.mutasim@uc.edu

CORRESP. AUTHOR: Mutasim D.F.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of  
Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH  
45267-0592, United States  
CORRESP. AUTHOR EMAIL: diya.mutasim@uc.edu

Therapeutics and Clinical Risk Management ( Ther. Clin. Risk Manage. ) ( New Zealand) May 30, 2007, 3/1 (29-40)  
ISSN: 11766336  
DOI: 10.2147/tcrm.2007.3.1.29  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 139

8/3/29 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081755259 EMBASE No: 2007189212  
Estimation of awareness of corticosteroid induced osteoporosis in patients with chronic skin diseases  
Ocena swiadomosci zagrozenia osteoporoza posteroidowa u pacjentow z przewleklymi chorobami skoly  
Kobierzycka M.; Cislo M.; Bialynicki-Birula R.; Nockowski P. // Simon-Blazewicz M. // Kobierzycka M.  
Katedra I Klinika Dermatologii, Wenerologii I Alergologii AM we Wroclawiu // Oddzial Dermatologiczny Wojewoldzkiego Szpitala Specjalistycznego we Wroclawiu // Katedra I Klinika Dermatologii, Wenerologii I Alergologii AM, ul. Chalubinskiego 1, 50-368 Wroclaw  
AUTHOR EMAIL: mkobierz@wp.pl; mkobierz@wp.pl  
CORRESP. AUTHOR: Kobierzycka M.  
CORRESP. AUTHOR AFFIL: Katedra I Klinika Dermatologii, Wenerologii I Alergologii AM, ul. Chalubinskiego 1, 50-368 Wroclaw  
CORRESP. AUTHOR EMAIL: mkobierz@wp.pl

Dermatologia Kliniczna ( Dematol. Kliniczna ) (Poland) April 30, 2007, 9/1 (29-33)  
ISSN: 17307201  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: Polish SUMMARY LANGUAGE: English; Polish  
NUMBER OF REFERENCES: 27

8/3/30 (Item 6 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081682257 EMBASE No: 2007115834  
Complications and Adverse Reactions in the Use of Newer Biologic Agents  
ISSUE TITLE: Complications and Adverse Events  
Callen J.P.  
Division of Dermatology, University of Louisville, Louisville, KY, United States  
AUTHOR EMAIL: jefca@aol.com  
CORRESP. AUTHOR: Callen J.P.  
CORRESP. AUTHOR AFFIL: Division of Dermatology, University of Louisville, Louisville, KY, United States  
CORRESP. AUTHOR EMAIL: jefca@aol.com

Seminars in Cutaneous Medicine and Surgery ( Semin. Cutaneous Med. Surg.



) (United States) March 1, 2007, 26/1 (6-14)  
CODEN: SCMSF ISSN: 10855629  
PUBLISHER ITEM IDENTIFIER: S108556290600112X  
DOI: 10.1016/j.sder.2006.12.002  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
CLINICAL TRIALS NUMBER: NCT00051662--ClinicalTrials.gov; NCT00302445--  
ClinicalTrials.gov  
NUMBER OF REFERENCES: 84

8/3/31 (Item 7 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081503650 EMBASE No: 2006567099  
Paraneoplastic autoimmune multiorgan syndrome: Review of the literature  
and support for a cytotoxic role in pathogenesis  
ISSUE TITLE: Immunology of Pemphigus and Treatment  
Billet S.E.; Pittelkow M.R. // Grando S.A.  
Department of Dermatology, Mayo Clinic, Rochester, MN, United States //  
University of California Davis, Sacramento, CA, United States  
CORRESP. AUTHOR: Pittelkow M.R.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, Mayo Clinic, Rochester,  
MN, United States

Autoimmunity ( Autoimmunity ) (United Kingdom) November 1, 2006, 39/7  
(617-630)  
CODEN: AUIME ISSN: 08916934 eISSN: 1607842X  
PUBLISHER ITEM IDENTIFIER: U501856727X93457  
DOI: 10.1080/08916930600972099  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 123

8/3/32 (Item 8 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081407991 EMBASE No: 2006470890  
Therapeutic modulation of cutaneous autoimmunity by regulatory T cells  
Beissert S. // Loser K.  
Interdisciplinary Clinical Research Center (IZKF), Munster, Germany //  
Department of Dermatology, University of Munster, Von-Esmarch-Strasse 58,  
D-48149 Munster, Germany  
AUTHOR EMAIL: beisser@uni-muenster.de  
CORRESP. AUTHOR: Beissert S.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Munster,  
Von-Esmarch-Strasse 58, D-48149 Munster, Germany  
CORRESP. AUTHOR EMAIL: beisser@uni-muenster.de

Rheumatology ( Rheumatology (UK) ) (United Kingdom) October 1, 2006,  
45/SUPPL. 3 (iii20-iii22)  
CODEN: RUMAF ISSN: 14620324 eISSN: 14620332  
DOI: 10.1093/rheumatology/kel286  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 10

8/3/33 (Item 9 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081384356 EMBASE No: 2006447143  
Inosine 5prime-monophosphate dehydrogenase inhibitors for the treatment  
of autoimmune diseases  
Ratcliffe A.J.  
UCB, Granta Park, Great Abington, Cambridge CB1 6GS, United Kingdom  
AUTHOR EMAIL: andrew.ratcliffe@ucb-group.com  
CORRESP. AUTHOR: Ratcliffe A.J.  
CORRESP. AUTHOR AFFIL: UCB, Granta Park, Great Abington, Cambridge CB1  
6GS, United Kingdom  
CORRESP. AUTHOR EMAIL: andrew.ratcliffe@ucb-group.com

Current Opinion in Drug Discovery and Development ( Curr. Opin. Drug  
Discov. Dev. ) (United Kingdom) September 1, 2006, 9/5 (595-605)  
CODEN: CODDF ISSN: 13676733  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 55

8/3/34 (Item 10 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081248610 EMBASE No: 2006310874  
B cells move to centre stage: Novel opportunities for autoimmune disease  
treatment  
Browning J.L.  
Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge,  
MA 02445, United States  
AUTHOR EMAIL: Jeff.Browning@biogenidec.com  
CORRESP. AUTHOR: Browning J.L.  
CORRESP. AUTHOR AFFIL: Department of Immunobiology USA, Biogen Idec, 12  
Cambridge Center, Cambridge, MA 02445, United States  
CORRESP. AUTHOR EMAIL: Jeff.Browning@biogenidec.com

Nature Reviews Drug Discovery ( Nat. Rev. Drug Discov. ) (United Kingdom)  
July 1, 2006, 5/7 (564-576)  
CODEN: NRDDA ISSN: 14741776 eISSN: 14741784  
PUBLISHER ITEM IDENTIFIER: N2085  
DOI: 10.1038/nrd2085  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 173

8/3/35 (Item 11 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081227105 EMBASE No: 2003062231  
Safety of cyclosporin A in the treatment of dermatological diseases [7]  
Veller Fornasa C.; Gai F.  
Institute of Dermatology, University of Padua, Padua, Italy  
AUTHOR EMAIL: cleto.vellerfordasa@UNIPD.IT  
CORRESP. AUTHOR: Veller Fornasa C.  
CORRESP. AUTHOR AFFIL: Institute of Dermatology, University of Padua,  
Padua, Italy

CORRESP. AUTHOR EMAIL: cleto.vellerfordasa@UNIPD.IT

Journal of the European Academy of Dermatology and Venereology ( J. Eur. Acad. Dermatol. Venereol. ) (United Kingdom) January 1, 2003, 17/1 (105-107)

CODEN: JEAIVE ISSN: 09269959

DOI: 10.1046/j.1468-3083.2003.00519 7.x

DOCUMENT TYPE: Journal; Letter RECORD TYPE: Citation

LANGUAGE: English

NUMBER OF REFERENCES: 10

8/3/36 (Item 12 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081160155 EMBASE No: 2006222321

Autoimmune Complications of Chronic Lymphocytic Leukemia

ISSUE TITLE: Chronic Lymphocytic Leukemia

Hamblin T.J.

Department of Immunohaematology, University of Southampton, Southampton General Hospital, London, United Kingdom

AUTHOR EMAIL: terjoha@aol.com

CORRESP. AUTHOR: Hamblin T.J.

CORRESP. AUTHOR AFFIL: Department of Immunohaematology, University of Southampton, Southampton General Hospital, London, United Kingdom

CORRESP. AUTHOR EMAIL: terjoha@aol.com

Seminars in Oncology ( Semin. Oncol. ) (United States) April 1, 2006, 33/2 (230-239)

CODEN: SOLGA ISSN: 00937754

PUBLISHER ITEM IDENTIFIER: S0093775406000200

DOI: 10.1053/j.seminoncol.2006.01.011

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 144

8/3/37 (Item 13 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081074574 EMBASE No: 2006134669

Pemphigus: Pathogenic mechanisms and potential therapeutic targets

Powell A.-M.; Black M.M.

Department of Immunodermatology, St. John's Institute of Dermatology, St. Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom

AUTHOR EMAIL: martin.black@kcl.ac.uk

CORRESP. AUTHOR: Black M.M.

CORRESP. AUTHOR AFFIL: Department of Immunodermatology, St. John's Institute of Dermatology, St. Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom

CORRESP. AUTHOR EMAIL: martin.black@kcl.ac.uk

Drug Discovery Today: Disease Mechanisms ( Drug Discov.Today Dis. Mech. ) (United Kingdom) December 1, 2005, 2/2 (269-274)

ISSN: 17406765

PUBLISHER ITEM IDENTIFIER: S1740676505000301

DOI: 10.1016/j.ddmec.2005.05.023

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 39

8/3/38 (Item 14 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081062976 EMBASE No: 2006123053

The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: Reconsideration of treatment with cryopoor plasma

Raife T.J. // Friedman K.D.; Dwyre D.M.

University of Iowa, College of Medicine, C250 GH, 200 Hawkins Drive, Iowa City, IA 52242, United States // Affiliation unspecified.

AUTHOR EMAIL: thomas-raife@uiowa.edu

CORRESP. AUTHOR: Raife T.J.

CORRESP. AUTHOR AFFIL: University of Iowa, College of Medicine, C250 GH, 200 Hawkins Drive, Iowa City, IA 52242, United States

CORRESP. AUTHOR EMAIL: thomas-raife@uiowa.edu

Transfusion ( Transfusion ) (United States) January 1, 2006, 46/1  
(74-79)

CODEN: TRANA ISSN: 00411132 eISSN: 15372995

DOI: 10.1111/j.1537-2995.2005.00674.x

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 62

8/3/39 (Item 15 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081049234 EMBASE No: 2006109249

Regulatory T cells

Beissert S. // Schwarz A.; Schwarz T. // Schwarz T.

Department of Dermatology, University of Munster, Munster, Germany //

Department of Dermatology, University of Kiel, Kiel, Germany //

Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, D-24105 Kiel, Germany

AUTHOR EMAIL: tschwarz@dermatology.uni-kiel.de;

tschwarz@dermatology.uni-kiel.de

CORRESP. AUTHOR: Schwarz T.

CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, D-24105 Kiel, Germany

CORRESP. AUTHOR EMAIL: tschwarz@dermatology.uni-kiel.de

Journal of Investigative Dermatology ( J. Invest. Dermatol. ) (United States) January 1, 2006, 126/1 (15-24)

CODEN: JIDEA ISSN: 0022202X eISSN: 15231747

PUBLISHER ITEM IDENTIFIER: 5700004

DOI: 10.1038/sj.jid.5700004

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 89

8/3/40 (Item 16 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081040121 EMBASE No: 2006100121

Biologic therapies in autoimmune diseases

Penn H. // Penn H.

Royal Free Hospital, London, United Kingdom // Department of Rheumatology, Royal Free Hospital, London NW3 2QG, United Kingdom

AUTHOR EMAIL: h.penn@medsch.ucl.ac.uk; h.penn@medsch.ucl.ac.uk

CORRESP. AUTHOR: Penn H.

CORRESP. AUTHOR AFFIL: Department of Rheumatology, Royal Free Hospital, London NW3 2QG, United Kingdom

CORRESP. AUTHOR EMAIL: h.penn@medsch.ucl.ac.uk

Clinical Medicine, Journal of the Royal College of Physicians of London ( Clin. Med. J. R. Coll. Phys. Lond. ) (United Kingdom) January 1, 2006, 6/1 (105-108)

CODEN: CMLUB ISSN: 14702118

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 6

8/3/41 (Item 17 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0080905189 EMBASE No: 2005550132

Number V. Oral lichen planus: Clinical features and management

Eisen D. // Carrozzo M. // Sebastian J.-V.B. // Thongprasom K. // Eisen D.

Dermatology Research Associates, Cincinnati, OH, United States // Department of Biomedical Sciences and Human Oncology, Oral Medicine, University of Turin, Turin, Italy // Hospital General Universitario de Valencia, Valencia, Spain // Oral Medicine Department, Chulalongkorn University, Bangkok, Thailand // Dermatology Research Associates, 7691 Five Mile Road, Cincinnati, OH 45230, United States

AUTHOR EMAIL: drdre@eos.net; drdre@eos.net

CORRESP. AUTHOR: Eisen D.

CORRESP. AUTHOR AFFIL: Dermatology Research Associates, 7691 Five Mile Road, Cincinnati, OH 45230, United States

CORRESP. AUTHOR EMAIL: drdre@eos.net

Oral Diseases ( Oral Dis. ) (Denmark) November 1, 2005, 11/6 (338-349)

CODEN: ORDIF ISSN: 1354523X

DOI: 10.1111/j.1601-0825.2005.01142.x

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 146

8/3/42 (Item 18 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0080904290 EMBASE No: 2005549233

Apoptosis in normal and diseased oral tissues

Loro L.L.; Johannessen A.C. // Vintermyr O.K. // Loro L.L.

Department of Odontology-Oral Pathology and Forensic Odontology, University of Bergen, Bergen, Norway // Department of Pathology, Haukeland University Hospital, University of Bergen, Bergen, Norway // Department of Odontology-Oral Pathology and Forensic Odontology, Gade Institute, Haukeland University Hospital, N5021 Bergen, Norway

AUTHOR EMAIL: lado.loro@gades.uib.no; lado.loro@gades.uib.no

CORRESP. AUTHOR: Loro L.L.

CORRESP. AUTHOR AFFIL: Department of Odontology-Oral Pathology and  
Forensic Odontology, Gade Institute, Haukeland University Hospital, N5021  
Bergen, Norway  
CORRESP. AUTHOR EMAIL: lado.loro@gades.uib.no

Oral Diseases ( Oral Dis. ) (Denmark) September 1, 2005, 11/5 (274-287)  
CODEN: ORDIF ISSN: 1354523X  
DOI: 10.1111/j.1601-0825.2005.01117.x  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 163

8/3/43 (Item 19 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080904288 EMBASE No: 2005549231  
Number IV: Erythema multiforme  
Farthing P. // Bagan J.-V. // Scully C. // Scully C.  
Charles Clifford Dental School, University of Sheffield, Sheffield,  
United Kingdom // University Hospital, University of Valencia, Spain //  
Eastman Dental Institute, University College London, London, United  
Kingdom // Eastman Dental Institute, University College London, 256 Grays  
Inn Road, London WC1X 8LD, United Kingdom  
AUTHOR EMAIL: cscully@eastman.ucl.ac.uk; cscully@eastman.ucl.ac.uk  
CORRESP. AUTHOR: Scully C.  
CORRESP. AUTHOR AFFIL: Eastman Dental Institute, University College  
London, 256 Grays Inn Road, London WC1X 8LD, United Kingdom  
CORRESP. AUTHOR EMAIL: cscully@eastman.ucl.ac.uk

Oral Diseases ( Oral Dis. ) (Denmark) September 1, 2005, 11/5 (261-267)  
CODEN: ORDIF ISSN: 1354523X  
DOI: 10.1111/j.1601-0825.2005.01141.x  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 45

8/3/44 (Item 20 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080886863 EMBASE No: 2005531783  
Mycophenolate mofetil  
Heymann W.R.  
Affiliation unspecified.

Journal of the American Academy of Dermatology ( J. Am. Acad. Dermatol. )  
(United States) December 1, 2005, 53/6 (1045-1046)  
CODEN: JAADD ISSN: 01909622  
PUBLISHER ITEM IDENTIFIER: S0190962205026782  
DOI: 10.1016/j.jaad.2005.08.034  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 8

8/3/45 (Item 21 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080779838 EMBASE No: 2005424454

An approach to the patient with a recalcitrant dermatosis

Callen J.P.

Division of Dermatology, University of Louisville, School of Medicine,  
Louisville, KY 40202, United States

AUTHOR EMAIL: jefca@aol.com

CORRESP. AUTHOR: Callen J.P.

CORRESP. AUTHOR AFFIL: Division of Dermatology, University of Louisville,  
School of Medicine, Louisville, KY 40202, United States

CORRESP. AUTHOR EMAIL: jefca@aol.com

Clinics in Dermatology ( Clin. Dermatol. ) (United States) September 1,  
2005, 23/5 (528-531)

CODEN: CLDEE ISSN: 0738081X

PUBLISHER ITEM IDENTIFIER: S0738081X05000623

DOI: 10.1016/j.clindermatol.2005.04.004

DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation

LANGUAGE: English

8/3/46 (Item 22 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0080659445 EMBASE No: 2005303751

Auto-immune manifestations in non-Hodgkin's lymphoma

Manifestations dysimmunitaires associees aux lymphomes

Jardin F.; Tilly H. // Levesque H.

Departement d'Hematologie Clinique et Groupe d'Etude des Syndromes  
Lymphoproliferatifs, Inserm U164, Centre Henri-Becquerel, 76000 Rouen,  
France // Departement de Medecine Interne, Centre Hospitalier  
Universitaire de Rouen, Hopital de Bois-Guillaume, Rouen, France

AUTHOR EMAIL: fabrice.jardin@rouen.fnclcc.fr

CORRESP. AUTHOR: Jardin F.

CORRESP. AUTHOR AFFIL: Departement d'Hematologie Clinique et Groupe  
d'Etude des Syndromes Lymphoproliferatifs, Inserm U164, Centre  
Henri-Becquerel, 76000 Rouen, France

CORRESP. AUTHOR EMAIL: fabrice.jardin@rouen.fnclcc.fr

Revue de Medecine Interne ( Rev. Med. Interne ) (France) July 1, 2005,  
26/7 (557-571)

CODEN: RMEID ISSN: 02488663

PUBLISHER ITEM IDENTIFIER: S024886630400459X

DOI: 10.1016/j.revmed.2004.11.011

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: French SUMMARY LANGUAGE: English; French

NUMBER OF REFERENCES: 169

8/3/47 (Item 23 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0080502689 EMBASE No: 2005146848

Mucosal diseases series

Scully C.

Eastman Dental Institute, University College London, 256 Grays Inn Road,  
London WC1X 8LD, United Kingdom

AUTHOR EMAIL: c.scully@eastman.ucl.ac.uk

CORRESP. AUTHOR: Scully C.

CORRESP. AUTHOR AFFIL: Eastman Dental Institute, University College  
London, 256 Grays Inn Road, London WC1X 8LD, United Kingdom  
CORRESP. AUTHOR EMAIL: c.scully@eastman.ucl.ac.uk

Oral Diseases ( Oral Dis. ) (Denmark) March 1, 2005, 11/2 (57)  
CODEN: ORDIF ISSN: 1354523X  
DOI: 10.1111/j.1601-0825.2005.01107.x  
DOCUMENT TYPE: Journal; Editorial RECORD TYPE: Citation  
LANGUAGE: English

8/3/48 (Item 24 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080301596 EMBASE No: 2004487365  
The role of pathogenic B-cell clones in antibody mediated autoimmune  
disorders  
Wang J.; Zhu X.  
Department of Dermatology, Peking University First Hospital, #8, Xishiku  
St., Beijing 100034, C.  
AUTHOR EMAIL: zhuxj@public.bta.net.cn  
CORRESP. AUTHOR AFFIL: Department of Dermatology, Peking University First  
Hospital, #8, Xishiku St., Beijing 100034, C.  
CORRESP. AUTHOR EMAIL: zhuxj@public.bta.net.cn

Journal of Dermatological Science ( J. Dermatol. Sci. ) (Ireland)  
December 1, 2004, 36/3 (141-148)  
CODEN: JDSCE ISSN: 09231811  
PUBLISHER ITEM IDENTIFIER: S0923181104001367  
DOI: 10.1016/j.jdermsci.2004.07.004  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 59

8/3/49 (Item 25 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080038967 EMBASE No: 2004224116  
Beneficial effects of topical tacrolimus on recalcitrant erosions of  
pemphigus vulgaris  
Gach J.E.; Ilchyshyn A. // Gach J.E.  
Department of Dermatology, Walsgrave Hospital, Univ. Hospitals Coventry  
W., Coventry, United Kingdom // Department of Dermatology, Walsgrave  
Hospital, Univ. Hospitals Coventry W., Clifford Bridge Road, Coventry,  
CV2 2DX, United Kingdom  
AUTHOR EMAIL: asia@jgach.freemove.co.uk; asia@jgach.freemove.co.uk  
CORRESP. AUTHOR: Gach J.E.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, Walsgrave Hospital,  
Univ. Hospitals Coventry W., Clifford Bridge Road, Coventry, CV2 2DX,  
United Kingdom  
CORRESP. AUTHOR EMAIL: asia@jgach.freemove.co.uk

Clinical and Experimental Dermatology ( Clin. Exp. Dermatol. ) (United  
Kingdom) May 1, 2004, 29/3 (271-272)  
CODEN: CEDED ISSN: 03076938  
DOI: 10.1111/j.1365-2230.2004.01499.x  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English



NUMBER OF REFERENCES: 4

8/3/50 (Item 26 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080018133 EMBASE No: 2004203297  
Nicotinamide as a potential addition to the anti-atopic dermatitis  
armamentarium  
Namazi M.R. // Namazi M.R.  
Dermatology Department, Shiraz Univ. of Medical Sciences, Shiraz, Iran,  
Islamic Republic of // P.O. Box 71955-687, Shiraz, Iran, Islamic Republic  
of  
AUTHOR EMAIL: namazi mr@yahoo.com; namazi mr@yahoo.com  
CORRESP. AUTHOR: Namazi M.R.  
CORRESP. AUTHOR AFFIL: Dermatology Department, Shiraz Univ. of Medical  
Sciences, Shiraz, Iran, Islamic Republic of  
CORRESP. AUTHOR EMAIL: namazi mr@yahoo.com

International Immunopharmacology ( Int. Immunopharmacol. ) (Netherlands)  
June 1, 2004, 4/6 (709-712)  
CODEN: IINMB ISSN: 15675769  
PUBLISHER ITEM IDENTIFIER: S156757690300287X  
DOI: 10.1016/j.intimp.2003.11.008  
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Citation  
LANGUAGE: English  
NUMBER OF REFERENCES: 25

8/3/51 (Item 27 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079923931 EMBASE No: 2004108954  
The addition of diuretics to corticosteroids with high mineralocorticoid  
activity may lead to the better control of humoral autoimmune disorders  
Namazi M.R.  
Dermatology Department, Shiraz Univ. of Medical Sciences, P.O. Box  
71955-687, Shiraz, Iran, Islamic Republic of  
AUTHOR EMAIL: namazi mr@yahoo.com  
CORRESP. AUTHOR: Namazi M.R.  
CORRESP. AUTHOR AFFIL: Dermatology Department, Shiraz Univ. of Medical  
Sciences, P.O. Box 71955-687, Shiraz, Iran, Islamic Republic of  
CORRESP. AUTHOR EMAIL: namazi mr@yahoo.com

International Immunopharmacology ( Int. Immunopharmacol. ) (Netherlands)  
February 1, 2004, 4/2 (325)  
CODEN: IINMB ISSN: 15675769  
PUBLISHER ITEM IDENTIFIER: S1567576903002959  
DOI: 10.1016/j.intimp.2003.12.008  
DOCUMENT TYPE: Journal; Letter RECORD TYPE: Citation  
LANGUAGE: English  
NUMBER OF REFERENCES: 5

8/3/52 (Item 28 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079779998 EMBASE No: 2003490472

CME examination for volume 48

Journal of the American Academy of Dermatology ( J. Am. Acad. Dermatol. )  
(United States) December 1, 2003, 49/6 (37A-40A)  
CODEN: JAADD ISSN: 01909622  
DOCUMENT TYPE: Journal; Note RECORD TYPE: Citation  
LANGUAGE: English

8/3/53 (Item 29 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079476456 EMBASE No: 2003181862  
Cytokines and chemokines in autoimmune disease: An overview  
Santamaria P. // Santamaria P.  
University of Calgary, Dept. Microbiol./Infect. Disease, Health Sciences  
Centre, Calgary, Alta., Canada // Dept. of Microbiol./Infect. Diseases,  
Faculty of Medicine, University of Calgary, Calgary, Alta., Canada  
CORRESP. AUTHOR: Santamaria P.  
CORRESP. AUTHOR AFFIL: Dept. of Microbiol./Infect. Diseases, Faculty of  
Medicine, University of Calgary, Calgary, Alta., Canada  
  
Advances in Experimental Medicine and Biology ( Adv. Exp. Med. Biol. ) (  
United States) May 17, 2003, 520/- (1-7)  
CODEN: AEMBA ISSN: 00652598  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation  
LANGUAGE: English  
NUMBER OF REFERENCES: 14

8/3/54 (Item 30 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079378560 EMBASE No: 2003082264  
11. Allergic and immunologic diseases of the skin  
Blauvelt A.; Hwang S.T.; Udey M.C. // Blauvelt A.  
Dermatology Branch, Center for Cancer Research, National Cancer  
Institute, Bethesda, MD, United States // Dermatology Branch, Center for  
Cancer Research, National Cancer Institute, 10 Center Dr MSC 1908,  
Bethesda, MD 20892-1908, United States  
CORRESP. AUTHOR: Blauvelt A.  
CORRESP. AUTHOR AFFIL: Dermatology Branch, Center for Cancer Research,  
National Cancer Institute, 10 Center Dr MSC 1908, Bethesda, MD 20892-1908  
, United States

Journal of Allergy and Clinical Immunology ( J. Allergy Clin. Immunol. )  
(United States) February 1, 2003, 111/2 SUPPL. 2 (S560-S570)  
CODEN: JACIB ISSN: 00916749  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 64

8/3/55 (Item 31 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0078719601 EMBASE No: 2001325932  
Norwegian scabies and immunodeficiency

Gale crouteuse et immunodepression propos de deux observations  
Marsit N.; Mokni M.; El Euch D.; Aissa F.; Cherif F.; Azaiez M.I.; Dhahri  
A.B.O.

Service de Dermatologie, CHU La Rabta, 1007 Bab Saadoun - Tunis, Tunisia

CORRESP. AUTHOR: Marsit N.

CORRESP. AUTHOR AFFIL: Service de Dermatologie, CHU La Rabta, 1007 Bab  
Saadoun - Tunis, Tunisia

Nouvelles Dermatologiques ( Nouv. Dermatol. ) (France) December 1, 2000  
, 19/9 (675-677)

CODEN: NODEE ISSN: 07525370

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: French SUMMARY LANGUAGE: English; French

NUMBER OF REFERENCES: 14

8/3/56 (Item 32 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0078511890 EMBASE No: 2001117978

Anti-CD20 monoclonal antibody (Rituximab) for refractory erosive  
stomatitis secondary to CD20 SUP + follicular lymphoma-associated  
paraneoplastic pemphigus

Borradori L.; Lombardi T.; Samson J.; Girardet C.; Saurat J.-H.; Hugli A.  
Department of Dermatology, University Hospital, Rue Micheli du Crest 24,  
CH-1211 Geneve 14, Switzerland

CORRESP. AUTHOR: Borradori L.

CORRESP. AUTHOR AFFIL: Department of Dermatology, University Hospital,  
Rue Micheli du Crest 24, CH-1211 Geneve 14, Switzerland

CORRESP. AUTHOR EMAIL: Luca.Borradori@hcuge.ch

Archives of Dermatology ( Arch. Dermatol. ) (United States) May 12, 2001  
, 137/3 (269-272)

CODEN: ARDEA ISSN: 0003987X

DOCUMENT TYPE: Journal; Article RECORD TYPE: Citation

LANGUAGE: English

NUMBER OF REFERENCES: 23

8/3/57 (Item 33 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0078409135 EMBASE No: 2001014946

Recent advances in phototherapy

Simon J.C.; Pflieger D.; Schopf E.

Department of Dermatology, University of Freiburg, Hauptstr. 7, Freiburg  
79104, Germany

CORRESP. AUTHOR: Simon J.C.

CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Freiburg,  
Hauptstr. 7, Freiburg 79104, Germany

CORRESP. AUTHOR EMAIL: simonj@haut.ukl.uni-freiburg.de

European Journal of Dermatology ( Eur. J. Dermatol. ) (France) December  
1, 2000, 10/8 (642-644)

CODEN: EJDEE ISSN: 11671122

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 44

8/3/58 (Item 34 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0078364443 EMBASE No: 2000414052  
Autoimmune skin diseases  
Le malattie autoimmuni della cute  
Malorgio C.; Panizon F.  
Clinica Pediatrica, IRCCS 'Burto Garofolo', Trieste, Italy  
CORRESP. AUTHOR: Malorgio C.  
CORRESP. AUTHOR AFFIL: Clinica Pediatrica, IRCCS 'Burto Garofolo',  
Trieste, Italy  
  
Medico e Bambino ( Med. Bambino ) (Italy) October 31, 2000, 19/8  
(495-503)  
CODEN: MBAMF  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: Italian SUMMARY LANGUAGE: English; Italian  
NUMBER OF REFERENCES: 61

8/3/59 (Item 35 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0078048898 EMBASE No: 2000098144  
Extracorporeal photopheresis: 4 years of experience in Geneva  
Photopherese extracorporelle: Quatre ans d'experience a geneve  
Prins C.; Laroutis M.R.; Blondel F.; Bouvier M.; Saurat J.-H.  
Clinique de Dermatologie, Hopital Cantonal Universitaire, 1211 Geneve 14,  
Switzerland  
CORRESP. AUTHOR: Prins C.  
CORRESP. AUTHOR AFFIL: Clinique de Dermatologie, Hopital Cantonal  
Universitaire, 1211 Geneve 14, Switzerland  
  
Medecine et Hygiene ( Med. Hyg. ) (Switzerland) March 8, 2000, 58/2291  
(554-559)  
CODEN: MEHGA ISSN: 00256749  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: French SUMMARY LANGUAGE: English; French  
NUMBER OF REFERENCES: 11

8/3/60 (Item 36 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0077861651 EMBASE No: 1999347983  
HLA class II restriction of autoreactive T cell responses in pemphigus  
vulgaris: Review of the literature and potential applications for the  
development of a specific immunotherapy  
Riechers R.; Hertl M. // Grotzinger J.  
Department of Dermatology, RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen  
, Germany // Institute of Biochemistry, RWTH Aachen, Pauwelsstrasse 30,  
D-52074 Aachen, Germany  
CORRESP. AUTHOR: Riechers R.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, RWTH Aachen,  
Pauwelsstrasse 30, D-52074 Aachen, Germany  
  
Autoimmunity ( Autoimmunity ) (United Kingdom) October 19, 1999, 30/3

(183-196)

CODEN: AUIME ISSN: 08916934  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 67

8/3/61 (Item 37 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0077306883 EMBASE No: 1998217045

Unresponsive discoid lupus erythematosus successfully controlled by  
extracorporeal photopheresis

Extrakorporale Photopherese bei therapieresistentem disseminiert  
diskoidem Lupus erythematosus (DDLE)

Richter H.I.; Krutmann J.; Goerz G. // Krutmann J.  
Hautklinik, Heinrich-Heine-Universität, Düsseldorf, Germany // Klinische  
und Experimentelle Photodermatologie, Hautklinik,  
Heinrich-Heine-Universitätskliniken, Moorenstrasse 5, D-40225 Düsseldorf,  
Germany

CORRESP. AUTHOR: Krutmann J.

CORRESP. AUTHOR AFFIL: Klin./Experimentelle Photodermatol., Hautklinik,  
Heinrich-Heine-Universitätskliniken, Moorenstrasse 5, D-40225 Düsseldorf,  
Germany

Hautarzt ( Hautarzt ) (Germany) June 1, 1998, 49/6 (487-491)

CODEN: HAUTA ISSN: 00178470

DOI: 10.1007/s001050050775

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: German SUMMARY LANGUAGE: English; German

NUMBER OF REFERENCES: 25

8/3/62 (Item 38 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0077100015 EMBASE No: 1998008440

T-helper 2 involvement in the pathogenesis of bullous pemphigoid: Role of  
soluble CD30 (sCD30)

De Pita O.; Frezzolini A.; Cianchini G.; Ruffelli M.; Teofoli P.; Puddu  
P.

Department of Immunodermatology, Ist. Dermatologico dell' Immacolata, IDI,  
Via Monti di Creta, 104-00167 Rome, Italy

AUTHOR EMAIL: a.frezzolini@idi.it

CORRESP. AUTHOR: De Pita O.

CORRESP. AUTHOR AFFIL: Department of Immunodermatology, Istituto  
Dermatologico dell' Immacolata, IRCCS, Via Monti di Creta, 104-00167 Rome,  
Italy

Archives of Dermatological Research ( Arch. Dermatol. Res. ) (Germany)

December 1, 1997, 289/12 (667-670)

CODEN: ADMFA ISSN: 03403696

DOI: 10.1007/s004030050259

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 27

8/3/63 (Item 39 from file: 73)

DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0077089535 EMBASE No: 1997382805

Mucocutaneous autoimmune syndrome following fludarabine therapy for  
low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL)

Braess J.; Hiddemann W.; Wormann B. // Willert S.; Strutz F. // Reich K.;  
Neumann C.

Dept. of Hematology and Oncology, Klinikum Gottingen, Georg August  
Universitat, Robert Koch Strasse, D-37075 Gottingen, Germany //  
Department of Nephrology, Klinikum Gottingen, Germany // Department of  
Dermatology, Klinikum Gottingen, Gottingen, Germany

CORRESP. AUTHOR: Braess J.

CORRESP. AUTHOR AFFIL: Department Hematology and Oncology, Klinikum  
Gottingen, Georg August Universitat, Robert Koch Strasse, D-37075  
Gottingen, Germany

Annals of Hematology ( ANN. HEMATOL. ) (Germany) November 1, 1997,  
75/5-6 (227-230)

CODEN: ANHEE ISSN: 09395555

DOI: 10.1007/s002770050347

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 25

8/3/64 (Item 40 from file: 73)

DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075944690 EMBASE No: 1994352172

Extracorporeal photopheresis

EXTRAKORPORALE PHOTOPHERESE

Prinz B.; Plewig G.

Dermatologische Klinik/Poliklinik, Ludwig-Maximilians-Universitat,  
Frauenlobstrasse 9-11, D-80337 Munchen, Germany

CORRESP. AUTHOR: Prinz B.

CORRESP. AUTHOR AFFIL: Dermatologische Klinik/Poliklinik,  
Ludwig-Maximilians-Universitat, Frauenlobstrasse 9-11, D-80337 Munchen,  
Germany

Hautarzt ( HAUTARZT ) (Germany) December 21, 1994, 45/11 (746-750)

CODEN: HAUTA ISSN: 00178470

DOI: 10.1007/s001050050164

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: German SUMMARY LANGUAGE: English; German

8/3/65 (Item 41 from file: 73)

DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075943261 EMBASE No: 1994360240

Photopheresis: Report of cases and review of the literature

FOTOFERESIS: REPORTE DE CASOS Y REVISION DE LA LITERATURA

Bogaert M.A.; Sisto M.; Kerdel F.A.

Dept. Dermatology/Cutaneous Surgery, University of Miami, School of  
Medicine, 1600 N.W. 10th Avenue, Miami, FL 33136, United States

CORRESP. AUTHOR: Kerdel F.A.

CORRESP. AUTHOR AFFIL: Dept. Dermatology/Cutaneous Surgery, University of  
Miami, School of Medicine, 1600 N.W. 10th Avenue, Miami, FL 33136, United

States

Medicina Cutanea Ibero-Latino-Americana ( MED. CUTANEA IBERO-LAT.-AM. ) ( Spain) December 1, 1994, 22/6 (278-283)  
CODEN: MCILB ISSN: 02105187  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: Spanish SUMMARY LANGUAGE: English; Spanish

8/3/66 (Item 42 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075922515 EMBASE No: 1994344026  
A case of pemphigus vulgaris expired by acute renal failure  
Yoo H.D.; Sim W.Y.  
Department of Dermatology, College of Medicine, Kyung Hee University,  
Seoul, Korea, Republic of  
CORRESP. AUTHOR: Yoo H.D.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, College of Medicine,  
Kyung Hee University, Seoul, Korea, Republic of  
  
Korean Journal of Dermatology ( KOREAN J. DERMATOL. ) (Korea, Republic of  
) November 28, 1994, 32/4 (713-717)  
CODEN: TPKCA ISSN: 04944739  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: Korean SUMMARY LANGUAGE: English

8/3/67 (Item 43 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075806162 EMBASE No: 1994232651  
Autoimmunity as a complication of interleukin 2 immunotherapy: Many  
unanswered questions  
Gaspari A.A.  
Department of Dermatology, University of Rochester, Box 697, 601 Elmwood  
Ave, New York, NY 14642, United States  
CORRESP. AUTHOR: Gaspari A.A.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of  
Rochester, Box 697, 601 Elmwood Ave, New York, NY 14642, United States  
  
Archives of Dermatology ( ARCH. DERMATOL. ) (United States) August 5,  
1994, 130/7 (894-897)  
CODEN: ARDEA ISSN: 0003987X  
DOI: 10.1001/archderm.130.7.894  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation  
LANGUAGE: English

8/3/68 (Item 44 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075803474 EMBASE No: 1994190202  
Extracorporeal photopheresis  
Gross M.; Boh E.E.; Millikan L.E.  
Department of Dermatology, Tulane University Medical Center, 1430 Tulane  
Avenue, New Orleans, LA 70112, United States  
CORRESP. AUTHOR: Gross M.

CORRESP. AUTHOR AFFIL: Department of Dermatology, Tulane University  
Medical Center, 1430 Tulane Avenue, New Orleans, LA 70112, United States

International Journal of Dermatology ( INT. J. DERMATOL. ) (Canada)  
August 8, 1994, 33/6 (407-411)  
CODEN: IJDEB ISSN: 00119059  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation  
LANGUAGE: English

8/3/69 (Item 45 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075770590 EMBASE No: 1994205185  
The immunological features and pathophysiology of ocular cicatricial  
pemphigoid  
Elder M.J.; Lightman S.  
Moorfields Eye Hospital, City Road, London EC1V 2PD, United Kingdom  
CORRESP. AUTHOR: Elder M.J.  
CORRESP. AUTHOR AFFIL: Moorfields Eye Hospital, City Road, London EC1V  
2PD, United Kingdom

Eye ( EYE ) (United Kingdom) July 7, 1994, 8/2 (196-199)  
CODEN: EYEEE ISSN: 0950222X  
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English

8/3/70 (Item 46 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075676152 EMBASE No: 1994100257  
Role of extracorporeal photopheresis in the treatment of cutaneous T-cell  
lymphoma, autoimmune disease, and allograft rejection  
Rook A.H.; Wolfe J.T.  
Department of Dermatology, University of Pennsylvania Hospital, 3400  
Spruce Street, Philadelphia, PA 19104, United States  
CORRESP. AUTHOR: Rook A.H.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of  
Pennsylvania Hospital, 3400 Spruce Street, Philadelphia, PA 19104, United  
States

Journal of Clinical Apheresis ( J. CLIN. APHERESIS ) (United States)  
April 11, 1994, 9/1 (28-30)  
CODEN: JCAPE ISSN: 07332459  
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English

8/3/71 (Item 47 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075450186 EMBASE No: 1993229742  
Pemphigus vulgaris and vegetans  
Becker B.A.; Gaspari A.A.  
Department of Dermatology, University of Rochester, School of  
Medicine/Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, United  
States



CORRESP. AUTHOR: Gaspari A.A.

CORRESP. AUTHOR AFFIL: Department of Dermatology, University of  
Rochester, School of Medicine/Dentistry, 601 Elmwood Avenue, Rochester,  
NY 14642, United States

Dermatologic Clinics ( DERMATOL. CLIN. ) (United States) August 23, 1993  
, 11/3 (429-452)

CODEN: DRMCD ISSN: 07338635

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

8/3/72 (Item 48 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0075326355 EMBASE No: 1993105897

Paraneoplastic pemphigus in a child with a T-cell lymphoblastic lymphoma  
Rybojad M.; Leblanc T.; Flageul B.; Bernard Ph.; Morel P.; Schaison G.;  
D'Agay M.-F.; Borradori L.

Service Dermatologie, Hopital Cantonal Universitaire, 24, Rue  
Micheli-du-Crest, CH-1211 Geneve, Switzerland

CORRESP. AUTHOR: Borradori L.

CORRESP. AUTHOR AFFIL: Service Dermatologie, Hopital Cantonal  
Universitaire, 24, Rue Micheli-du-Crest, CH-1211 Geneve, Switzerland

British Journal of Dermatology ( BR. J. DERMATOL. ) (United Kingdom)

April 28, 1993, 128/4 (418-422)

CODEN: BJDEA ISSN: 00070963

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

8/3/73 (Item 49 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0075072132 EMBASE No: 1992223805

Photopheresis in the 1990s

Christensen I.; Heald P.

500 LCI, 333 Cedar Street, New Haven, CT 06510, United States

CORRESP. AUTHOR: Christensen I.

CORRESP. AUTHOR AFFIL: 500 LCI, 333 Cedar Street, New Haven, CT 06510,  
United States

Journal of Clinical Apheresis ( J. CLIN. APHERESIS ) (United States)

December 1, 1991, 6/4 (216-220)

CODEN: JCAPE ISSN: 07332459

DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Citation

LANGUAGE: English

8/3/74 (Item 50 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0074873316 EMBASE No: 1992024988

The role of cyclosporine A in the treatment of pemphigus erythematosus  
Campolmi P.; Bonan P.; Lotti T.; Palleschi G.M.; Fabbri P.; Panconesi E.  
Clinica Dermatologica, Via Alfani 37, 50121 Firenze, Italy

CORRESP. AUTHOR: Bonan P.

CORRESP. AUTHOR AFFIL: Clinica Dermatologica, Via Alfani 37, 50121  
Firenze, Italy

International Journal of Dermatology ( INT. J. DERMATOL. ) (United States  
) December 1, 1991, 30/12 (890-892)

CODEN: IJDEB ISSN: 00119059

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

8/3/75 (Item 51 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0074446101 EMBASE No: 1990345667

Cyclosporin in dermatology

LA CYCLOSPORINE EN DERMATOLOGIE

Salomon D.; Halioua B.

Clinique de Dermatologie, Hopital Cantonal Universitaire, 1211 Geneva 4,  
Switzerland

CORRESP. AUTHOR AFFIL: Clinique de Dermatologie, Hopital Cantonal  
Universitaire, 1211 Geneva 4, Switzerland

Schweizerische Rundschau fur Medizin/Praxis ( SCHWEIZ. RUNDSCH. MED.  
PRAX. ) (Switzerland) November 22, 1990, 79/42 (1258-1261)

CODEN: SRMPD ISSN: 03698394

DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Citation

LANGUAGE: French SUMMARY LANGUAGE: English; German

8/3/76 (Item 52 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0074308283 EMBASE No: 1990202296

Photopheresis: A new therapeutic concept

Edelson R.L.

Department of Dermatology, Yale University School of Medicine, New Haven,  
CT, United States

CORRESP. AUTHOR AFFIL: Department of Dermatology, Yale University School  
of Medicine, New Haven, CT, United States

Yale Journal of Biology and Medicine ( YALE J. BIOL. MED. ) (United  
States) December 1, 1989, 62/6 (565-577)

CODEN: YJBMA ISSN: 00440086

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

8/3/77 (Item 53 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0073492421 EMBASE No: 1987020814

When to discontinue therapy in pemphigus vulgaris?

WANN IST ES MOGLICH, DIE THERAPIE BEIM PEMPHIGUS VULGARIS ABZUSETZEN?

Mashkilleyson N.; Eskelinen A.

Department fur Dermatologie, Stomatologisches Institut Moskau, Moskau,  
U.S.S.R.

CORRESP. AUTHOR AFFIL: Department fur Dermatologie, Stomatologisches  
Institut Moskau, Moskau, U.S.S.R.

H+G Zeitschrift fur Hautkrankheiten ( H G Z. HAUTKR. ) (Germany)  
December 1, 1986, 61/22 (1596-1602)  
CODEN: ZHKRA ISSN: 03010481  
DOCUMENT TYPE: Journal RECORD TYPE: Abstract  
LANGUAGE: German SUMMARY LANGUAGE: English

8/3/78 (Item 54 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0073249693 EMBASE No: 1986058727  
Heparin action in pemphigus vulgaris: Clinical and immunologic studies  
Mashkilleyson N.A.  
Department of Dermatology, Moscow Medical Stomatological Institute,  
Moscow, U.S.S.R.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, Moscow Medical  
Stomatological Institute, Moscow, U.S.S.R.

Acta Dermato-Venereologica ( ACTA DERM.-VENEREOL. ) (Sweden) December 1,  
1985, 65/6 (545-547)  
CODEN: ADVEA ISSN: 00015555  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Citation  
LANGUAGE: English

8/3/79 (Item 55 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0073194646 EMBASE No: 1986093680  
Deficiency of interleukin-2 in pemphigus vulgaris  
INTERLEUKIN-2-MANGEL BEI PEMPHIGUS VULGARIS  
Blitstein-Willinger E.; Stuttgart G.  
Universitäts-Hautklinik und -Poliklinik im Rudolph-Virchow-Krankenhaus,  
FU, D-1000 Berlin 65, Germany  
CORRESP. AUTHOR AFFIL: Universitäts-Hautklinik und -Poliklinik im  
Rudolph-Virchow-Krankenhaus, FU, D-1000 Berlin 65, Germany

H+G Zeitschrift fur Hautkrankheiten ( H G Z. HAUTKR. ) (Germany) May 14,  
1986, 61/1-2 (82-85)  
CODEN: ZHKRA ISSN: 03010481  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: German SUMMARY LANGUAGE: English

8/3/80 (Item 56 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0073173784 EMBASE No: 1986117818  
Cutaneous immunological studies in diagnosis of acute graft-versus-host  
disease  
Dreno B.; Milpied N.; Harousseau J.L.; et-al  
Clinique Dermatologique, Hematologie, Hotel Dieu, 44035 Nantes, France  
CORRESP. AUTHOR AFFIL: Clinique Dermatologique, Hematologie, Hotel Dieu,  
44035 Nantes, France

British Journal of Dermatology ( BR. J. DERMATOL. ) (United Kingdom)  
June 18, 1986, 114/1 (7-15)

CODEN: BJDEA ISSN: 00070963  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English

8/3/81 (Item 57 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0072541205 EMBASE No: 1983026673  
Use of monoclonal antibodies specific for T cell subsets in cutaneous disorders: I. Quantitative analysis of peripheral blood lymphocytes  
Faure M.; Thivolet J.  
Inserm U 209, Lab. Rech. Dermatol. Immunol., Hop. E. Herriot, 69374 Lyon Cedex 2, France  
CORRESP. AUTHOR AFFIL: Inserm U 209, Lab. Rech. Dermatol. Immunol., Hop. E. Herriot, 69374 Lyon Cedex 2, France  
  
Journal of Clinical Immunology ( J. CLIN. IMMUNOL. ) (United States)  
December 1, 1982, 2/Suppl. 3 (103S-110S)  
CODEN: JCIMD ISSN: 02719142  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English

8/3/82 (Item 58 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0071805404 EMBASE No: 1981251814  
Use of orthoclone monoclonal antibodies in the study of selected dermatologic conditions  
Berger C.L.; Kung P.; Goldstein G.; et-al  
Dept. Dermatol., Columbia Univ., New York, NY 10032, United States  
CORRESP. AUTHOR AFFIL: Dept. Dermatol., Columbia Univ., New York, NY 10032, United States

International Journal of Immunopharmacology ( INT. J. IMMUNOPHARMACOL. )  
(United Kingdom) December 29, 1981, 3/3 (275-282)  
CODEN: IJIMD ISSN: 01920561  
DOI: 10.1016/0192-0561(81)90021-7  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English

8/3/83 (Item 59 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0071256724 EMBASE No: 1978401631  
Pemphigus vulgaris and thymoma. A T-lymphocyte defect?  
Kavli G.  
Dept. Dermatol., Univ. 9012 Tromso, Norway  
CORRESP. AUTHOR AFFIL: Dept. Dermatol., Univ. 9012 Tromso, Norway

British Journal of Dermatology ( BR. J. DERMATOL. ) (United Kingdom)  
December 11, 1978, 99/1 (97-98)  
CODEN: BJDEA ISSN: 00070963  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English

8/3/84 (Item 60 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0071200319 EMBASE No: 1978343401  
Immunosuppressive effect of serum from patients with skin diseases  
DIE IMMUNITATSCHEMMENDE WIRKUNG DES BLUTSERUMS BEI DERMATOSEN  
Somos S.  
Hautklin., Univ. Pecs, Hungary  
CORRESP. AUTHOR AFFIL: Hautklin., Univ. Pecs, Hungary  
  
Dermatologische Monatsschrift ( DERMATOL. MONATSSCHR. ) (German  
Democratic Republic) August 18, 1978, 164/3 (186-192)  
CODEN: DMONB ISSN: 00119083  
DOCUMENT TYPE: Journal RECORD TYPE: Abstract  
LANGUAGE: German SUMMARY LANGUAGE: English

8/3/85 (Item 61 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0070779654 EMBASE No: 1977136545  
Hodgkin's disease and pemphigus  
Naysmith A.; Hancock B.W.  
Univ. Dept. Med., Roy. Hosp., Sheffield, United Kingdom  
CORRESP. AUTHOR AFFIL: Univ. Dept. Med., Roy. Hosp., Sheffield, United  
Kingdom  
  
British Journal of Dermatology ( BR. J. DERMATOL. ) December 1, 1976,  
94/6 (695-696)  
CODEN: BJDEA ISSN: 00070963  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English

8/3/86 (Item 62 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0070392933 EMBASE No: 1975176789  
'Opportunistic' auto immune disease and 'opportunistic' malignancy from  
impaired cell mediated immunity?  
Cairns R.J.  
St Bartholomew's Hosp., Rochester, United Kingdom  
CORRESP. AUTHOR AFFIL: St Bartholomew's Hosp., Rochester, United Kingdom  
  
British Journal of Dermatology ( BR. J. DERMATOL. ) December 1, 1974,  
91/5 (601-602)  
CODEN: BJDEA ISSN: 00070963  
DOCUMENT TYPE: Journal RECORD TYPE: Citation  
LANGUAGE: English

8/3/87 (Item 63 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0070262085 EMBASE No: 1975045851  
Pemphigus and Hodgkin's disease

Sood V.D.; Pasricha J.S.

Dept. Dermatol. Venereol., All India Inst. Med. Sch., New Delhi, India  
CORRESP. AUTHOR AFFIL: Dept. Dermatol. Venereol., All India Inst. Med.  
Sch., New Delhi, India

British Journal of Dermatology ( BR. J. DERMATOL. ) December 1, 1974,  
90/5 (575-578)

CODEN: BJDEA ISSN: 00070963

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English

8/3/88 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

17756072 PMID: 17598863

Clinical-scale generation of strongly CD83-expressing dendritic cells  
using extracorporeal photopheresis.

Bredberg Anders; Jonsson Svante; Lindblom Anders; Bjork Peter

Department of Medical Microbiology, Malmo University Hospital, Lund  
University, Malmo, Sweden.

Photodermatology, photoimmunology & photomedicine (Denmark) Aug 2007,

23 (4) p113-9, ISSN 0905-4383--Print Journal Code: 9013641

Publishing Model Print

Document type: Evaluation Studies; Journal Article; Research Support,  
Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/89 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

17458661 PMID: 17097371

Lichenoid paraneoplastic pemphigus in the absence of detectable  
antibodies.

Cummins Deborah L; Mimouni Daniel; Tzu Julia; Owens Nicole; Anhalt Grant  
J; Meyerle Jon H

Department of Dermatology, Johns Hopkins Hospital, Baltimore, MD 21205,  
USA.

Journal of the American Academy of Dermatology (United States) Jan 2007

, 56 (1) p153-9, ISSN 1097-6787--Electronic Journal Code: 7907132

Publishing Model Print-Electronic

Document type: Case Reports; Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/90 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

16839443 PMID: 16417225

Tolerance induction by the blockade of CD40/CD154 interaction in  
pemphigus vulgaris mouse model.

Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki; Iwasaki  
Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji; Amagai Masayuki

Department of Dermatology, Keio University School of Medicine,  
Shinjuku-ku, Tokyo, Japan.

Journal of investigative dermatology (United States) Jan 2006, 126  
(1) p105-13, ISSN 0022-202X--Print Journal Code: 0426720

Publishing Model Print; Comment in J Invest Dermatol. 2006  
Jan;126(1) 11-3; Comment in PMID 16417211

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/91 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

15542509 PMID: 14761596

[A clinicopathological study of Castleman's disease]

Na Jia; Liu Ping; Wang Ren-gui; Wang Liang-chun; Zou Wan-zhong

Department of Pathology, Peking University First Hospital, Beijing  
100034, China.

Zhonghua bing li xue za zhi Chinese journal of pathology (China) Dec  
2003, 32 (6) p521-4, ISSN 0529-5807--Print Journal Code: 0005331

Publishing Model Print

Document type: English Abstract; Journal Article

Languages: CHINESE

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/92 (Item 5 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

12747263 PMID: 9675577

[Extracorporeal photopheresis in therapy-refractory disseminated discoid  
lupus erythematosus]

Extrakorporale Photopherese bei therapieresistentem disseminiert  
diskoidem Lupus erythematosus (DDLE).

Richter H I; Krutmann J; Goerz G

Hautklinik, der Heinrich-Heine-Universitat, Dusseldorf.

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte  
Gebiete (GERMANY) Jun 1998, 49 (6) p487-91, ISSN 0017-8470--Print

Journal Code: 0372755

Publishing Model Print

Document type: Case Reports; English Abstract; Journal Article

Languages: GERMAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/93 (Item 6 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

11939831 PMID: 8868455

[Therapeutic experiences with extracorporeal photopheresis. Technical  
procedure, follow-up and clinical outcome in 31 skin diseases]

Therapeutische Erfahrungen mit der Extrakorporalen Photopherese.  
Technisches Vorgehen, Uberwachung und klinische Ergebnisse bei 41  
Hautkranken.

Owsianowski M; Garbe C; Ramaker J; Orfanos C E; Gollnick H  
Universittis-Hautklinik und Poliklinik, Freie Universitat, Berlin.  
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte  
Gebiete (GERMANY) Feb 1996, 47 (2) p114-23, ISSN 0017-8470--Print  
Journal Code: 0372755  
Publishing Model Print  
Document type: English Abstract; Journal Article  
Languages: GERMAN  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/94 (Item 7 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

11883255 PMID: 8804843  
Coexistence of superficial pemphigus and psoriasis.  
Panzarella K; Camisa C  
Department of Dermatology, Cleveland Clinic Foundation, Ohio 44195, USA.  
Cutis; cutaneous medicine for the practitioner (UNITED STATES) Jun 1996  
, 57 (6) p414-8, ISSN 0011-4162--Print Journal Code: 0006440  
Publishing Model Print  
Document type: Case Reports; Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/95 (Item 8 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

10013351 PMID: 1793210  
Photopheresis in the treatment of autoimmune disease: experience with  
pemphigus vulgaris and systemic sclerosis.  
Rook A H  
Department of Dermatology, Hospital of the University of Pennsylvania,  
Philadelphia 19104.  
Annals of the New York Academy of Sciences (UNITED STATES) Dec 30 1991,  
636 p209-16, ISSN 0077-8923--Print Journal Code: 7506858  
Publishing Model Print  
Document type: Journal Article; Review  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/96 (Item 9 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

09859874 PMID: 1887157  
[The application of photopheresis in the therapy of cancerous and  
autoimmune diseases]  
Applicazione della fotoferesi nella terapia di malattie oncologiche ed  
autoimmuni.  
Dall'Amico R; Zacchello G; Heald P  
Dipartimento di Pediatria, Universita, Padova.  
Recenti progressi in medicina (ITALY) May 1991, 82 (5) p294-9,  
ISSN 0034-1193--Print Journal Code: 0401271



Publishing Model Print  
Document type: Clinical Trial; English Abstract; Journal Article; Review  
Languages: ITALIAN  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/97 (Item 10 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

09261567 PMID: 2636804  
Treatment of autoimmune disease with extracorporeal photochemotherapy:  
pemphigus vulgaris--preliminary report.  
Rook A H; Heald P W; Nahass G T; Macey W; Witmer W K; Lazarus G S;  
Jegasothy B V  
General Clinical Research Center, Hospital of University of Pennsylvania,  
Philadelphia 19104.  
Yale journal of biology and medicine (UNITED STATES) Nov-Dec 1989, 62  
(6) p647-52, ISSN 0044-0086--Print Journal Code: 0417414  
Contract/Grant No.: M01 RR00040-29; RR; United States NCRR  
Publishing Model Print  
Document type: Case Reports; Journal Article; Research Support, U.S.  
Gov't, P.H.S.  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/98 (Item 11 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

08747618 PMID: 2460382  
Immunohistological study of captopril-induced late cutaneous eruptions.  
Bretin N; Dreno B; Bureau B; Litoux P  
Department of Dermatology, Nantes, France.  
Dermatologica (SWITZERLAND) 1988, 177 (1) p11-5, ISSN 0011-9075--  
Print Journal Code: 0211607  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/99 (Item 12 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

08141983 PMID: 3101298  
[When is it possible to discontinue therapy in pemphigus vulgaris?]  
Wann ist es möglich, die Therapie beim Pemphigus vulgaris abzusetzen?  
Mashkilleyson N; Eskelinen A  
Zeitschrift fur Hautkrankheiten (GERMANY, WEST) Nov 15 1986, 61 (22)  
p1596-602, ISSN 0301-0481--Print Journal Code: 0367576  
Publishing Model Print  
Document type: Case Reports; English Abstract; Journal Article  
Languages: GERMAN  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/100 (Item 13 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

07804869 PMID: 3936658  
Normalization of defective interleukin 1 and interleukin 2 production in patients with pemphigus vulgaris following chrysotherapy.  
Blitstein-Willinger E  
Clinical and experimental immunology (ENGLAND) Dec 1985, 62 (3)  
p705-14, ISSN 0009-9104--Print Journal Code: 0057202  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/101 (Item 14 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

07255837 PMID: 6422017  
Glucocorticosteroids and oral medicine.  
Pedersen A; Klausen B  
Journal of oral pathology (DENMARK) Feb 1984, 13 (1) p1-15, ISSN 0300-9777--Print Journal Code: 0342050  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/102 (Item 15 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

06495871 PMID: 6974011  
Cell-mediated immunity in patients with less than pemphigus vulgaris greater than before, during and after prolonged treatment with steroids.  
Shohat B; David M; Feuerman E J  
Biomedicine / publiee pour l'A.A.I.C.I.G. (FRANCE) Jul 1981, 35 (3)  
p101-3, ISSN 0300-0893--Print Journal Code: 0361342  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/103 (Item 16 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

05608378 PMID: 347546  
[Immunological aspects of malignant lymphomas]  
Aspetti immunologici dei linfomi maligni.  
Hancock B W; Richmond J  
Recenti progressi in medicina (ITALY) Feb 1978, 64 (2) p217-29,

ISSN 0034-1193--Print Journal Code: 0401271  
Publishing Model Print  
Document type: Journal Article; Review  
Languages: ITALIAN  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/104 (Item 17 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

05482935 PMID: 144706  
Antilymphocyte globulin and its use in skin diseases.  
Barrett A J  
International journal of dermatology (UNITED STATES) Nov 1977, 16 (9)  
p738-9, ISSN 0011-9059--Print Journal Code: 0243704  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

8/3/105 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

148031934 CA: 148(2)31934m PATENT  
Ligands or antibodies capable of binding to CD3 and CD55 for producing  
regulatory CD4+ T cells to treat antibody- or cell-mediated autoimmune  
disease  
INVENTOR(AUTHOR): Spendlove, Ian; Durrant, Linda Gillian  
LOCATION: UK,  
ASSIGNEE: The University of Nottingham  
PATENT: PCT International ; WO 2007135401 A2 DATE: 20071129  
APPLICATION: WO 2007GB1864 (20070518) \*GB 20069924 (20060519)  
PAGES: 65pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
IPCR/8 + Level Value Position Status Version Action Source Office:  
A61K-0039/395 A I F B 20060101 H EP  
A61P-0037/00 A I L B 20060101 H EP  
A61K-0038/17 A I L B 20060101 H EP  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;  
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;  
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;  
NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;  
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/106 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

147446877 CA: 147(21)446877x PATENT  
Combination therapy for treating autoimmune diseases

INVENTOR(AUTHOR): Koenig, Scott  
LOCATION: USA  
ASSIGNEE: Macrogenics, Inc.  
PATENT: PCT International ; WO 2007117600 A2 DATE: 20071018  
APPLICATION: WO 2007US8579 (20070406) \*US 2006PV789899 (20060407) \*US  
2006PV844095 (20060913)

PAGES: 38pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0039/395 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;  
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;  
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ;  
NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL;  
SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/107 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

147446856 CA: 147(21)446856q PATENT  
Isolation and use of human regulatory T cells  
INVENTOR(AUTHOR): Yun, Theodore J.  
LOCATION: USA  
ASSIGNEE: Biogen Idec Ma Inc.  
PATENT: PCT International ; WO 2007117602 A2 DATE: 20071018  
APPLICATION: WO 2007US8581 (20070406) \*US 2006PV789918 (20060407)  
PAGES: 74pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

C12N-0005/08 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;  
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;  
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;  
NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;  
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/108 (Item 4 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

147235154 CA: 147(11)235154w PATENT  
Preparation of thiazole and thiadiazole compounds for treating  
inflammation, immune disorders, and other diseases  
INVENTOR(AUTHOR): Vo, Nha Huu; Chen, Shoujun; Che, Qinglin; Xie, Yu  
LOCATION: USA  
ASSIGNEE: Synta Pharmaceuticals Corp.  
PATENT: PCT International ; WO 200787427 A2 DATE: 20070802  
APPLICATION: WO 2007US2121 (20070125) \*US 2006PV761974 (20060125) \*US

2006PV761933 (20060125)

PAGES: 210pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0031/433 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/109 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

147203924 CA: 147(10)203924f PATENT

Compositions and methods for modulation of suppressor T cell activation

INVENTOR(AUTHOR): Wang, Bin; Greene, Mark I.; Saquaf, Sandra; Li, Bin; Zhang, Hongtao; Hancock, Wayne W.

LOCATION: USA

ASSIGNEE: The Trustees of the University of Pennsylvania; The Children's Hospital of Philadelphia

PATENT: PCT International ; WO 200784775 A2 DATE: 20070726

APPLICATION: WO 2007US1677 (20070122) \*US 2006PV760549 (20060120) \*US 2006PV794670 (20060424)

PAGES: 77pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0035/14 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/110 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

147141190 CA: 147(7)141190c JOURNAL

Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients

AUTHOR(S): Goh, M. S. Y.; McCormack, C.; Dinh, H. V.; Welsh, B.; Foley, P.; Prince, H. M.

LOCATION: Dermatology Service and Clinical Cancer Services, Peter MacCallum Cancer Centre, Melbourne, Vic., 8006, Australia

JOURNAL: Br. J. Dermatol. (British Journal of Dermatology) DATE: 2007

VOLUME: 156 NUMBER: 5 PAGES: 990-996 CODEN: BJDEAZ ISSN: 0007-0963

LANGUAGE: English PUBLISHER: Blackwell Publishing Ltd.

8/3/111 (Item 7 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

146460616 CA: 146(23)460616x PATENT  
Apoptotic cells ex vivo use to generate regulatory T cells (Treg) and  
disease treatment using Treg  
INVENTOR(AUTHOR): Peritt, David; Campbell, Kim; Krutsick, Amy  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20070098686 A1 DATE: 20070503  
APPLICATION: US 2006555978 (20061102) \*US 2005PV732847 (20051102)  
PAGES: 15pp. CODEN: USXXCO LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 424085200  
IPCR/8 + Level Value Position Status Version Action Source Office:  
A61K-0038/20 A I F B 20060101 20070503 H US  
A61K-0031/366 A I L B 20060101 20070503 H US  
A61K-0031/59 A I L B 20060101 20070503 H US

8/3/112 (Item 8 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

146357227 CA: 146(18)357227x PATENT  
Diastereomeric peptides for modulating T cell immunity  
INVENTOR(AUTHOR): Shai, Yechiel; Cohen, Irun R.; Quintana, Francisco;  
Gerber, Doron  
LOCATION: Israel  
ASSIGNEE: Yeda Research and Development Co., Ltd.  
PATENT: PCT International ; WO 200734490 A2 DATE: 20070329  
APPLICATION: WO 2006IL1113 (20060921) \*US 2005PV719169 (20050922)  
PAGES: 79pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
IPCR/8 + Level Value Position Status Version Action Source Office:  
C07K-0014/07 A I F B 20060101 H US  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA;  
LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG;  
NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV;  
SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/113 (Item 9 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

146272528 CA: 146(14)272528w PATENT  
Human Ig comprising antigen T cell epitope for activating selective  
subsets of antigen presenting cells to treat viral infection, cancer and  
autoimmune disease  
INVENTOR(AUTHOR): Wang, Lilin; Smith, Dan; Phillips, Bill; Bot, Adrian  
LOCATION: USA  
ASSIGNEE: Multicell Immunotherapeutics, Inc.

PATENT: PCT International ; WO 200722477 A2 DATE: 20070222  
APPLICATION: WO 2006US32512 (20060817) \*US 2005PV708980 (20050817)  
PAGES: 197pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0039/395 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/114 (Item 10 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146252109 CA: 146(13)252109g PATENT

Preparation of amino acid and peptide aldehyde imines as inhibitors of cancer cell, T-cell and keratinocyte proliferation for the treatment of proliferative diseases

INVENTOR(AUTHOR): Leban, Johann; Kralik, Martin

LOCATION: Germany,

ASSIGNEE: 4SC AG

PATENT: PCT International ; WO 200717284 A2 DATE: 20070215

APPLICATION: WO 2006EP7933 (20060810) \*EP 200517391 (20050810)

PAGES: 57pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

C07K-0005/04 A I F B 20060101 H EP

C07K-0005/06 A I L B 20060101 H EP

C07K-0005/08 A I L B 20060101 H EP

C07K-0005/10 A I L B 20060101 H EP

A61K-0038/04 A I L B 20060101 H EP

C07D-0233/00 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/115 (Item 11 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146006355 CA: 146(1)6355z PATENT

Biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

INVENTOR(AUTHOR): Aukerman, Sharon Lea; Jallal, Bahija; Luqman, Mohammad

LOCATION: USA  
ASSIGNEE: Novartis AG; Xoma Technology  
PATENT: PCT International ; WO 2006125117 A2 DATE: 20061123  
APPLICATION: WO 2006US19325 (20060518) \*US 2005PV682575 (20050518) \*US  
2005PV749336 (20051209)  
PAGES: 145pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

G01N-0033/564 A I F B 20060101 H EP

G01N-0033/68 A I L B 20060101 H EP

A61P-0037/00 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK;  
LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ;  
OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR;  
TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/116 (Item 12 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

145437248 CA: 145(22)437248z PATENT  
Detection and isolation of immunosuppressive regulatory T cells and uses  
thereof in treatment of autoimmune disease and prevention of graft  
rejection

INVENTOR(AUTHOR): Borsellino, Giovanna; Battistini, Luca; Roetzschke,  
Olaf; Falk, Kirsten

LOCATION: Italy

ASSIGNEE: Fondazione Santa Lucia I.R.C.C.S.

PATENT: PCT International ; WO 2006111986 A1 DATE: 20061026

APPLICATION: WO 2005IT227 (20050419)

PAGES: 18pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

G01N-0033/566 A I F B 20060101 H EP

A61K-0035/00 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR;  
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH;  
PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA;  
UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: AT; BE; BG; CH; CY  
; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL; PL;  
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;  
SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM;  
AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/117 (Item 13 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

144312116 CA: 144(17)312116c PATENT

Preparation of piperidinylthiazolecarboxamides as inhibitors of T-cell  
proliferation



INVENTOR(AUTHOR): Leban, Johann; Schmitt, Harald; Wolf, Kristina  
LOCATION: Germany,  
ASSIGNEE: 4SC AG  
PATENT: European Pat. Appl. ; EP 1637529 A1 DATE: 20060322  
APPLICATION: EP 200422363 (20040920)  
PAGES: 22 pp. CODEN: EPXXDW LANGUAGE: English  
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

C07D-0401/14	A	I	F	B		H	EP
A61K-0031/4535	A	I	L	B		H	EP
C07D-0495/04	A	I	L	B		H	EP
C07D-0401/04	A	I	L	B		H	EP
C07D-0487/04	A	I	L	B		H	EP
A61P-0025/28	A	I	L	B		H	EP
A61P-0035/00	A	I	L	B		H	EP

DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;  
SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR; BG; CZ; EE; HU; PL; SK;  
HR

8/3/118 (Item 14 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

144286710 CA: 144(16)286710v PATENT  
Methods for restoring immune balance for the treatment of T-cell mediated  
diseases with human chorionic gonadotropin  
INVENTOR(AUTHOR): Yoon, Ji-Won  
LOCATION: S. Korea  
ASSIGNEE: Biotech Institute for International Innovation Inc.  
PATENT: PCT International ; WO 200629088 A2 DATE: 20060316  
APPLICATION: WO 2005US31554 (20050901) \*US 2004PV606831 (20040902)  
PAGES: 47 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0038/22	A	I	F	B	20060101	H	US
--------------	---	---	---	---	----------	---	----

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR;  
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG;  
PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ;  
UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/119 (Item 15 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

144231353 CA: 144(13)231353a JOURNAL  
Inhibition of the Transcription Factor Foxp3 Converts Desmoglein  
3-Specific Type 1 Regulatory T Cells into Th2-Like Cells  
AUTHOR(S): Veldman, Christian; Pahl, Andreas; Beissert, Stefan; Hansen,  
Wiebke; Buer, Jan; Dieckmann, Detlef; Schuler, Gerold; Hertl, Michael  
LOCATION: Department of Dermatology, University of Erlangen-Nuernberg,  
Erlangen, Germany,  
JOURNAL: J. Immunol. (Journal of Immunology) DATE: 2006 VOLUME: 176  
NUMBER: 5 PAGES: 3215-3222 CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE:

English PUBLISHER: American Association of Immunologists

8/3/120 (Item 16 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

144156641 CA: 144(9)156641n PATENT

Use of a steroid for enhancement of skin permeability of agents used to treat inflammation, hyperproliferative disorders, disorders involving T cells, and other disorders

INVENTOR(AUTHOR): Meingassner, Josef Gottfried

LOCATION: Switz.

ASSIGNEE: Novartis AG; Novartis Pharma GmbH

PATENT: PCT International ; WO 200608092 A1 DATE: 20060126

APPLICATION: WO 2005EP7740 (20050715) \*GB 200415994 (20040716) \*GB 200417205 (20040802) \*US 2004PV605328 (20040827)

PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-031/436A; A61K-047/28B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/121 (Item 17 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

143440276 CA: 143(24)440276w PATENT

Phenanthridine analogues, their preparation, pharmaceutical compositions, and uses as inhibitors of hyperproliferation of T cells and keratinocytes

INVENTOR(AUTHOR): Pegoraro, Stefano; Lang, Martin; Feurle, Juliane;

Krauss, Juergen

LOCATION: Germany,

ASSIGNEE: 4SC AG; Switch Biotech AG

PATENT: PCT International ; WO 2005105752 A1 DATE: 20051110

APPLICATION: WO 2004EP11121 (20041005) \*EP 200410341 (20040430) \*US 2004PV566820 (20040430)

PAGES: 92 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C07D-221/12A; C07D-401/04B; C07D-401/14B; C07D-405/06B; C07D-405/14B; C07D-409/14B; C07D-405/04B; C07D-233/18B; A61K-031/473B; A61K-031/55B; A61P-017/00B; C07D-409/04B; C07D-409/12B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/122 (Item 18 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

143241985 CA: 143(14)241985b PATENT  
Inhibition of T cell activation in the treatment of immunological disease  
by blocking class II MHC antigen function  
INVENTOR(AUTHOR): Chung, Yong-Hoon; Cho, Hoon-Sik; Park, Hong-Gyu; Yi,  
Ki-Wan  
LOCATION: S. Korea  
ASSIGNEE: Medexgen Inc.  
PATENT: PCT International ; WO 200577415 A1 DATE: 20050825  
APPLICATION: WO 2005KR457 (20050218) \*KR 10835 (20040218)  
PAGES: 141 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/395A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU;  
MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG

8/3/123 (Item 19 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

142480777 CA: 142(26)480777w PATENT  
Antagonistic anti-human CD40 monoclonal antibodies and fragments for  
treating proliferative, cancerous and autoimmune disease  
INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror,  
Isabel; Chen, Bao-Lu; Lu, Xiaofeng; Lee, Sang Hoon; Hurst, Deborah  
LOCATION: USA  
ASSIGNEE: Chiron Corporation  
PATENT: PCT International ; WO 200544854 A2 DATE: 20050519  
APPLICATION: WO 2004US37152 (20041104) \*US 2003PV517337 (20031104) \*US  
2003PV525579 (20031126) \*US 2004PV565710 (20040427)  
PAGES: 176 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C07K-016/00A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG

8/3/124 (Item 20 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142480770 CA: 142(26)480770p PATENT  
Antagonistic monoclonal antibodies and derivatives specific to human CD40  
antigen for treatment of autoimmune and inflammatory diseases  
INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror,  
Isabel  
LOCATION: USA  
ASSIGNEE: Chiron Corporation  
PATENT: PCT International ; WO 200544306 A2 DATE: 20050519  
APPLICATION: WO 2004US36957 (20041104) \*US 2003PV517337 (20031104) \*US  
2003PV525579 (20031126) \*US 2004PV565710 (20040427)  
PAGES: 114 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/395A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG

8/3/125 (Item 21 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142233317 CA: 142(13)233317z PATENT  
 $\beta$ -galactosyl ceramide compounds complexed with CD1d peptide for  
therapeutic reduction of natural killer T cells in immune disorders or  
associated diseases in humans  
INVENTOR(AUTHOR): Ortaldo, John; Wiltrout, Robert  
LOCATION: USA  
ASSIGNEE: The Government of the United States of America, as Represented  
by the Secretary Department of Health and Human Services  
PATENT: PCT International ; WO 200514008 A2 DATE: 20050217  
APPLICATION: WO 2004US22913 (20040716) \*US 2003PV488339 (20030717)  
PAGES: 72 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-031/70A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ;  
VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA  
; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;  
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;  
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;  
SN; TD; TG

8/3/126 (Item 22 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142000710 CA: 142(1)710g PATENT

Use of diketopiperazine derivatives for the treatment of T-cell-mediated diseases

INVENTOR(AUTHOR): Bar-Or, David; Bar-Or, Raphael; Shimonkovitz, Richard

LOCATION: USA

ASSIGNEE: DMI Biosciences, Inc.

PATENT: PCT International ; WO 2004103304 A2 DATE: 20041202

APPLICATION: WO 2004US15340 (20040514) \*US 2003PV471017 (20030515) \*US 2003PV489270 (20030721) \*US 2003PV514930 (20031027) \*US 2003PV517338 (20031104)

PAGES: 47 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/127 (Item 23 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

140092608 CA: 140(7)92608q PATENT

Use of CD152 for treating autoimmune diseases and inflammations

INVENTOR(AUTHOR): Brunner-Weinzierl, Monika

LOCATION: Germany,

ASSIGNEE: Universitaetsklinikum Charite Medizinische Fakultat Der Humboldt-Universitaet Zu Berlin

PATENT: PCT International ; WO 200406950 A2 DATE: 20040122

APPLICATION: WO 2003EP7665 (20030715) \*DE 10232697 (20020715)

PAGES: 39 pp. CODEN: PIXXD2 LANGUAGE: German

PATENT CLASSIFICATIONS:

CLASS: A61K-039/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/128 (Item 24 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

139336934 CA: 139(22)336934r PATENT

IL-21 mutants and antagonists for modulating IL-21-mediated T cell response and for diagnosis, prognosis and treatment of autoimmune diseases and transplant

INVENTOR(AUTHOR): Moll, Thomas; Strom, Terry B.; Zheng, Xin Xiao

LOCATION: USA

ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.

PATENT: PCT International ; WO 200387320 A2 DATE: 20031023  
APPLICATION: WO 2003US10736 (20030408) \*US PV371038 (20020409)  
PAGES: 65 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;  
SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM;  
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ  
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI;  
FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG;  
CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/129 (Item 25 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

139322294 CA: 139(21)322294v PATENT  
Treating or preventing autoimmune disease using an IL-16 inhibitor  
INVENTOR(AUTHOR): Delovitch, Terry L.  
LOCATION: Can.,  
ASSIGNEE: The John P. Robarts Research Institute  
PATENT: PCT International ; WO 200386457 A2 DATE: 20031023  
APPLICATION: WO 2003CA501 (20030407) \*US PV370535 (20020408)  
PAGES: 36 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC;  
SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE  
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;  
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;  
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/130 (Item 26 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

138168815 CA: 138(12)168815m PATENT  
B7-related nucleic acids and polypeptides useful for immunomodulation  
INVENTOR(AUTHOR): Mikesell, Glen E.; Shen, Henry  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20030031675 A1 DATE: 20030213  
APPLICATION: US 77023 (20020215) \*US PV209811 (20000606) \*US PV272107  
(20010228) \*US 875338 (20010606)  
PAGES: 163 pp., Cont.-in-part of U.S. Ser. No. 875,338. CODEN: USXXCO  
LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 424178100; A61K-039/395A; C07H-021/04B; C12P-021/04B;  
C12N-001/21B; C12N-005/04B; C12N-005/06B

8/3/131 (Item 27 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

137321349 CA: 137(22)321349p PATENT  
Diagnostic and therapeutic compositions and methods which utilize the  
human T cell receptor  $\beta$  gene region  
INVENTOR(AUTHOR): Hood, Leroy E.; Rowen, Lee  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20020150891 A1 DATE: 20021017  
APPLICATION: US 263959 (19990305) \*US 309335 (19940919) \*US 531241  
(19950919)  
PAGES: 164 pp., Cont. of U. S. Ser. No. 531,241, abandoned. CODEN:  
USXXCO LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 435006000; C12Q-001/68A; G01N-033/53B; A01N-043/04B

8/3/132 (Item 28 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

137257652 CA: 137(18)257652c PATENT  
Method of attenuating reactions to skin irritants  
INVENTOR(AUTHOR): Wilson, S. Brian; Dranoff, Glenn; Gillessen, Silke  
LOCATION: USA  
ASSIGNEE: Dana-Farber Cancer Institute, Inc.  
PATENT: PCT International ; WO 200276401 A2 DATE: 20021003  
APPLICATION: WO 2002US9378 (20020326) \*US PV278837 (20010326)  
PAGES: 52 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-000/A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;  
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW;  
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW  
; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG

8/3/133 (Item 29 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

136278158 CA: 136(18)278158r PATENT  
Control of T cell processes using combinations of antagonists of  
interleukin-2 and interleukin-15  
INVENTOR(AUTHOR): Li, Xian Chang; Strom, Terry; Zheng, Xin Xiao  
LOCATION: USA  
ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.  
PATENT: PCT International ; WO 200222805 A2 DATE: 20020321  
APPLICATION: WO 2001US28612 (20010914) \*US PV232251 (20000914)  
PAGES: 80 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-015/00A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SD; SE; SG;  
SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY;

KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL  
; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;  
MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN;  
TD; TG

8/3/134 (Item 30 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

135206452 CA: 135(15)206452p PATENT

Phage display libraries of the T cell receptor and the selection of T  
cell receptor reagents for diagnostic and therapeutic use

INVENTOR(AUTHOR): Nissim, Ahuva

LOCATION: Israel

PATENT: PCT International ; WO 200162908 A2 DATE: 20010830

APPLICATION: WO 2001IL120 (20010205) \*US 510361 (20000222)

PAGES: 132 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-015/10A; C12N-015/11B; C12N-015/13B; C12N-015/62B;  
C12N-015/85B; C12N-007/01B; C07K-014/705B; C07K-016/00B; C12Q-001/68B;  
G01N-033/68B; A61K-038/00B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;  
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;  
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;  
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

8/3/135 (Item 31 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

132075702 CA: 132(7)75702h PATENT

MUC-1 mucin in detecting T-cell activation and treating disorders

INVENTOR(AUTHOR): Agrawal, Babita; Longenecker, B. Michael

LOCATION: Can.,

ASSIGNEE: Biomira Inc.

PATENT: PCT International ; WO 200000828 A1 DATE: 20000106

APPLICATION: WO 99US12820 (19990625) \*US 90916 (19980626)

PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: G01N-033/569A; G01N-033/50B

DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH;  
CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KE;  
KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ;  
PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN;  
YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM  
; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR;  
NE; SN; TD; TG

8/3/136 (Item 32 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

131057772 CA: 131(5)57772f PATENT



Methods to treat undesirable immune responses

INVENTOR(AUTHOR): Conti-Fine, Bianca M.

LOCATION: USA

ASSIGNEE: Regents of the University of Minnesota

PATENT: PCT International ; WO 9930736 A2 DATE: 19990624

APPLICATION: WO 98US26787 (19981216) \*US 991143 (19971216)

PAGES: 221 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/00A

DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

8/3/137 (Item 33 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

126130578 CA: 126(10)130578a PATENT

Oral tolerance in skin diseases presenting with T-cell mediated inflammation

INVENTOR(AUTHOR): Weiner, Howard L.; Kupper, Thomas S.; Chen, Youhai

LOCATION: USA

ASSIGNEE: Autoimmune, Inc.

PATENT: PCT International ; WO 9640232 A1 DATE: 19961219

APPLICATION: WO 96US10384 (19960605) \*US 486190 (19950607)

PAGES: 28 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/00A; A61K-038/16B; A61K-038/17B; A61K-038/39B; A61K-045/00B; C07K-014/00B; C07K-014/435B; C07K-014/47B; C07K-014/78B; C12N-009/00B

DESIGNATED COUNTRIES: AU; BR; CA; HU; IL; JP; KR; NO

DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

8/3/138 (Item 34 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

125026266 CA: 125(3)26266r PATENT

Methods and polycyclic aromatic compound containing compositions for treating T-cell-mediated diseases

INVENTOR(AUTHOR): Meruelo, Daniel; Lavie, Gad

LOCATION: USA

ASSIGNEE: New York University

PATENT: United States ; US 5514714 A DATE: 960507

APPLICATION: US 39790 (930330) \*US 572085 (900823) \*US 784952 (911101)

PAGES: 21 pp. Cont.-in-part of U.S. Ser. No. 784, 952, abandoned.

CODEN: USXXAM LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 514561000; A61K-031/195A; A61K-031/19B; A61K-031/12B

8/3/139 (Item 35 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

121170550 CA: 121(15)170550p PATENT  
Method using Staphylococcus enterotoxin B for treating autoimmune diseases  
INVENTOR(AUTHOR): Ochi, Atsuo  
LOCATION: Can.,  
ASSIGNEE: Mount Sinai Hospital Corp.  
PATENT: Canada Pat Appl ; CA 2084120 AA DATE: 940531  
APPLICATION: CA 2084120 (921130)  
PAGES: 81 pp. CODEN: CPXXEB LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/085A

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)
S7	185	(PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR THERAP- ?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?)
S8	139	RD S7 (unique items)
? s s8 and py=2001		
	139	S8
	2343842	PY=2001
	S9	3 S8 AND PY=2001
? t s9/7/all		

9/7/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

16399955 BIOSIS NO.: 200100571794  
Induction of apoptosis, depletion of glutathione, and DNA damage by  
extracorporeal photochemotherapy and psoralen with exposure to UV light  
in vitro  
AUTHOR: Efferth Thomas (Reprint); Fabry Ursula; Osieka Rainhardt  
AUTHOR ADDRESS: Virtual Campus Rhineland-Palatinate, 55033, Mainz, Germany  
\*\*Germany  
JOURNAL: Anticancer Research 21 (4A): p2777-2784 July-August, 2001  
2001  
MEDIUM: print  
ISSN: 0250-7005  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Extracorporeal photochemotherapy (ECPT) is a novel  
treatment for disorders caused by aberrant T  
\*\*\*lymphocytes\*\*\*. The effects of ECPT were investigated in mononuclear  
cells (MNC) of six patients suffering from either Sezary syndrome,  
mycosis fungoides, systemic sclerosis, pemphigus vulgaris or  
Hodgkin's disease. ECPT caused moderate to severe induction of apoptosis  
and depletion of glutathione in the MNC of two out of these six patients.  
The MNC were then treated with 8-methoxypsoralen (8-MOP) and UV light in

vitro and analyzed for apoptosis and glutathione levels. 8-MOP and UV light induced a profile of cellular alterations that is similar to ECPT. In addition, we measured DNA damage by means of a PCR-based methodology. As exemplified by the T-cell receptor-delta and glucose-6-phosphate dehydrogenase genes, DNA damage correlated with induction of apoptosis and depletion of glutathione. It is, therefore, reasonable to propose that UV-induced glutathione depletion contributes to DNA lesions which ultimately account for the onset of apoptosis.

9/7/2 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0078511890 EMBASE No: 2001117978  
Anti-CD20 monoclonal antibody (Rituximab) for refractory erosive stomatitis secondary to CD20 SUP + follicular lymphoma-associated paraneoplastic pemphigus  
Borradori L.; Lombardi T.; Samson J.; Girardet C.; Saurat J.-H.; Hugli A.  
Department of Dermatology, University Hospital, Rue Micheli du Crest 24, CH-1211 Geneve 14, Switzerland  
CORRESP. AUTHOR: Borradori L.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University Hospital, Rue Micheli du Crest 24, CH-1211 Geneve 14, Switzerland  
CORRESP. AUTHOR EMAIL: Luca.Borradori@hcuge.ch

Archives of Dermatology ( Arch. Dermatol. ) (United States) May 12, 2001  
, 137/3 (269-272)  
CODEN: ARDEA ISSN: 0003987X  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Citation  
LANGUAGE: English  
NUMBER OF REFERENCES: 23

9/7/3 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

135206452 CA: 135(15)206452p PATENT  
Phage display libraries of the T cell receptor and the selection of T cell receptor reagents for diagnostic and therapeutic use  
INVENTOR(AUTHOR): Nissim, Ahuva  
LOCATION: Israel  
PATENT: PCT International ; WO 200162908 A2 DATE: 20010830  
APPLICATION: WO 2001IL120 (20010205) \*US 510361 (20000222)  
PAGES: 132 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-015/10A; C12N-015/11B; C12N-015/13B; C12N-015/62B;  
C12N-015/85B; C12N-007/01B; C07K-014/705B; C07K-016/00B; C12Q-001/68B;  
G01N-033/68B; A61K-038/00B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;  
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;  
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;  
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;  
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG;  
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG  
SECTION:  
CA203002 Biochemical Genetics  
CA215XXX Immunochemistry

IDENTIFIERS: T cell receptor phage display library, Ig TCR fusion protein  
phage display library

DESCRIPTORS:

Spinal column...

ankylosing spondylitis, TCR variants for diagnosis and treatment of  
autoimmune disease associated with; phage display libraries of T cell  
receptor and selection of T cell receptor reagents for diagnostic

Alopecia...

areata, TCR variants for diagnosis and treatment of autoimmune disease  
associated with; phage display libraries of T cell receptor and selection  
of T cell receptor reagents for diagnostic and therapeutic

Thyroid gland,disease...

autoimmune thyroiditis, TCR variants for diagnosis and treatment of  
autoimmune disease associated with; phage display libraries of T cell  
receptor and selection of T cell receptor reagents for diagnostic

Uterus,neoplasm...

cervix, squamous cell carcinoma, TCR variants for diagnosis and  
treatment of autoimmune disease associated with; phage display libraries  
of T cell receptor and selection of T cell receptor reagents for d

CD8(antigen)...

complexes with MHC antigens, ligands of, for increasing avidity of T  
cell receptor derivs.; phage display libraries of T cell receptor and  
selection of T cell receptor reagents for diagnostic and ther

Skin,disease...

epidermolysis bullosa, TCR variants for diagnosis and treatment of  
autoimmune disease associated with; phage display libraries of T cell  
receptor and selection of T cell receptor reagents for diagnostic

PCR(polymerase chain reaction)... Primers(nucleic acid)...

for amplification of T cell receptor variable regions; phage display  
libraries of T cell receptor and selection of T cell receptor reagents  
for diagnostic and therapeutic use

DNA... RNA... Peptides,biological studies... Proteins,general,biological

studies... Enzymes,biological studies... Carbohydrates,biological studies

... Glycosphingolipids... Fatty acids,biological studies...

for increasing avidity of T cell receptor derivs.; phage display  
libraries of T cell receptor and selection of T cell receptor reagents  
for diagnostic and therapeutic use

Genetic vectors...

for manufacture of T cell receptor variants; phage display libraries of T  
cell receptor and selection of T cell receptor reagents for diagnostic  
and therapeutic use

Immunoglobulins...

fusion products, with T cell receptor, display libraries of; phage  
display libraries of T cell receptor and selection of T cell receptor  
reagents for diagnostic and therapeutic use

Kidney,disease...

Goodpasture's syndrome, TCR variants for diagnosis and treatment of  
autoimmune disease associated with; phage display libraries of T cell  
receptor and selection of T cell receptor reagents for diagnostic

Immunoglobulins...

heavy chains, fusion products with T cell receptor, display libraries  
of; phage display libraries of T cell receptor and selection of T cell  
receptor reagents for diagnostic and therapeutic use

Histocompatibility antigens...

HLA, class I, TCR variants for diagnosis and treatment of autoimmune  
disease associated with; phage display libraries of T cell receptor and  
selection of T cell receptor reagents for diagnostic and thera

Diagnosis...

immunodiagnosis, T cell receptor reagents for; phage display libraries  
of T cell receptor and selection of T cell receptor reagents for  
diagnostic and therapeutic use

Diabetes mellitus...  
insulin-dependent, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and

Rheumatoid arthritis...  
juvenile, pauciarticular, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnost

Immunoglobulins...  
light chains, fusion products with T cell receptor, display libraries of; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Histocompatibility antigens...  
MHC (major histocompatibility complex), complexes with CD8 antigens, ligands of, for increasing avidity of T cell receptor derivs.; phage display libraries of T cell receptor and selection of T cell r

Sleep...  
narcolepsy, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therape

Nerve,disease...  
optic, neuritis, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and th

Plasmid vectors...  
pCDV, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Skin,disease...  
pemphigus vulgaris, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and

TCR(T cell receptors)... Phage display library...  
phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Plasmid vectors...  
pJS, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Plasmid vectors...  
pNMV, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Biliary tract...  
primary biliary cirrhosis, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnos

Plasmid vectors...  
pUC19-CK-CH1, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Plasmid vectors...  
pUM19-CK-CH1, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Plasmid vectors...  
p1PP12, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Arthritis...  
Reiter's syndrome, TCR variants for diagnosis and treatment of

autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and Lupus erythematosus...  
systemic, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use  
Immunotherapy...  
T cell receptor variants for; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use  
Behcet's syndrome... Rheumatoid arthritis... Sjogren's syndrome...  
Addison's disease... Graves' disease... Celiac disease... Hodgkin's disease  
... Multiple sclerosis... Myasthenia gravis...  
TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use  
Autoimmune disease...  
TCR variants for diagnosis and treatment of; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use  
CAS REGISTRY NUMBERS:  
358018-07-2 358018-08-3 358018-09-4 358018-10-7 358018-11-8  
358018-12-9 358018-13-0 358018-14-1 358018-15-2 358018-16-3  
358018-17-4 358018-18-5 358018-19-6 358018-20-9 357141-59-4  
357141-60-7 357141-61-8 357141-62-9 358018-21-0 357141-64-1  
358018-22-1 357141-66-3 357141-67-4 358018-23-2 357141-69-6  
357141-71-0 357141-72-1 357141-73-2 357141-75-4 358018-24-3  
357141-77-6 357141-78-7 357141-79-8 358018-25-4 358018-26-5  
358018-27-6 357141-83-4 357141-84-5 357141-85-6 357141-86-7  
357141-87-8 357141-88-9 357141-89-0 357141-90-3 357141-91-4  
357141-92-5 357141-93-6 357141-94-7 357141-95-8 357141-96-9  
unclaimed nucleotide sequence; phage display libraries of the T cell receptor and the selection of T cell receptor reagents for diagnostic and therapeutic use  
357141-70-9 357141-74-3 160573-53-5 167731-68-2 unclaimed sequence;  
phage display libraries of the T cell receptor and the selection of T cell receptor reagents for diagnostic and therapeutic use

? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)
S7	185	(PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR THERAP- ?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?)
S8	139	RD S7 (unique items)
S9	3	S8 AND PY=2001

? s s8 and (review? or overview?)  
>>>File 5 processing for REVIEW? stopped at REVIEW MONKEY CAT  
139 S8  
4910206 REVIEW?  
149848 OVERVIEW?  
S10 31 S8 AND (REVIEW? OR OVERVIEW?)  
? t s10/3/all

10/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

12658117 BIOSIS NO.: 199598125950  
Review of immunomodulation by photopheresis: Treatment of cutaneous  
T-cell lymphoma, autoimmune disease, and allograft rejection  
AUTHOR: Wolfe Jonathan T; Lessin Stuart R; Singh Anjali H; Rook Alain H  
(Reprint)  
AUTHOR ADDRESS: Dep. Dermatol., Hosp. Univ. Pennsylvania, 3400 Spruce St.,  
Philadelphia, PA 19104, USA\*\*USA  
JOURNAL: Artificial Organs 18 (12): p888-897 1994 1994  
ISSN: 0160-564X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

10/3/2 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0082112095 EMBASE No: 2007548047  
The selective immunotherapy of pemphigus  
Bystryn J.C.; Czernik A. // Bystryn J.C.  
Ronald O. Perelman Department of Dermatology, New York University School  
of Medicine, New York, NY, United States // NYU Medical Center, 560 1st  
Avenue, New York, NY 10016, United States  
AUTHOR EMAIL: bystryn@nyu.edu; bystryn@nyu.edu  
CORRESP. AUTHOR: Bystryn J.C.  
CORRESP. AUTHOR AFFIL: NYU Medical Center, 560 1st Avenue, New York, NY  
10016, United States  
CORRESP. AUTHOR EMAIL: bystryn@nyu.edu

Giornale Italiano di Dermatologia e Venereologia ( G. Ital. Dermatol.  
Venereol. ) (Italy) August 1, 2007, 142/4 (381-390)  
CODEN: GIDVD ISSN: 00264741  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English; Italian  
NUMBER OF REFERENCES: 63

10/3/3 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081949325 EMBASE No: 2007383664  
Red blood cell anemia in a patient with pemphigus vulgaris induced by the  
use of mycophenolate mofetil and prednisone  
Scheinfeld N. // Scheinfeld N.  
Department of Dermatology, St. Luke's-Roosevelt, New York, NY USA //  
Department of Dermatology, St. Luke's-Roosevelt, 1090 Amsterdam Ave, New  
York, NY 10025, United States  
AUTHOR EMAIL: NSS32@columbia.edu; NSS32@columbia.edu  
CORRESP. AUTHOR: Scheinfeld N.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, St. Luke's-Roosevelt,  
1090 Amsterdam Ave, New York, NY 10025, United States  
CORRESP. AUTHOR EMAIL: NSS32@columbia.edu

Journal of Dermatological Treatment ( J. Dermatol. Treat. ) (United  
Kingdom) September 5, 2007, 18/4 (243-245)  
CODEN: JD TRE ISSN: 09546634 eISSN: 14711753

PUBLISHER ITEM IDENTIFIER: 779333677  
DOI: 10.1080/09546630701287324  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 9

10/3/4 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081810060 EMBASE No: 2007244126  
Role of regulatory T cells in the development of skin diseases  
Lima H.C. // Lima H.C. // Lima H.C.  
Department of Pathology, Universidade Federal do Parana - UFPR, Curitiba  
(PR), Brazil // Service of Dermatology and Research Nucleus in  
Immunodermatology and Clinical Immunology, Universidade Federal do Parana  
- UFPR, Curitiba (PR), Brazil // Rua XV de Novembro, 1206, 80060-000 -  
Curitiba - PR  
AUTHOR EMAIL: hclima@ufpr.br; hclima@ufpr.br; hclima@ufpr.br  
CORRESP. AUTHOR: Lima H.C.  
CORRESP. AUTHOR AFFIL: Rua XV de Novembro, 1206, 80060-000 - Curitiba -  
PR  
CORRESP. AUTHOR EMAIL: hclima@ufpr.br

Anais Brasileiros de Dermatologia ( An. Bras. Dermatol. ) (Brazil) May  
1, 2006, 81/3 (269-281)  
CODEN: ABDEB ISSN: 03650596 eISSN: 18064841  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English; Portuguese  
NUMBER OF REFERENCES: 121

10/3/5 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081779408 EMBASE No: 2007213412  
Therapy of autoimmune bullous diseases  
Mutasim D.F.  
Department of Dermatology, University of Cincinnati College of Medicine,  
231 Albert Sabin Way, Cincinnati, OH 45267-0592, United States  
AUTHOR EMAIL: diya.mutasim@uc.edu  
CORRESP. AUTHOR: Mutasim D.F.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of  
Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH  
45267-0592, United States  
CORRESP. AUTHOR EMAIL: diya.mutasim@uc.edu

Therapeutics and Clinical Risk Management ( Ther. Clin. Risk Manage. ) ( New Zealand) May 30, 2007, 3/1 (29-40)  
ISSN: 11766336  
DOI: 10.2147/tcrm.2007.3.1.29  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 139

10/3/6 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.



0081682257      EMBASE No: 2007115834  
Complications and Adverse Reactions in the Use of Newer Biologic Agents  
ISSUE TITLE: Complications and Adverse Events  
Callen J.P.  
Division of Dermatology, University of Louisville, Louisville, KY, United States  
AUTHOR EMAIL: jefca@aol.com  
CORRESP. AUTHOR: Callen J.P.  
CORRESP. AUTHOR AFFIL: Division of Dermatology, University of Louisville, Louisville, KY, United States  
CORRESP. AUTHOR EMAIL: jefca@aol.com

Seminars in Cutaneous Medicine and Surgery ( Semin. Cutaneous Med. Surg.  
) (United States) March 1, 2007, 26/1 (6-14)  
CODEN: SCMSF      ISSN: 10855629  
PUBLISHER ITEM IDENTIFIER: S108556290600112X  
DOI: 10.1016/j.sder.2006.12.002  
DOCUMENT TYPE: Journal; Review      RECORD TYPE: Abstract  
LANGUAGE: English      SUMMARY LANGUAGE: English  
CLINICAL TRIALS NUMBER: NCT00051662--ClinicalTrials.gov; NCT00302445--ClinicalTrials.gov  
NUMBER OF REFERENCES: 84

10/3/7      (Item 6 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081503650      EMBASE No: 2006567099  
Paraneoplastic autoimmune multiorgan syndrome: Review of the literature and support for a cytotoxic role in pathogenesis  
ISSUE TITLE: Immunology of Pemphigus and Treatment  
Billet S.E.; Pittelkow M.R. // Grando S.A.  
Department of Dermatology, Mayo Clinic, Rochester, MN, United States // University of California Davis, Sacramento, CA, United States  
CORRESP. AUTHOR: Pittelkow M.R.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, Mayo Clinic, Rochester, MN, United States

Autoimmunity ( Autoimmunity ) (United Kingdom) November 1, 2006, 39/7 (617-630)  
CODEN: AUIME      ISSN: 08916934      eISSN: 1607842X  
PUBLISHER ITEM IDENTIFIER: U501856727X93457  
DOI: 10.1080/08916930600972099  
DOCUMENT TYPE: Journal; Review      RECORD TYPE: Abstract  
LANGUAGE: English      SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 123

10/3/8      (Item 7 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081384356      EMBASE No: 2006447143  
Inosine 5prime-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases  
Ratcliffe A.J.  
UCB, Granta Park, Great Abington, Cambridge CB1 6GS, United Kingdom  
AUTHOR EMAIL: andrew.ratcliffe@ucb-group.com  
CORRESP. AUTHOR: Ratcliffe A.J.

CORRESP. AUTHOR AFFIL: UCB, Granta Park, Great Abington, Cambridge CB1  
6GS, United Kingdom  
CORRESP. AUTHOR EMAIL: andrew.ratcliffe@ucb-group.com

Current Opinion in Drug Discovery and Development ( Curr. Opin. Drug  
Discov. Dev. ) (United Kingdom) September 1, 2006, 9/5 (595-605)  
CODEN: CODDF ISSN: 13676733  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 55

10/3/9 (Item 8 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081248610 EMBASE No: 2006310874  
B cells move to centre stage: Novel opportunities for autoimmune disease  
treatment  
Browning J.L.  
Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge,  
MA 02445, United States  
AUTHOR EMAIL: Jeff.Browning@biogenidec.com  
CORRESP. AUTHOR: Browning J.L.  
CORRESP. AUTHOR AFFIL: Department of Immunobiology USA, Biogen Idec, 12  
Cambridge Center, Cambridge, MA 02445, United States  
CORRESP. AUTHOR EMAIL: Jeff.Browning@biogenidec.com

Nature Reviews Drug Discovery ( Nat. Rev. Drug Discov. ) (United Kingdom)  
July 1, 2006, 5/7 (564-576)  
CODEN: NRDDA ISSN: 14741776 eISSN: 14741784  
PUBLISHER ITEM IDENTIFIER: N2085  
DOI: 10.1038/nrd2085  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 173

10/3/10 (Item 9 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081074574 EMBASE No: 2006134669  
Pemphigus: Pathogenic mechanisms and potential therapeutic targets  
Powell A.-M.; Black M.M.  
Department of Immunodermatology, St. John's Institute of Dermatology, St.  
Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom  
AUTHOR EMAIL: martin.black@kcl.ac.uk  
CORRESP. AUTHOR: Black M.M.  
CORRESP. AUTHOR AFFIL: Department of Immunodermatology, St. John's  
Institute of Dermatology, St. Thomas' Hospital, Lambeth Palace Road,  
London SE1 7EH, United Kingdom  
CORRESP. AUTHOR EMAIL: martin.black@kcl.ac.uk

Drug Discovery Today: Disease Mechanisms ( Drug Discov.Today Dis. Mech. )  
(United Kingdom) December 1, 2005, 2/2 (269-274)  
ISSN: 17406765  
PUBLISHER ITEM IDENTIFIER: S1740676505000301  
DOI: 10.1016/j.ddmec.2005.05.023  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 39

10/3/11 (Item 10 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081049234 EMBASE No: 2006109249  
Regulatory T cells  
Beissert S. // Schwarz A.; Schwarz T. // Schwarz T.  
Department of Dermatology, University of Munster, Munster, Germany //  
Department of Dermatology, University of Kiel, Kiel, Germany //  
Department of Dermatology, University of Kiel, Schittenhelmstrasse 7,  
D-24105 Kiel, Germany  
AUTHOR EMAIL: tschwarz@dermatology.uni-kiel.de;  
tschwarz@dermatology.uni-kiel.de  
CORRESP. AUTHOR: Schwarz T.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Kiel,  
Schittenhelmstrasse 7, D-24105 Kiel, Germany  
CORRESP. AUTHOR EMAIL: tschwarz@dermatology.uni-kiel.de  
  
Journal of Investigative Dermatology ( J. Invest. Dermatol. ) (United  
States) January 1, 2006, 126/1 (15-24)  
CODEN: JIDEA ISSN: 0022202X eISSN: 15231747  
PUBLISHER ITEM IDENTIFIER: 5700004  
DOI: 10.1038/sj.jid.5700004  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 89

10/3/12 (Item 11 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081040121 EMBASE No: 2006100121  
Biologic therapies in autoimmune diseases  
Penn H. // Penn H.  
Royal Free Hospital, London, United Kingdom // Department of  
Rheumatology, Royal Free Hospital, London NW3 2QG, United Kingdom  
AUTHOR EMAIL: h.penn@medsch.ucl.ac.uk; h.penn@medsch.ucl.ac.uk  
CORRESP. AUTHOR: Penn H.  
CORRESP. AUTHOR AFFIL: Department of Rheumatology, Royal Free Hospital,  
London NW3 2QG, United Kingdom  
CORRESP. AUTHOR EMAIL: h.penn@medsch.ucl.ac.uk  
  
Clinical Medicine, Journal of the Royal College of Physicians of London ( Clin. Med. J. R. Coll. Phys. Lond. ) (United Kingdom) January 1, 2006,  
6/1 (105-108)  
CODEN: CMLUB ISSN: 14702118  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 6

10/3/13 (Item 12 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080905189 EMBASE No: 2005550132  
Number V. Oral lichen planus: Clinical features and management

Eisen D. // Carrozzo M. // Sebastian J.-V.B. // Thongprasom K. // Eisen D.

Dermatology Research Associates, Cincinnati, OH, United States // Department of Biomedical Sciences and Human Oncology, Oral Medicine, University of Turin, Turin, Italy // Hospital General Universitario de Valencia, Valencia, Spain // Oral Medicine Department, Chulalongkorn University, Bangkok, Thailand // Dermatology Research Associates, 7691 Five Mile Road, Cincinnati, OH 45230, United States

AUTHOR EMAIL: drore@eos.net; drore@eos.net

CORRESP. AUTHOR: Eisen D.

CORRESP. AUTHOR AFFIL: Dermatology Research Associates, 7691 Five Mile Road, Cincinnati, OH 45230, United States

CORRESP. AUTHOR EMAIL: drore@eos.net

Oral Diseases ( Oral Dis. ) (Denmark) November 1, 2005, 11/6 (338-349)

CODEN: ORDIF ISSN: 1354523X

DOI: 10.1111/j.1601-0825.2005.01142.x

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 146

10/3/14 (Item 13 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0080904290 EMBASE No: 2005549233

Apoptosis in normal and diseased oral tissues

Loro L.L.; Johannessen A.C. // Vintermyr O.K. // Loro L.L.

Department of Odontology-Oral Pathology and Forensic Odontology, University of Bergen, Bergen, Norway // Department of Pathology, Haukeland University Hospital, University of Bergen, Bergen, Norway // Department of Odontology-Oral Pathology and Forensic Odontology, Gade Institute, Haukeland University Hospital, N5021 Bergen, Norway

AUTHOR EMAIL: lado.loro@gades.uib.no; lado.loro@gades.uib.no

CORRESP. AUTHOR: Loro L.L.

CORRESP. AUTHOR AFFIL: Department of Odontology-Oral Pathology and Forensic Odontology, Gade Institute, Haukeland University Hospital, N5021 Bergen, Norway

CORRESP. AUTHOR EMAIL: lado.loro@gades.uib.no

Oral Diseases ( Oral Dis. ) (Denmark) September 1, 2005, 11/5 (274-287)

CODEN: ORDIF ISSN: 1354523X

DOI: 10.1111/j.1601-0825.2005.01117.x

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 163

10/3/15 (Item 14 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0080904288 EMBASE No: 2005549231

Number IV: Erythema multiforme

Farthing P. // Bagan J.-V. // Scully C. // Scully C.

Charles Clifford Dental School, University of Sheffield, Sheffield, United Kingdom // University Hospital, University of Valencia, Spain // Eastman Dental Institute, University College London, London, United Kingdom // Eastman Dental Institute, University College London, 256 Grays Inn Road, London WC1X 8LD, United Kingdom

AUTHOR EMAIL: cscully@eastman.ucl.ac.uk; cscully@eastman.ucl.ac.uk  
CORRESP. AUTHOR: Scully C.  
CORRESP. AUTHOR AFFIL: Eastman Dental Institute, University College  
London, 256 Grays Inn Road, London WC1X 8LD, United Kingdom  
CORRESP. AUTHOR EMAIL: cscully@eastman.ucl.ac.uk

Oral Diseases ( Oral Dis. ) (Denmark) September 1, 2005, 11/5 (261-267)  
CODEN: ORDIF ISSN: 1354523X  
DOI: 10.1111/j.1601-0825.2005.01141.x  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 45

10/3/16 (Item 15 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080886863 EMBASE No: 2005531783  
Mycophenolate mofetil  
Heymann W.R.  
Affiliation unspecified.

Journal of the American Academy of Dermatology ( J. Am. Acad. Dermatol. )  
(United States) December 1, 2005, 53/6 (1045-1046)  
CODEN: JAADD ISSN: 01909622  
PUBLISHER ITEM IDENTIFIER: S0190962205026782  
DOI: 10.1016/j.jaad.2005.08.034  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 8

10/3/17 (Item 16 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080779838 EMBASE No: 2005424454  
An approach to the patient with a recalcitrant dermatosis  
Callen J.P.  
Division of Dermatology, University of Louisville, School of Medicine,  
Louisville, KY 40202, United States  
AUTHOR EMAIL: jefca@aol.com  
CORRESP. AUTHOR: Callen J.P.  
CORRESP. AUTHOR AFFIL: Division of Dermatology, University of Louisville,  
School of Medicine, Louisville, KY 40202, United States  
CORRESP. AUTHOR EMAIL: jefca@aol.com

Clinics in Dermatology ( Clin. Dermatol. ) (United States) September 1,  
2005, 23/5 (528-531)  
CODEN: CLDEE ISSN: 0738081X  
PUBLISHER ITEM IDENTIFIER: S0738081X05000623  
DOI: 10.1016/j.clindermatol.2005.04.004  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation  
LANGUAGE: English

10/3/18 (Item 17 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080659445 EMBASE No: 2005303751

Auto-immune manifestations in non-Hodgkin's lymphoma  
Manifestations dysimmunitaires associees aux lymphomes  
Jardin F.; Tilly H. // Levesque H.  
Departement d'Hematologie Clinique et Groupe d'Etude des Syndromes  
Lymphoproliferatifs, Inserm U164, Centre Henri-Becquerel, 76000 Rouen,  
France // Departement de Medecine Interne, Centre Hospitalier  
Universitaire de Rouen, Hopital de Bois-Guillaume, Rouen, France  
AUTHOR EMAIL: fabrice.jardin@rouen.fnclcc.fr  
CORRESP. AUTHOR: Jardin F.  
CORRESP. AUTHOR AFFIL: Departement d'Hematologie Clinique et Groupe  
d'Etude des Syndromes Lymphoproliferatifs, Inserm U164, Centre  
Henri-Becquerel, 76000 Rouen, France  
CORRESP. AUTHOR EMAIL: fabrice.jardin@rouen.fnclcc.fr

Revue de Medecine Interne ( Rev. Med. Interne ) (France) July 1, 2005,  
26/7 (557-571)  
CODEN: RMEID ISSN: 02488663  
PUBLISHER ITEM IDENTIFIER: S024886630400459X  
DOI: 10.1016/j.revmed.2004.11.011  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: French SUMMARY LANGUAGE: English; French  
NUMBER OF REFERENCES: 169

10/3/19 (Item 18 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080301596 EMBASE No: 2004487365

The role of pathogenic B-cell clones in antibody mediated autoimmune  
disorders  
Wang J.; Zhu X.  
Department of Dermatology, Peking University First Hospital, #8, Xishiku  
St., Beijing 100034, C.  
AUTHOR EMAIL: zhuxj@public.bta.net.cn  
CORRESP. AUTHOR AFFIL: Department of Dermatology, Peking University First  
Hospital, #8, Xishiku St., Beijing 100034, C.  
CORRESP. AUTHOR EMAIL: zhuxj@public.bta.net.cn

Journal of Dermatological Science ( J. Dermatol. Sci. ) (Ireland)  
December 1, 2004, 36/3 (141-148)  
CODEN: JDSCE ISSN: 09231811  
PUBLISHER ITEM IDENTIFIER: S0923181104001367  
DOI: 10.1016/j.jdermsci.2004.07.004  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 59

10/3/20 (Item 19 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0079476456 EMBASE No: 2003181862

Cytokines and chemokines in autoimmune disease: An overview  
Santamaria P. // Santamaria P.  
University of Calgary, Dept. Microbiol./Infect. Disease, Health Sciences  
Centre, Calgary, Alta., Canada // Dept. of Microbiol./Infect. Diseases,  
Faculty of Medicine, University of Calgary, Calgary, Alta., Canada  
CORRESP. AUTHOR: Santamaria P.

CORRESP. AUTHOR AFFIL: Dept. of Microbiol./Infect. Diseases, Faculty of  
Medicine, University of Calgary, Calgary, Alta., Canada

Advances in Experimental Medicine and Biology ( Adv. Exp. Med. Biol. ) ( United States) May 17, 2003, 520/- (1-7)

CODEN: AEMBA ISSN: 00652598

DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation

LANGUAGE: English

NUMBER OF REFERENCES: 14

10/3/21 (Item 20 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0079378560 EMBASE No: 2003082264

11. Allergic and immunologic diseases of the skin

Blauvelt A.; Hwang S.T.; Udey M.C. // Blauvelt A.

Dermatology Branch, Center for Cancer Research, National Cancer

Institute, Bethesda, MD, United States // Dermatology Branch, Center for

Cancer Research, National Cancer Institute, 10 Center Dr MSC 1908,

Bethesda, MD 20892-1908, United States

CORRESP. AUTHOR: Blauvelt A.

CORRESP. AUTHOR AFFIL: Dermatology Branch, Center for Cancer Research,

National Cancer Institute, 10 Center Dr MSC 1908, Bethesda, MD 20892-1908

, United States

Journal of Allergy and Clinical Immunology ( J. Allergy Clin. Immunol. ) (United States) February 1, 2003, 111/2 SUPPL. 2 (S560-S570)

CODEN: JACIB ISSN: 00916749

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 64

10/3/22 (Item 21 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0078409135 EMBASE No: 2001014946

Recent advances in phototherapy

Simon J.C.; Pflieger D.; Schopf E.

Department of Dermatology, University of Freiburg, Hauptstr. 7, Freiburg

79104, Germany

CORRESP. AUTHOR: Simon J.C.

CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Freiburg,

Hauptstr. 7, Freiburg 79104, Germany

CORRESP. AUTHOR EMAIL: simonj@haut.ukl.uni-freiburg.de

European Journal of Dermatology ( Eur. J. Dermatol. ) (France) December 1, 2000, 10/8 (642-644)

CODEN: EJDEE ISSN: 11671122

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 44

10/3/23 (Item 22 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0078048898 EMBASE No: 2000098144

Extracorporeal photopheresis: 4 years of experience in Geneva  
Photopherese extracorporelle: Quatre ans d'experience a geneve  
Prins C.; Laroutis M.R.; Blondel F.; Bouvier M.; Saurat J.-H.  
Clinique de Dermatologie, Hopital Cantonal Universitaire, 1211 Geneve 14,  
Switzerland

CORRESP. AUTHOR: Prins C.

CORRESP. AUTHOR AFFIL: Clinique de Dermatologie, Hopital Cantonal  
Universitaire, 1211 Geneve 14, Switzerland

Medecine et Hygiene ( Med. Hyg. ) (Switzerland) March 8, 2000, 58/2291  
(554-559)

CODEN: MEHGA ISSN: 00256749

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: French SUMMARY LANGUAGE: English; French

NUMBER OF REFERENCES: 11

10/3/24 (Item 23 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0077861651 EMBASE No: 1999347983

HLA class II restriction of autoreactive T cell responses in pemphigus  
vulgaris: Review of the literature and potential applications for the  
development of a specific immunotherapy

Riechers R.; Hertl M. // Grotzinger J.

Department of Dermatology, RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen  
, Germany // Institute of Biochemistry, RWTH Aachen, Pauwelsstrasse 30,  
D-52074 Aachen, Germany

CORRESP. AUTHOR: Riechers R.

CORRESP. AUTHOR AFFIL: Department of Dermatology, RWTH Aachen,  
Pauwelsstrasse 30, D-52074 Aachen, Germany

Autoimmunity ( Autoimmunity ) (United Kingdom) October 19, 1999, 30/3  
(183-196)

CODEN: AUIME ISSN: 08916934

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 67

10/3/25 (Item 24 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0077306883 EMBASE No: 1998217045

Unresponsive discoid lupus erythematosus successfully controlled by  
extracorporeal photopheresis

Extrakorporale Photopherese bei therapieresistentem disseminiert  
diskoidem Lupus erythematodes (DDLE)

Richter H.I.; Krutmann J.; Goerz G. // Krutmann J.

Hautklinik, Heinrich-Heine-Universitat, Dusseldorf, Germany // Klinische  
und Experimentelle Photodermatologie, Hautklinik,  
Heinrich-Heine-Universitätskliniken, Moorenstrasse 5, D-40225 Dusseldorf,  
Germany

CORRESP. AUTHOR: Krutmann J.

CORRESP. AUTHOR AFFIL: Klin./Experimentelle Photodermatol., Hautklinik,  
Heinrich-Heine-Universitätskliniken, Moorenstrasse 5, D-40225 Dusseldorf,  
Germany



Hautarzt ( Hautarzt ) (Germany) June 1, 1998, 49/6 (487-491)  
CODEN: HAUTA ISSN: 00178470  
DOI: 10.1007/s001050050775  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: German SUMMARY LANGUAGE: English; German  
NUMBER OF REFERENCES: 25

10/3/26 (Item 25 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075944690 EMBASE No: 1994352172  
Extracorporeal photopheresis  
EXTRAKORPORALE PHOTOPHERESE  
Prinz B.; Plewig G.  
Dermatologische Klinik/Poliklinik, Ludwig-Maximilians-Universitat,  
Frauenlobstrasse 9-11, D-80337 Munchen, Germany  
CORRESP. AUTHOR: Prinz B.  
CORRESP. AUTHOR AFFIL: Dermatologische Klinik/Poliklinik,  
Ludwig-Maximilians-Universitat, Frauenlobstrasse 9-11, D-80337 Munchen,  
Germany

Hautarzt ( HAUTARZT ) (Germany) December 21, 1994, 45/11 (746-750)  
CODEN: HAUTA ISSN: 00178470  
DOI: 10.1007/s001050050164  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: German SUMMARY LANGUAGE: English; German

10/3/27 (Item 26 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075943261 EMBASE No: 1994360240  
Photopheresis: Report of cases and review of the literature  
FOTOFERESIS: REPORTE DE CASOS Y REVISION DE LA LITERATURA  
Bogaert M.A.; Sisto M.; Kerdel F.A.  
Dept. Dermatology/Cutaneous Surgery, University of Miami, School of  
Medicine, 1600 N.W. 10th Avenue, Miami, FL 33136, United States  
CORRESP. AUTHOR: Kerdel F.A.  
CORRESP. AUTHOR AFFIL: Dept. Dermatology/Cutaneous Surgery, University of  
Miami, School of Medicine, 1600 N.W. 10th Avenue, Miami, FL 33136, United  
States

Medicina Cutanea Ibero-Latino-Americana ( MED. CUTANEA IBERO-LAT.-AM. ) ( Spain)  
December 1, 1994, 22/6 (278-283)  
CODEN: MCILB ISSN: 02105187  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: Spanish SUMMARY LANGUAGE: English; Spanish

10/3/28 (Item 27 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075806162 EMBASE No: 1994232651  
Autoimmunity as a complication of interleukin 2 immunotherapy: Many  
unanswered questions  
Gaspari A.A.  
Department of Dermatology, University of Rochester, Box 697, 601 Elmwood

Ave, New York, NY 14642, United States  
CORRESP. AUTHOR: Gaspari A.A.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of  
Rochester, Box 697, 601 Elmwood Ave, New York, NY 14642, United States

Archives of Dermatology ( ARCH. DERMATOL. ) (United States) August 5,  
1994, 130/7 (894-897)  
CODEN: ARDEA ISSN: 0003987X  
DOI: 10.1001/archderm.130.7.894  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation  
LANGUAGE: English

10/3/29 (Item 28 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075803474 EMBASE No: 1994190202  
Extracorporeal photopheresis  
Gross M.; Boh E.E.; Millikan L.E.  
Department of Dermatology, Tulane University Medical Center, 1430 Tulane  
Avenue, New Orleans, LA 70112, United States  
CORRESP. AUTHOR: Gross M.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, Tulane University  
Medical Center, 1430 Tulane Avenue, New Orleans, LA 70112, United States

International Journal of Dermatology ( INT. J. DERMATOL. ) (Canada)  
August 8, 1994, 33/6 (407-411)  
CODEN: IJDEB ISSN: 00119059  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation  
LANGUAGE: English

10/3/30 (Item 29 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075450186 EMBASE No: 1993229742  
Pemphigus vulgaris and vegetans  
Becker B.A.; Gaspari A.A.  
Department of Dermatology, University of Rochester, School of  
Medicine/Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, United  
States  
CORRESP. AUTHOR: Gaspari A.A.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of  
Rochester, School of Medicine/Dentistry, 601 Elmwood Avenue, Rochester,  
NY 14642, United States

Dermatologic Clinics ( DERMATOL. CLIN. ) (United States) August 23, 1993  
, 11/3 (429-452)  
CODEN: DRMCD ISSN: 07338635  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English

10/3/31 (Item 30 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0070392933 EMBASE No: 1975176789  
'Opportunistic' auto immune disease and 'opportunistic' malignancy from

impaired cell mediated immunity?

Cairns R.J.

St Bartholomew's Hosp., Rochester, United Kingdom

CORRESP. AUTHOR AFFIL: St Bartholomew's Hosp., Rochester, United Kingdom

British Journal of Dermatology ( BR. J. DERMATOL. ) December 1, 1974,  
91/5 (601-602)

CODEN: BJDEA ISSN: 00070963

DOCUMENT TYPE: Journal RECORD TYPE: Citation

LANGUAGE: English

? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)
S7	185	(PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR THERAP- ?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?)
S8	139	RD S7 (unique items)
S9	3	S8 AND PY=2001
S10	31	S8 AND (REVIEW? OR OVERVIEW?)

? s (pemphigus) (20n) (inhibit? or suppress? or treat? or therap?) (20n) (cd4? or  
t(w)cell? or t(w)lymphocyte?) (20n) (antibod?)

>>>File 5 processing for CELL? stopped at CELLULLASE

Processing

Processing

Processing

Processing

Processing

Processing

	18072	PEMPHIGUS
	5242236	INHIBIT?
	1100686	SUPPRESS?
	8765477	TREAT?
	8195076	THERAP?
	376008	CD4?
	2212549	T
	13302071	CELL?
	815677	T(W)CELL?
	2212549	T
	1329311	LYMPHOCYTE?
	542775	T(W)LYMPHOCYTE?
	2323344	ANTIBOD?
S11	51	(PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR THERAP?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?) (20N) (ANTIBOD?)

? rd s11

S12	34	RD S11 (unique items)
-----	----	-----------------------

? t s12/3/all

12/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

19227223 BIOSIS NO.: 200600572618

Polymorphism of the promoter region and exon 1 of the CTLA4 gene in endemic

pemphigus foliaceus (fogo selvagem)  
AUTHOR: Pavoni D P; Cerqueira L B; Roxo V M M S; Petzl-Erler M L (Reprint)  
AUTHOR ADDRESS: Univ Fed Parana, Dept Genet, Lab Genet Mol Humana,  
BR-81531990 Curitiba, Parana, Brazil\*\*Brazil  
AUTHOR E-MAIL ADDRESS: perler@ufpr.br  
JOURNAL: Brazilian Journal of Medical and Biological Research 39 (9): p  
1227-1232 SEP 2006 2006  
ISSN: 0100-879X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

18897249 BIOSIS NO.: 200600242644  
Serum antidesmoglein-3 antibodies in patients with pemphigus before and  
after therapy  
AUTHOR: Matushevskaya E V; Svirshchevskaya E V; Dzutseva I R; Togoeva L T;  
Lapshina T P  
JOURNAL: Vestnik Dermatologii i Venerologii (6): p12-16 2005 2005  
ISSN: 0042-4609  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: Russian

12/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

17781306 BIOSIS NO.: 200400147967  
Immune reconstitution after autologous CD34 cell transplantation for  
autoimmune diseases.  
AUTHOR: Storek Jan (Reprint); Zhao Zhao (Reprint); Dawson Monja A (Reprint)  
; Sunderhaus Julie (Reprint); McSweeney Peter A (Reprint); Nash Richard A  
(Reprint); Sullivan Keith M (Reprint); Furst Daniel E (Reprint); Kraft  
George H (Reprint); Wener Mark H (Reprint); Lu Hailing (Reprint); Maloney  
David G (Reprint)  
AUTHOR ADDRESS: Fred Hutchinson Cancer Research Center and University of  
Washington, Seattle, WA, USA\*\*USA  
JOURNAL: Blood 102 (11): p715a November 16, 2003 2003  
MEDIUM: print  
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of  
Hematology San Diego, CA, USA December 06-09, 2003; 20031206  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

15406625 BIOSIS NO.: 200000124938  
The use of chlorambucil with prednisone in the treatment of pemphigus  
AUTHOR: Shah Neha; Green Andy R; Elgart George W; Kerdel Francisco

(Reprint)

AUTHOR ADDRESS: Department of Dermatology and Cutaneous Surgery, University  
of Miami School of Medicine, Miami, FL, 33101, USA\*\*USA  
JOURNAL: Journal of the American Academy of Dermatology 42 (1 Part 1): p  
85-88 Jan., 2000 2000  
MEDIUM: print  
ISSN: 0190-9622  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

14434848 BIOSIS NO.: 199800229095  
Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3  
specific T cell responses in pemphigus vulgaris patients and normals  
AUTHOR: Hertl Michael; Karr Robert W; Amagai Masayuki; Katz Stephen I  
AUTHOR ADDRESS: Hautklin., Universitaetsklinikum der RWTH, Pauwelsstr. 30,  
D-52072 Aachen, Germany\*\*Germany  
JOURNAL: Journal of Investigative Dermatology 110 (4): p388-392 April,  
1998 1998  
MEDIUM: print  
ISSN: 0022-202X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13932220 BIOSIS NO.: 199799566280  
Gelatinases A and B are expressed in late lesions in autoimmune bullous  
disorders  
AUTHOR: Feliciani C (Reprint); Toto P; Coscione G; Pour S Mohammad;  
Allegretti T; Proietto G; Amerio P  
AUTHOR ADDRESS: Clinica Dermatol., Universita "G.d'Annunzio", 66013 Chieti,  
Italy\*\*Italy  
JOURNAL: International Journal of Immunopathology and Pharmacology 10 (1):  
p103-105 1997 1997  
ISSN: 0394-6320  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

13236989 BIOSIS NO.: 199698704822  
Long-term interferon-alpha therapy induces autoantibodies against epidermis  
AUTHOR: Fleischmann M; Celerier P; Bernard P; Litoux P; Dreno B (Reprint)  
AUTHOR ADDRESS: Dep. Dermatol., Hotel-Dieu, Pl. A. Ricordeau, F-44035  
Nantes Cedex 01, France\*\*France  
JOURNAL: Dermatology (Basel) 192 (1): p50-55 1996 1996  
ISSN: 1018-8665

DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

12/3/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

09634928 BIOSIS NO.: 198987082819  
THE MECHANISMS OF THE THERAPEUTIC ACTION OF EXTRACORPOREAL DETOXIFICATION  
IN AUTOIMMUNE BULLOUS DERMATOSES  
AUTHOR: GRANDO S A (Reprint); GLUKHEN'KII B T; ROMANENKO A B; CHAYUN O A;  
DOLYA S V  
AUTHOR ADDRESS: DIV DERMATOL VENEROL, KIEV INST POSTGRAD MED, KIEV, USSR\*\*  
USSR  
JOURNAL: Vestnik Dermatologii i Venerologii (7): p6-11 1988  
ISSN: 0042-4609  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: RUSSIAN

12/3/9 (Item 9 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

08744158 BIOSIS NO.: 198784098307  
T AND B-LYMPHOCYTES IN PEMPHIGUS VULGARIS A CLINICO-IMMUNOLOGICAL FOLLOW-UP  
STUDY OF FIFTY PATIENTS WITH PEMPHIGUS VULGARIS  
AUTHOR: MASHKILLEYSON N (Reprint)  
AUTHOR ADDRESS: DEP DERMATOL, HELSINKI UNIV CENTRAL HOSP, SNELLMANINKATU  
14, SF-00170 HELSINKI 17, FINLAND\*\*FINLAND  
JOURNAL: Acta Dermato-Venereologica 67 (3): p218-224 1987  
ISSN: 0001-5555  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

12/3/10 (Item 10 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

08618769 BIOSIS NO.: 198783097660  
MONONUCLEAR CELL INFILTRATES IN BULLOUS DISEASE  
AUTHOR: NESTOR M S (Reprint); COCHRAN A J; AHMED A R  
AUTHOR ADDRESS: DIV SURG ONCOL, 9-267 LOUIS FACTOR BUILD, UCLA SCH MED, LOS  
ANGELES, CALIF 90024, USA\*\*USA  
JOURNAL: Journal of Investigative Dermatology 88 (2): p172-175 1987  
ISSN: 0022-202X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

12/3/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

06996601 BIOSIS NO.: 198376088036

PRODUCTION OF PEMPHIGUS ANTIBODY IN-VITRO AND ANALYSIS OF T CELL SUBSETS  
AUTHOR: AHMED A R (Reprint); MURAHATA R I; SCHROFF R W; STEVENS R M; SAXON  
A S  
AUTHOR ADDRESS: DIVISION OF DERMATOLOGY, DEPARTMENT OF MEDICINE, UCLA  
SCHOOL OF MEDICINE, LOS ANGELES, CALIFORNIA 90024, USA\*\*USA  
JOURNAL: Journal of Clinical Immunology 3 (3): p241-252 1983  
ISSN: 0271-9142  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

12/3/12 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0082112095 EMBASE No: 2007548047  
The selective immunotherapy of pemphigus  
Bystryn J.C.; Czernik A. // Bystryn J.C.  
Ronald O. Perelman Department of Dermatology, New York University School  
of Medicine, New York, NY, United States // NYU Medical Center, 560 1st  
Avenue, New York, NY 10016, United States  
AUTHOR EMAIL: bystryn@nyu.edu; bystryn@nyu.edu  
CORRESP. AUTHOR: Bystryn J.C.  
CORRESP. AUTHOR AFFIL: NYU Medical Center, 560 1st Avenue, New York, NY  
10016, United States  
CORRESP. AUTHOR EMAIL: bystryn@nyu.edu

Giornale Italiano di Dermatologia e Venereologia ( G. Ital. Dermatol.  
Venereol. ) (Italy) August 1, 2007, 142/4 (381-390)  
CODEN: GIDVD ISSN: 00264741  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English; Italian  
NUMBER OF REFERENCES: 63

12/3/13 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0081441538 EMBASE No: 2006504612  
Polymorphism of the promoter region and exon 1 of the CLTA4 gene in  
endemic pemphigus foliaceus (fogo selvagem)  
Pavoni D.P.; Cerqueira L.B.; Roxo V.M.M.S.; Petzl-Erler M.L.  
Laboratorio de Genetica Molecular Humana, Universidade Federal do Parana,  
81531-990 Curitiba, PR, Brazil  
AUTHOR EMAIL: perler@ufpr.br  
CORRESP. AUTHOR: Petzl-Erler M.L.  
CORRESP. AUTHOR AFFIL: Departamento de Genetica, Universidade Federal do  
Parana, 81531-990 Curitiba, PR, Brazil  
CORRESP. AUTHOR EMAIL: perler@ufpr.br

Brazilian Journal of Medical and Biological Research ( Braz. J. Med.  
Biol. Res. ) (Brazil) September 1, 2006, 39/9 (1227-1232)  
CODEN: RBPMB ISSN: 0100879X eISSN: 16784510  
DOI: 10.1590/S0100-879X2006000900010  
URL: <http://www.scielo.br/scielo.php?script=sciarttext&pid=S0100-879X2006000900010&lng=en&nrm=iso&tlng=en>  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 26

12/3/14 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080639138 EMBASE No: 2005283430  
The role of cytokines in the pathogenesis of autoimmune bullous skin disease  
Rola cytokin w patomechanizmie chorob pecherzowych  
Waszczykowska E.; Wysoczanska K.; Zebrowska A.  
Katedra Dermatologii i Wenerologii, Uniwersytetu Medycznego, ul.  
Krzemieniecka 5, 94-017 LoLdzL, Poland  
CORRESP. AUTHOR: Waszczykowska E.  
CORRESP. AUTHOR AFFIL: Katedra Dermatologii i Wenerologii, Uniwersytetu  
Medycznego, ul. Krzemieniecka 5, 94-017 LoLdzL, Poland  
  
Alergia Astma Immunologia ( Alergia Astma Immunol. ) (Poland) December  
1, 2004, 9/4 (179-186)  
CODEN: AAIMF ISSN: 14273101  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: Polish SUMMARY LANGUAGE: English; Polish  
NUMBER OF REFERENCES: 48

12/3/15 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0080278996 EMBASE No: 2004458124  
Management of autoimmune skin disorders in the elderly  
Loo W.J.; Burrows N.P. // Loo W.J.  
Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, United  
Kingdom // Department of Dermatology, Addenbrooke's NHS Trust, Hills  
Road, Cambridge, CB2 2QQ, United Kingdom  
AUTHOR EMAIL: wjl00@hotmail.com; wjl00@hotmail.com  
CORRESP. AUTHOR: Loo W.J.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, Addenbrooke's NHS  
Trust, Hills Road, Cambridge, CB2 2QQ, United Kingdom  
CORRESP. AUTHOR EMAIL: wjl00@hotmail.com

Drugs and Aging ( Drugs Aging ) (New Zealand) November 9, 2004, 21/12  
(767-777)  
CODEN: DRAGE ISSN: 1170229X  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract  
LANGUAGE: English SUMMARY LANGUAGE: English  
NUMBER OF REFERENCES: 50

12/3/16 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0078364443 EMBASE No: 2000414052  
Autoimmune skin diseases  
Le malattie autoimmuni della cute  
Malorgio C.; Panizon F.  
Clinica Pediatrica, IRCCS 'Burto Garofolo', Trieste, Italy  
CORRESP. AUTHOR: Malorgio C.  
CORRESP. AUTHOR AFFIL: Clinica Pediatrica, IRCCS 'Burto Garofolo',  
Trieste, Italy



Medico e Bambino ( Med. Bambino ) (Italy) October 31, 2000, 19/8  
(495-503)  
CODEN: MBAMF  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: Italian SUMMARY LANGUAGE: English; Italian  
NUMBER OF REFERENCES: 61

12/3/17 (Item 6 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0075806162 EMBASE No: 1994232651  
Autoimmunity as a complication of interleukin 2 immunotherapy: Many  
unanswered questions  
Gaspari A.A.  
Department of Dermatology, University of Rochester, Box 697, 601 Elmwood  
Ave, New York, NY 14642, United States  
CORRESP. AUTHOR: Gaspari A.A.  
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of  
Rochester, Box 697, 601 Elmwood Ave, New York, NY 14642, United States  
  
Archives of Dermatology ( ARCH. DERMATOL. ) (United States) August 5,  
1994, 130/7 (894-897)  
CODEN: ARDEA ISSN: 0003987X  
DOI: 10.1001/archderm.130.7.894  
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation  
LANGUAGE: English

12/3/18 (Item 7 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0073492421 EMBASE No: 1987020814  
When to discontinue therapy in pemphigus vulgaris?  
WANN IST ES MOGLICH, DIE THERAPIE BEIM PEMPHIGUS VULGARIS ABZUSETZEN?  
Mashkilleyson N.; Eskelinen A.  
Department fur Dermatologie, Stomatologisches Institut Moskau, Moskau,  
U.S.S.R.  
CORRESP. AUTHOR AFFIL: Department fur Dermatologie, Stomatologisches  
Institut Moskau, Moskau, U.S.S.R.

H+G Zeitschrift fur Hautkrankheiten ( H G Z. HAUTKR. ) (Germany)  
December 1, 1986, 61/22 (1596-1602)  
CODEN: ZHKRA ISSN: 03010481  
DOCUMENT TYPE: Journal RECORD TYPE: Abstract  
LANGUAGE: German SUMMARY LANGUAGE: English

12/3/19 (Item 8 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0071805404 EMBASE No: 1981251814  
Use of orthoclone monoclonal antibodies in the study of selected  
dermatologic conditions  
Berger C.L.; Kung P.; Goldstein G.; et-al  
Dept. Dermatol., Columbia Univ., New York, NY 10032, United States  
CORRESP. AUTHOR AFFIL: Dept. Dermatol., Columbia Univ., New York, NY

10032, United States

International Journal of Immunopharmacology ( INT. J. IMMUNOPHARMACOL. )  
(United Kingdom) December 29, 1981, 3/3 (275-282)  
CODEN: IJIMD ISSN: 01920561  
DOI: 10.1016/0192-0561(81)90021-7  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English

12/3/20 (Item 9 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2008 Elsevier B.V. All rts. reserv.

0071256724 EMBASE No: 1978401631  
Pemphigus vulgaris and thymoma. A T-lymphocyte defect?  
Kavli G.  
Dept. Dermatol., Univ. 9012 Tromso, Norway  
CORRESP. AUTHOR AFFIL: Dept. Dermatol., Univ. 9012 Tromso, Norway

British Journal of Dermatology ( BR. J. DERMATOL. ) (United Kingdom)  
December 11, 1978, 99/1 (97-98)  
CODEN: BJDEA ISSN: 00070963  
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract  
LANGUAGE: English

12/3/21 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

16839443 PMID: 16417225  
Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model.  
Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki; Iwasaki Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji; Amagai Masayuki  
Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.  
Journal of investigative dermatology (United States) Jan 2006, 126  
(1) p105-13, ISSN 0022-202X--Print Journal Code: 0426720  
Publishing Model Print; Comment in J Invest Dermatol. 2006 Jan;126(1) 11-3; Comment in PMID 16417211  
Document type: Journal Article; Research Support, Non-U.S. Gov't  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

12/3/22 (Item 2 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

08141983 PMID: 3101298  
[When is it possible to discontinue therapy in pemphigus vulgaris?]  
Wann ist es möglich, die Therapie beim Pemphigus vulgaris abzusetzen?  
Mashkilleyson N; Eskelinen A  
Zeitschrift für Hautkrankheiten (GERMANY, WEST) Nov 15 1986, 61 (22)  
p1596-602, ISSN 0301-0481--Print Journal Code: 0367576  
Publishing Model Print  
Document type: Case Reports; English Abstract; Journal Article  
Languages: GERMAN

Main Citation Owner: NLM  
Record type: MEDLINE; Completed

12/3/23 (Item 3 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

06809937 PMID: 6215423  
Use of monoclonal antibodies specific for T cell subsets in cutaneous disorders: I. Quantitative analysis of peripheral blood lymphocytes.  
Faure M; Thivolet J  
Journal of clinical immunology (UNITED STATES) Jul 1982, 2 (3 Suppl)  
p103S-110S, ISSN 0271-9142--Print Journal Code: 8102137  
Publishing Model Print  
Document type: Journal Article  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

12/3/24 (Item 4 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2008 Dialog. All rts. reserv.

05608378 PMID: 347546  
[Immunological aspects of malignant lymphomas]  
Aspetti immunologici dei linfomi maligni.  
Hancock B W; Richmond J  
Recenti progressi in medicina (ITALY) Feb 1978, 64 (2) p217-29,  
ISSN 0034-1193--Print Journal Code: 0401271  
Publishing Model Print  
Document type: Journal Article; Review  
Languages: ITALIAN  
Main Citation Owner: NLM  
Record type: MEDLINE; Completed

12/3/25 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

148031934 CA: 148(2)31934m PATENT  
Ligands or antibodies capable of binding to CD3 and CD55 for producing regulatory CD4+ T cells to treat antibody- or cell-mediated autoimmune disease  
INVENTOR(AUTHOR): Spendlove, Ian; Durrant, Linda Gillian  
LOCATION: UK,  
ASSIGNEE: The University of Nottingham  
PATENT: PCT International ; WO 2007135401 A2 DATE: 20071129  
APPLICATION: WO 2007GB1864 (20070518) \*GB 20069924 (20060519)  
PAGES: 65pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
IPCR/8 + Level Value Position Status Version Action Source Office:  
A61K-0039/395 A I F B 20060101 H EP  
A61P-0037/00 A I L B 20060101 H EP  
A61K-0038/17 A I L B 20060101 H EP  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;  
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;  
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;

NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;  
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/26 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

147446877 CA: 147(21)446877x PATENT  
Combination therapy for treating autoimmune diseases  
INVENTOR(AUTHOR): Koenig, Scott  
LOCATION: USA  
ASSIGNEE: Macrogenics, Inc.  
PATENT: PCT International ; WO 2007117600 A2 DATE: 20071018  
APPLICATION: WO 2007US8579 (20070406) \*US 2006PV789899 (20060407) \*US  
2006PV844095 (20060913)  
PAGES: 38pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
IPCR/8 + Level Value Position Status Version Action Source Office:  
A61K-0039/395 A I F B 20060101 H US  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;  
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;  
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;  
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ;  
NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL;  
SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/27 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

146006355 CA: 146(1)6355z PATENT  
Biomarkers for diagnosis and treatment of diseases having an autoimmune  
and/or inflammatory component responsive to anti-CD40 monoclonal  
antibodies  
INVENTOR(AUTHOR): Aukerman, Sharon Lea; Jallal, Bahija; Luqman, Mohammad  
LOCATION: USA  
ASSIGNEE: Novartis AG; Xoma Technology  
PATENT: PCT International ; WO 2006125117 A2 DATE: 20061123  
APPLICATION: WO 2006US19325 (20060518) \*US 2005PV682575 (20050518) \*US  
2005PV749336 (20051209)  
PAGES: 145pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
IPCR/8 + Level Value Position Status Version Action Source Office:  
G01N-0033/564 A I F B 20060101 H EP  
G01N-0033/68 A I L B 20060101 H EP  
A61P-0037/00 A I L B 20060101 H EP  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK;  
LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ;  
OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR;

TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH  
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/28 (Item 4 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

145025794 CA: 145(2)25794n JOURNAL  
Inhibition of pemphigus vulgaris by targeting of the CD40-CD154  
co-stimulatory pathway: a step toward antigen-specific therapy?  
AUTHOR(S): Liu, Zhi; Li, Ning; Diaz, Luis A.  
LOCATION: Department of Dermatology, University of North Carolina at  
Chapel Hill, Chapel Hill, NC, USA  
JOURNAL: J. Invest. Dermatol. (Journal of Investigative Dermatology)  
DATE: 2006 VOLUME: 126 NUMBER: 1 PAGES: 11-13 CODEN: JIDEAE ISSN:  
0022-202X LANGUAGE: English PUBLISHER: Nature Publishing Group

12/3/29 (Item 5 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

142480777 CA: 142(26)480777w PATENT  
Antagonistic anti-human CD40 monoclonal antibodies and fragments for  
treating proliferative, cancerous and autoimmune disease  
INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror,  
Isabel; Chen, Bao-Lu; Lu, Xiaofeng; Lee, Sang Hoon; Hurst, Deborah  
LOCATION: USA  
ASSIGNEE: Chiron Corporation  
PATENT: PCT International ; WO 200544854 A2 DATE: 20050519  
APPLICATION: WO 2004US37152 (20041104) \*US 2003PV517337 (20031104) \*US  
2003PV525579 (20031126) \*US 2004PV565710 (20040427)  
PAGES: 176 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C07K-016/00A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG

12/3/30 (Item 6 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

142480770 CA: 142(26)480770p PATENT  
Antagonistic monoclonal antibodies and derivatives specific to human CD40  
antigen for treatment of autoimmune and inflammatory diseases  
INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror,  
Isabel  
LOCATION: USA

ASSIGNEE: Chiron Corporation  
PATENT: PCT International ; WO 200544306 A2 DATE: 20050519  
APPLICATION: WO 2004US36957 (20041104) \*US 2003PV517337 (20031104) \*US  
2003PV525579 (20031126) \*US 2004PV565710 (20040427)  
PAGES: 114 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/395A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;  
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;  
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;  
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;  
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;  
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ  
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;  
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;  
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;  
MR; NE; SN; TD; TG

12/3/31 (Item 7 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

139322294 CA: 139(21)322294v PATENT  
Treating or preventing autoimmune disease using an IL-16 inhibitor  
INVENTOR(AUTHOR): Delovitch, Terry L.  
LOCATION: Can.,  
ASSIGNEE: The John P. Robarts Research Institute  
PATENT: PCT International ; WO 200386457 A2 DATE: 20031023  
APPLICATION: WO 2003CA501 (20030407) \*US PV370535 (20020408)  
PAGES: 36 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/395A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC;  
SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA;  
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE  
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;  
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;  
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

12/3/32 (Item 8 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

138168815 CA: 138(12)168815m PATENT  
B7-related nucleic acids and polypeptides useful for immunomodulation  
INVENTOR(AUTHOR): Mikesell, Glen E.; Shen, Henry  
LOCATION: USA  
PATENT: U.S. Pat. Appl. Publ. ; US 20030031675 A1 DATE: 20030213  
APPLICATION: US 77023 (20020215) \*US PV209811 (20000606) \*US PV272107  
(20010228) \*US 875338 (20010606)  
PAGES: 163 pp., Cont.-in-part of U.S. Ser. No. 875,338. CODEN: USXXCO  
LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: 424178100; A61K-039/395A; C07H-021/04B; C12P-021/04B;  
C12N-001/21B; C12N-005/04B; C12N-005/06B

12/3/33 (Item 9 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

136278158 CA: 136(18)278158r PATENT  
Control of T cell processes using combinations of antagonists of  
interleukin-2 and interleukin-15  
INVENTOR(AUTHOR): Li, Xian Chang; Strom, Terry; Zheng, Xin Xiao  
LOCATION: USA  
ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.  
PATENT: PCT International ; WO 200222805 A2 DATE: 20020321  
APPLICATION: WO 2001US28612 (20010914) \*US PV232251 (20000914)  
PAGES: 80 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: C12N-015/00A  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SD; SE; SG;  
SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY;  
KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL  
; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;  
MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN;  
TD; TG

12/3/34 (Item 10 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2008 American Chemical Society. All rts. reserv.

131057772 CA: 131(5)57772f PATENT  
Methods to treat undesirable immune responses  
INVENTOR(AUTHOR): Conti-Fine, Bianca M.  
LOCATION: USA  
ASSIGNEE: Regents of the University of Minnesota  
PATENT: PCT International ; WO 9930736 A2 DATE: 19990624  
APPLICATION: WO 98US26787 (19981216) \*US 991143 (19971216)  
PAGES: 221 pp. CODEN: PIXXD2 LANGUAGE: English  
PATENT CLASSIFICATIONS:  
CLASS: A61K-039/00A  
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;  
CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP;  
KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO;  
NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ;  
VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM  
; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;  
IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE;  
SN; TD; TG  
?